WO1991009073A1 - Uncharged morpholino-based polymers having achiral intersubunit linkages - Google Patents
Uncharged morpholino-based polymers having achiral intersubunit linkages Download PDFInfo
- Publication number
- WO1991009073A1 WO1991009073A1 PCT/US1990/007565 US9007565W WO9109073A1 WO 1991009073 A1 WO1991009073 A1 WO 1991009073A1 US 9007565 W US9007565 W US 9007565W WO 9109073 A1 WO9109073 A1 WO 9109073A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- subunit
- polymer
- morpholino
- base
- composition
- Prior art date
Links
- 229920000642 polymer Polymers 0.000 title claims abstract description 233
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 title claims abstract description 112
- 239000000203 mixture Substances 0.000 claims abstract description 51
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 33
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 33
- 239000002157 polynucleotide Substances 0.000 claims abstract description 32
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 claims abstract description 29
- MHCMWGPPLOSCJY-UHFFFAOYSA-N 4-$l^{1}-azanylmorpholine Chemical compound [N]N1CCOCC1 MHCMWGPPLOSCJY-UHFFFAOYSA-N 0.000 claims abstract description 16
- 239000001257 hydrogen Substances 0.000 claims abstract description 16
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 16
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 14
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims abstract description 11
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000002202 Polyethylene glycol Substances 0.000 claims description 12
- 229920001223 polyethylene glycol Polymers 0.000 claims description 12
- 150000003212 purines Chemical class 0.000 claims description 8
- MSSXOMSJDRHRMC-UHFFFAOYSA-N 9H-purine-2,6-diamine Chemical compound NC1=NC(N)=C2NC=NC2=N1 MSSXOMSJDRHRMC-UHFFFAOYSA-N 0.000 claims description 7
- CNPURSDMOWDNOQ-UHFFFAOYSA-N 4-methoxy-7h-pyrrolo[2,3-d]pyrimidin-2-amine Chemical compound COC1=NC(N)=NC2=C1C=CN2 CNPURSDMOWDNOQ-UHFFFAOYSA-N 0.000 claims 1
- 239000012736 aqueous medium Substances 0.000 claims 1
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 93
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 71
- 238000009739 binding Methods 0.000 description 63
- 230000027455 binding Effects 0.000 description 62
- 238000005859 coupling reaction Methods 0.000 description 55
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 54
- 238000010168 coupling process Methods 0.000 description 51
- 238000000034 method Methods 0.000 description 51
- 230000008878 coupling Effects 0.000 description 50
- 230000015572 biosynthetic process Effects 0.000 description 47
- 238000003786 synthesis reaction Methods 0.000 description 47
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 45
- 239000000243 solution Substances 0.000 description 42
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 40
- 108020004414 DNA Proteins 0.000 description 38
- -1 morpholino carbon Chemical compound 0.000 description 37
- 229910052757 nitrogen Inorganic materials 0.000 description 37
- 239000000047 product Substances 0.000 description 34
- 239000002904 solvent Substances 0.000 description 31
- 239000007787 solid Substances 0.000 description 28
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 26
- 150000001412 amines Chemical class 0.000 description 26
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 24
- 238000002360 preparation method Methods 0.000 description 24
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 23
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 22
- 239000000539 dimer Substances 0.000 description 22
- 238000001994 activation Methods 0.000 description 21
- 230000004913 activation Effects 0.000 description 21
- 238000006243 chemical reaction Methods 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 20
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 19
- 238000000746 purification Methods 0.000 description 19
- 239000002342 ribonucleoside Substances 0.000 description 19
- 229910001868 water Inorganic materials 0.000 description 19
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 17
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 17
- 230000000875 corresponding effect Effects 0.000 description 17
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 16
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 16
- 150000007523 nucleic acids Chemical class 0.000 description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 15
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 15
- 102000039446 nucleic acids Human genes 0.000 description 15
- 108020004707 nucleic acids Proteins 0.000 description 15
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 14
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 14
- 229940086542 triethylamine Drugs 0.000 description 14
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 13
- 238000003556 assay Methods 0.000 description 13
- 125000004429 atom Chemical group 0.000 description 13
- 238000002844 melting Methods 0.000 description 13
- 230000008018 melting Effects 0.000 description 13
- 125000006239 protecting group Chemical group 0.000 description 13
- 230000002829 reductive effect Effects 0.000 description 13
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 12
- 238000010511 deprotection reaction Methods 0.000 description 12
- RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 description 11
- 229910052760 oxygen Inorganic materials 0.000 description 11
- 239000011541 reaction mixture Substances 0.000 description 11
- NVBFHJWHLNUMCV-UHFFFAOYSA-N sulfamide Chemical compound NS(N)(=O)=O NVBFHJWHLNUMCV-UHFFFAOYSA-N 0.000 description 11
- 229910021529 ammonia Inorganic materials 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 229940104302 cytosine Drugs 0.000 description 10
- 239000000463 material Substances 0.000 description 10
- 239000002777 nucleoside Substances 0.000 description 10
- 229920002523 polyethylene Glycol 1000 Polymers 0.000 description 10
- 150000003141 primary amines Chemical class 0.000 description 10
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 10
- 238000010898 silica gel chromatography Methods 0.000 description 10
- ZNZYKNKBJPZETN-WELNAUFTSA-N Dialdehyde 11678 Chemical compound N1C2=CC=CC=C2C2=C1[C@H](C[C@H](/C(=C/O)C(=O)OC)[C@@H](C=C)C=O)NCC2 ZNZYKNKBJPZETN-WELNAUFTSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical group O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- 238000004587 chromatography analysis Methods 0.000 description 9
- 239000000178 monomer Substances 0.000 description 9
- 230000009870 specific binding Effects 0.000 description 9
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 9
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 8
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 8
- 229930024421 Adenine Natural products 0.000 description 8
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 8
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 8
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 8
- 229960000643 adenine Drugs 0.000 description 8
- 150000001408 amides Chemical class 0.000 description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 230000000295 complement effect Effects 0.000 description 8
- 235000019253 formic acid Nutrition 0.000 description 8
- 230000002068 genetic effect Effects 0.000 description 8
- 229940029575 guanosine Drugs 0.000 description 8
- 238000009396 hybridization Methods 0.000 description 8
- 125000005647 linker group Chemical group 0.000 description 8
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 8
- 230000000269 nucleophilic effect Effects 0.000 description 8
- 239000001301 oxygen Substances 0.000 description 8
- 238000005406 washing Methods 0.000 description 8
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 7
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 7
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical group CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 7
- 108091034117 Oligonucleotide Proteins 0.000 description 7
- 238000002835 absorbance Methods 0.000 description 7
- 239000002253 acid Substances 0.000 description 7
- 239000012491 analyte Substances 0.000 description 7
- 238000006642 detritylation reaction Methods 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 239000000741 silica gel Substances 0.000 description 7
- 229910002027 silica gel Inorganic materials 0.000 description 7
- IIACRCGMVDHOTQ-UHFFFAOYSA-M sulfamate Chemical compound NS([O-])(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-M 0.000 description 7
- QAHVHSLSRLSVGS-UHFFFAOYSA-N sulfamoyl chloride Chemical compound NS(Cl)(=O)=O QAHVHSLSRLSVGS-UHFFFAOYSA-N 0.000 description 7
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 6
- 239000004743 Polypropylene Substances 0.000 description 6
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 6
- 239000012267 brine Substances 0.000 description 6
- 238000003776 cleavage reaction Methods 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 238000012790 confirmation Methods 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 150000002500 ions Chemical class 0.000 description 6
- 229920001155 polypropylene Polymers 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 238000006722 reduction reaction Methods 0.000 description 6
- 125000006853 reporter group Chemical group 0.000 description 6
- 230000007017 scission Effects 0.000 description 6
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 6
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
- 239000007858 starting material Substances 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 239000011550 stock solution Substances 0.000 description 6
- 229940124530 sulfonamide Drugs 0.000 description 6
- 229910052717 sulfur Inorganic materials 0.000 description 6
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical group CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 6
- HVCNXQOWACZAFN-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound CCN1CCOCC1 HVCNXQOWACZAFN-UHFFFAOYSA-N 0.000 description 5
- BTJIUGUIPKRLHP-UHFFFAOYSA-N 4-nitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1 BTJIUGUIPKRLHP-UHFFFAOYSA-N 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 5
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 5
- 230000002378 acidificating effect Effects 0.000 description 5
- 150000001299 aldehydes Chemical class 0.000 description 5
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 5
- OBESRABRARNZJB-UHFFFAOYSA-N aminomethanesulfonic acid Chemical compound NCS(O)(=O)=O OBESRABRARNZJB-UHFFFAOYSA-N 0.000 description 5
- QRUDEWIWKLJBPS-UHFFFAOYSA-N benzotriazole Chemical compound C1=CC=C2N[N][N]C2=C1 QRUDEWIWKLJBPS-UHFFFAOYSA-N 0.000 description 5
- 239000012964 benzotriazole Substances 0.000 description 5
- 229940093499 ethyl acetate Drugs 0.000 description 5
- 235000019439 ethyl acetate Nutrition 0.000 description 5
- 238000001704 evaporation Methods 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 5
- 150000003230 pyrimidines Chemical class 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 230000003381 solubilizing effect Effects 0.000 description 5
- 150000003456 sulfonamides Chemical class 0.000 description 5
- JBWKIWSBJXDJDT-UHFFFAOYSA-N triphenylmethyl chloride Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(Cl)C1=CC=CC=C1 JBWKIWSBJXDJDT-UHFFFAOYSA-N 0.000 description 5
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- 229920002684 Sepharose Polymers 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- 239000000908 ammonium hydroxide Substances 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 4
- 238000007068 beta-elimination reaction Methods 0.000 description 4
- ACBQROXDOHKANW-UHFFFAOYSA-N bis(4-nitrophenyl) carbonate Chemical compound C1=CC([N+](=O)[O-])=CC=C1OC(=O)OC1=CC=C([N+]([O-])=O)C=C1 ACBQROXDOHKANW-UHFFFAOYSA-N 0.000 description 4
- 238000005277 cation exchange chromatography Methods 0.000 description 4
- 230000036425 denaturation Effects 0.000 description 4
- 238000004925 denaturation Methods 0.000 description 4
- 239000005549 deoxyribonucleoside Substances 0.000 description 4
- JXTHNDFMNIQAHM-UHFFFAOYSA-N dichloroacetic acid Chemical compound OC(=O)C(Cl)Cl JXTHNDFMNIQAHM-UHFFFAOYSA-N 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 238000010265 fast atom bombardment Methods 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- IRXSLJNXXZKURP-UHFFFAOYSA-N fluorenylmethyloxycarbonyl chloride Chemical compound C1=CC=C2C(COC(=O)Cl)C3=CC=CC=C3C2=C1 IRXSLJNXXZKURP-UHFFFAOYSA-N 0.000 description 4
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 4
- 238000004949 mass spectrometry Methods 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 150000002825 nitriles Chemical class 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 238000001243 protein synthesis Methods 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 description 4
- 235000011152 sodium sulphate Nutrition 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid group Chemical class S(N)(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 4
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- 230000014616 translation Effects 0.000 description 4
- 229940035893 uracil Drugs 0.000 description 4
- OTDJAMXESTUWLO-UUOKFMHZSA-N 2-amino-9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)-2-oxolanyl]-3H-purine-6-thione Chemical compound C12=NC(N)=NC(S)=C2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OTDJAMXESTUWLO-UUOKFMHZSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 3
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- 241000907681 Morpho Species 0.000 description 3
- 238000005481 NMR spectroscopy Methods 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 3
- 239000006227 byproduct Substances 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 150000001793 charged compounds Chemical class 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 3
- 239000012039 electrophile Substances 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000007429 general method Methods 0.000 description 3
- 230000000415 inactivating effect Effects 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 229940098779 methanesulfonic acid Drugs 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 238000000302 molecular modelling Methods 0.000 description 3
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 3
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 3
- 238000006386 neutralization reaction Methods 0.000 description 3
- 125000003835 nucleoside group Chemical group 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 230000001590 oxidative effect Effects 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 238000005932 reductive alkylation reaction Methods 0.000 description 3
- 150000003335 secondary amines Chemical class 0.000 description 3
- 239000007790 solid phase Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 3
- 150000003460 sulfonic acids Chemical class 0.000 description 3
- 229940113082 thymine Drugs 0.000 description 3
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 3
- 229940045145 uridine Drugs 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- NSMXQKNUPPXBRG-SECBINFHSA-N (R)-lisofylline Chemical compound O=C1N(CCCC[C@H](O)C)C(=O)N(C)C2=C1N(C)C=N2 NSMXQKNUPPXBRG-SECBINFHSA-N 0.000 description 2
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 2
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 2
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 2
- MWBWWFOAEOYUST-UHFFFAOYSA-N 2-aminopurine Chemical compound NC1=NC=C2N=CNC2=N1 MWBWWFOAEOYUST-UHFFFAOYSA-N 0.000 description 2
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 2
- QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 description 2
- 108020004635 Complementary DNA Proteins 0.000 description 2
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 101710163270 Nuclease Proteins 0.000 description 2
- 239000012564 Q sepharose fast flow resin Substances 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
- 229960005305 adenosine Drugs 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 238000005349 anion exchange Methods 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 239000012300 argon atmosphere Substances 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
- 150000007942 carboxylates Chemical group 0.000 description 2
- 238000005341 cation exchange Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- CZKMPDNXOGQMFW-UHFFFAOYSA-N chloro(triethyl)germane Chemical compound CC[Ge](Cl)(CC)CC CZKMPDNXOGQMFW-UHFFFAOYSA-N 0.000 description 2
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 2
- 238000005100 correlation spectroscopy Methods 0.000 description 2
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 2
- 239000005547 deoxyribonucleotide Substances 0.000 description 2
- 238000001212 derivatisation Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 229960005215 dichloroacetic acid Drugs 0.000 description 2
- BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000006345 epimerization reaction Methods 0.000 description 2
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 229920001519 homopolymer Polymers 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 2
- BNXBRFDWSPXODM-BPGGGUHBSA-N n-[1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-oxopyrimidin-4-yl]benzamide Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)N=C(NC(=O)C=2C=CC=CC=2)C=C1 BNXBRFDWSPXODM-BPGGGUHBSA-N 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 150000003833 nucleoside derivatives Chemical class 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 229940113116 polyethylene glycol 1000 Drugs 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000010532 solid phase synthesis reaction Methods 0.000 description 2
- 238000005063 solubilization Methods 0.000 description 2
- 230000007928 solubilization Effects 0.000 description 2
- 238000010183 spectrum analysis Methods 0.000 description 2
- 230000001180 sulfating effect Effects 0.000 description 2
- 150000003457 sulfones Chemical class 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 229960003087 tioguanine Drugs 0.000 description 2
- 238000010626 work up procedure Methods 0.000 description 2
- YBADLXQNJCMBKR-UHFFFAOYSA-M (4-nitrophenyl)acetate Chemical compound [O-]C(=O)CC1=CC=C([N+]([O-])=O)C=C1 YBADLXQNJCMBKR-UHFFFAOYSA-M 0.000 description 1
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- BHKKSKOHRFHHIN-MRVPVSSYSA-N 1-[[2-[(1R)-1-aminoethyl]-4-chlorophenyl]methyl]-2-sulfanylidene-5H-pyrrolo[3,2-d]pyrimidin-4-one Chemical compound N[C@H](C)C1=C(CN2C(NC(C3=C2C=CN3)=O)=S)C=CC(=C1)Cl BHKKSKOHRFHHIN-MRVPVSSYSA-N 0.000 description 1
- LOSXTWDYAWERDB-UHFFFAOYSA-N 1-[chloro(diphenyl)methyl]-2,3-dimethoxybenzene Chemical compound COC1=CC=CC(C(Cl)(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1OC LOSXTWDYAWERDB-UHFFFAOYSA-N 0.000 description 1
- MCTWTZJPVLRJOU-UHFFFAOYSA-N 1-methyl-1H-imidazole Chemical compound CN1C=CN=C1 MCTWTZJPVLRJOU-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- LTMRRSWNXVJMBA-UHFFFAOYSA-L 2,2-diethylpropanedioate Chemical compound CCC(CC)(C([O-])=O)C([O-])=O LTMRRSWNXVJMBA-UHFFFAOYSA-L 0.000 description 1
- HVHZEKKZMFRULH-UHFFFAOYSA-N 2,6-ditert-butyl-4-methylpyridine Chemical compound CC1=CC(C(C)(C)C)=NC(C(C)(C)C)=C1 HVHZEKKZMFRULH-UHFFFAOYSA-N 0.000 description 1
- GKAVOHSJEWKJFB-UHFFFAOYSA-N 2-(benzenesulfonyl)ethyl carbonochloridate Chemical compound ClC(=O)OCCS(=O)(=O)C1=CC=CC=C1 GKAVOHSJEWKJFB-UHFFFAOYSA-N 0.000 description 1
- ZDTFMPXQUSBYRL-UUOKFMHZSA-N 2-Aminoadenosine Chemical class C12=NC(N)=NC(N)=C2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O ZDTFMPXQUSBYRL-UUOKFMHZSA-N 0.000 description 1
- HDECRAPHCDXMIJ-UHFFFAOYSA-N 2-methylbenzenesulfonyl chloride Chemical compound CC1=CC=CC=C1S(Cl)(=O)=O HDECRAPHCDXMIJ-UHFFFAOYSA-N 0.000 description 1
- IQUPABOKLQSFBK-UHFFFAOYSA-N 2-nitrophenol Chemical compound OC1=CC=CC=C1[N+]([O-])=O IQUPABOKLQSFBK-UHFFFAOYSA-N 0.000 description 1
- YNJSNEKCXVFDKW-UHFFFAOYSA-N 3-(5-amino-1h-indol-3-yl)-2-azaniumylpropanoate Chemical compound C1=C(N)C=C2C(CC(N)C(O)=O)=CNC2=C1 YNJSNEKCXVFDKW-UHFFFAOYSA-N 0.000 description 1
- CWNPOQFCIIFQDM-UHFFFAOYSA-N 3-nitrobenzyl alcohol Chemical compound OCC1=CC=CC([N+]([O-])=O)=C1 CWNPOQFCIIFQDM-UHFFFAOYSA-N 0.000 description 1
- SKDHHIUENRGTHK-UHFFFAOYSA-N 4-nitrobenzoyl chloride Chemical compound [O-][N+](=O)C1=CC=C(C(Cl)=O)C=C1 SKDHHIUENRGTHK-UHFFFAOYSA-N 0.000 description 1
- LQLQRFGHAALLLE-UHFFFAOYSA-N 5-bromouracil Chemical group BrC1=CNC(=O)NC1=O LQLQRFGHAALLLE-UHFFFAOYSA-N 0.000 description 1
- AGFIRQJZCNVMCW-UAKXSSHOSA-N 5-bromouridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 AGFIRQJZCNVMCW-UAKXSSHOSA-N 0.000 description 1
- 108091027075 5S-rRNA precursor Proteins 0.000 description 1
- VKKXEIQIGGPMHT-UHFFFAOYSA-N 7h-purine-2,8-diamine Chemical compound NC1=NC=C2NC(N)=NC2=N1 VKKXEIQIGGPMHT-UHFFFAOYSA-N 0.000 description 1
- CZVCGJBESNRLEQ-UHFFFAOYSA-N 7h-purine;pyrimidine Chemical compound C1=CN=CN=C1.C1=NC=C2NC=NC2=N1 CZVCGJBESNRLEQ-UHFFFAOYSA-N 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- UPNIUCXMHULFFK-UHFFFAOYSA-N CCC(O)OC(CCO[NH+](C)[O-])COC Chemical compound CCC(O)OC(CCO[NH+](C)[O-])COC UPNIUCXMHULFFK-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical group NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 241000725101 Clea Species 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 101100536354 Drosophila melanogaster tant gene Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000371 Esterases Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 1
- OXTYJSXVUGJSGM-HTVVRFAVSA-N N-Isobutyrylguanosine Chemical compound C1=2NC(NC(=O)C(C)C)=NC(=O)C=2N=CN1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OXTYJSXVUGJSGM-HTVVRFAVSA-N 0.000 description 1
- BQUZOXAZSKGJGC-VGKBRBPRSA-N N-[9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]purin-6-yl]naphthalene-2-carboxamide Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(NC(=O)C=3C=C4C=CC=CC4=CC=3)=C2N=C1 BQUZOXAZSKGJGC-VGKBRBPRSA-N 0.000 description 1
- GRSMWKLPSNHDHA-UHFFFAOYSA-N Naphthalic anhydride Chemical compound C1=CC(C(=O)OC2=O)=C3C2=CC=CC3=C1 GRSMWKLPSNHDHA-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 241001237728 Precis Species 0.000 description 1
- 102000002067 Protein Subunits Human genes 0.000 description 1
- 108010001267 Protein Subunits Proteins 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
- 102100036378 T-cell immunomodulatory protein Human genes 0.000 description 1
- 101710194900 T-cell immunomodulatory protein Proteins 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- HOSGEEHMYVXHFO-PCYKNENESA-N [(2s,3r,4s,5r)-2-(6-aminopurin-9-yl)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-(4-nitrophenyl)methanone Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@]1(C(=O)C=2C=CC(=CC=2)[N+]([O-])=O)O[C@H](CO)[C@@H](O)[C@H]1O HOSGEEHMYVXHFO-PCYKNENESA-N 0.000 description 1
- CKUAXEQHGKSLHN-UHFFFAOYSA-N [C].[N] Chemical compound [C].[N] CKUAXEQHGKSLHN-UHFFFAOYSA-N 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 235000012501 ammonium carbonate Nutrition 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- ARDXQWVIVIPNFO-UHFFFAOYSA-N benzhydryl (2-nitrophenyl) carbonate Chemical compound [O-][N+](=O)C1=CC=CC=C1OC(=O)OC(C=1C=CC=CC=1)C1=CC=CC=C1 ARDXQWVIVIPNFO-UHFFFAOYSA-N 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- HROGQYMZWGPHIB-UHFFFAOYSA-N bis(4-methoxyphenyl)methanamine Chemical compound C1=CC(OC)=CC=C1C(N)C1=CC=C(OC)C=C1 HROGQYMZWGPHIB-UHFFFAOYSA-N 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000001767 cationic compounds Chemical class 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- YGZSVWMBUCGDCV-UHFFFAOYSA-N chloro(methyl)silane Chemical compound C[SiH2]Cl YGZSVWMBUCGDCV-UHFFFAOYSA-N 0.000 description 1
- FOCAUTSVDIKZOP-UHFFFAOYSA-N chloroacetic acid Chemical compound OC(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-N 0.000 description 1
- 229940106681 chloroacetic acid Drugs 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000005289 controlled pore glass Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 150000002009 diols Chemical class 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- AFOSIXZFDONLBT-UHFFFAOYSA-N divinyl sulfone Chemical compound C=CS(=O)(=O)C=C AFOSIXZFDONLBT-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 125000006575 electron-withdrawing group Chemical group 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- WBJINCZRORDGAQ-UHFFFAOYSA-N ethyl formate Chemical compound CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 238000004896 high resolution mass spectrometry Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- LSACYLWPPQLVSM-UHFFFAOYSA-N isobutyric acid anhydride Chemical compound CC(C)C(=O)OC(=O)C(C)C LSACYLWPPQLVSM-UHFFFAOYSA-N 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- HZVOZRGWRWCICA-UHFFFAOYSA-N methanediyl Chemical compound [CH2] HZVOZRGWRWCICA-UHFFFAOYSA-N 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- VKTOBGBZBCELGC-UHFFFAOYSA-M methyl(triphenoxy)phosphanium;iodide Chemical compound [I-].C=1C=CC=CC=1O[P+](OC=1C=CC=CC=1)(C)OC1=CC=CC=C1 VKTOBGBZBCELGC-UHFFFAOYSA-M 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000037230 mobility Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- RCQVHNTXMQCQLT-AUIRFOQBSA-N n-[1-[(2r,6s)-6-[[chloro(dimethylamino)phosphoryl]oxymethyl]-4-tritylmorpholin-2-yl]-2-oxopyrimidin-4-yl]benzamide Chemical compound N=1C(=O)N([C@H]2CN(C[C@H](O2)COP(Cl)(=O)N(C)C)C(C=2C=CC=CC=2)(C=2C=CC=CC=2)C=2C=CC=CC=2)C=CC=1NC(=O)C1=CC=CC=C1 RCQVHNTXMQCQLT-AUIRFOQBSA-N 0.000 description 1
- WZKJANWNNBJHRS-UBEDBUPSSA-N n-[9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-oxo-3h-purin-2-yl]benzamide Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(NC(NC(=O)C=2C=CC=CC=2)=NC2=O)=C2N=C1 WZKJANWNNBJHRS-UBEDBUPSSA-N 0.000 description 1
- NZDWTKFDAUOODA-CNEMSGBDSA-N n-[9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]purin-6-yl]benzamide Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(NC(=O)C=3C=CC=CC=3)=C2N=C1 NZDWTKFDAUOODA-CNEMSGBDSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- OKXGHXHZNCJMSV-UHFFFAOYSA-N nitro phenyl carbonate Chemical compound [O-][N+](=O)OC(=O)OC1=CC=CC=C1 OKXGHXHZNCJMSV-UHFFFAOYSA-N 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 229940124276 oligodeoxyribonucleotide Drugs 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000003232 p-nitrobenzoyl group Chemical group [N+](=O)([O-])C1=CC=C(C(=O)*)C=C1 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000003444 phase transfer catalyst Substances 0.000 description 1
- JWGMRCQNJTZMAK-UHFFFAOYSA-N phenyl diphenylphosphorylmethanesulfonate Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)(=O)CS(=O)(=O)OC1=CC=CC=C1 JWGMRCQNJTZMAK-UHFFFAOYSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000004713 phosphodiesters Chemical class 0.000 description 1
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical group 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 238000010094 polymer processing Methods 0.000 description 1
- NNFCIKHAZHQZJG-UHFFFAOYSA-N potassium cyanide Chemical compound [K+].N#[C-] NNFCIKHAZHQZJG-UHFFFAOYSA-N 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- IGFXRKMLLMBKSA-UHFFFAOYSA-N purine Chemical compound N1=C[N]C2=NC=NC2=C1 IGFXRKMLLMBKSA-UHFFFAOYSA-N 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 230000006340 racemization Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- MHOVAHRLVXNVSD-UHFFFAOYSA-N rhodium atom Chemical compound [Rh] MHOVAHRLVXNVSD-UHFFFAOYSA-N 0.000 description 1
- 150000008223 ribosides Chemical class 0.000 description 1
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- DWRXFEITVBNRMK-JXOAFFINSA-N ribothymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 DWRXFEITVBNRMK-JXOAFFINSA-N 0.000 description 1
- 238000006798 ring closing metathesis reaction Methods 0.000 description 1
- QIHGNZUUVQXXNF-UHFFFAOYSA-N s-(4-nitrophenyl) chloromethanethioate Chemical compound [O-][N+](=O)C1=CC=C(SC(Cl)=O)C=C1 QIHGNZUUVQXXNF-UHFFFAOYSA-N 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- HYHCSLBZRBJJCH-UHFFFAOYSA-M sodium hydrosulfide Chemical compound [Na+].[SH-] HYHCSLBZRBJJCH-UHFFFAOYSA-M 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 239000011343 solid material Substances 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000002311 subsequent effect Effects 0.000 description 1
- 238000005670 sulfation reaction Methods 0.000 description 1
- 125000001273 sulfonato group Chemical group [O-]S(*)(=O)=O 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- YMBCJWGVCUEGHA-UHFFFAOYSA-M tetraethylammonium chloride Chemical compound [Cl-].CC[N+](CC)(CC)CC YMBCJWGVCUEGHA-UHFFFAOYSA-M 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 125000004665 trialkylsilyl group Chemical group 0.000 description 1
- ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 239000005051 trimethylchlorosilane Substances 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
- JABYJIQOLGWMQW-UHFFFAOYSA-N undec-4-ene Chemical compound CCCCCCC=CCCC JABYJIQOLGWMQW-UHFFFAOYSA-N 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G75/00—Macromolecular compounds obtained by reactions forming a linkage containing sulfur with or without nitrogen, oxygen, or carbon in the main chain of the macromolecule
- C08G75/18—Polysulfoxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/545—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
- C07K14/003—Peptide-nucleic acids (PNAs)
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G75/00—Macromolecular compounds obtained by reactions forming a linkage containing sulfur with or without nitrogen, oxygen, or carbon in the main chain of the macromolecule
- C08G75/20—Polysulfones
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G75/00—Macromolecular compounds obtained by reactions forming a linkage containing sulfur with or without nitrogen, oxygen, or carbon in the main chain of the macromolecule
- C08G75/24—Polysulfonates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6816—Hybridisation assays characterised by the detection means
- C12Q1/682—Signal amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6839—Triple helix formation or other higher order conformations in hybridisation assays
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J2219/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
- B01J2219/00274—Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
- B01J2219/00718—Type of compounds synthesised
- B01J2219/0072—Organic compounds
Definitions
- the present invention relates to morpholino-based polymers.
- Polymers which are designed for base-specific bind ⁇ ing to polynucleotides have significant potential both for in vitro detection of specific genetic sequences characteristic of pathogens (Ler an) and for in vivo inactivation of genetic sequences causing many diseases—particularly viral diseases (Belikova, Summerton) .
- Standard ribo- and deoxyribonucleotide polymers have been widely used both for detection of complementary genetic sequences, and more recently, for inactivating targeted genetic sequences.
- standard polynucle- otides suffer from a number of limitations when used for base-specific binding to target oligonucleotides. These limitations include (i) restricted passage across biolo ⁇ gical membranes, (ii) nuclease sensitivity, (iii) target binding which is sensitive to ionic concentration, and (iv) susceptibility to cellular strand-separating mecha ⁇ nisms.
- polymers cannot be used for base-specific binding to selected target sequence ⁇ olynucleotide analogs containing uncharged, but stereoisomeric, methylphospho- nate linkages between the deoxyribonucleoside subunits have been reported (Miller, 1979, 1980; Jayaraman; Murakami; Blake, 1985a, 1985b; Smith) . More recently a variety of analogous uncharged phosphoramidate-linked oligonucleotide analogs have also been reported (Froehler, 1988) . These polymers comprise deoxynucleo- sides linked by the 3'OH group of one subunit and the 5'OH group of another subunit via an uncharged chiral phosphorous-containing group.
- deoxyribonucleotide analogs having un- charged and achiral intersubunit linkages have been constructed (Stirchak 1987) . Since these polymers are stereoregular, all polymers having a given subunit se ⁇ quence will have the same Tm value for a given target nucleotide sequence, thus avoiding some of the limita- tions inherent in chirally-linked polymers. These un ⁇ charged, achiral deoxyribonucleoside-derived analogs, however, are limited by relatively high cost of starting materials.
- the invention includes a polymer composition con ⁇ taining morpholino ring structures of the form:
- the ring structures are linked together by uncharged, achiral linkages, one to three atoms long, joining the morpholino nitrogen of one ring structure to the 5' exocyclic carbon of an adjacent ring structure.
- Each ring structure includes a purine or pyrimidine base-pairing moiety P i which is effective to bind by base-specific hydrogen bonding to a base in a target sequence in a polynucleotide.
- Figure 1 shows a basic ⁇ -morpholino ring structure which is linked through uncharged, achiral linkages to form the polymer of the present invention.
- P is a purine or pyrimidine base pairing moiety.
- Figure 3 shows several preferred subunits having 5- atom (A) , six-atom (B and C) and seven-atom (D-G) linkin groups suitable for forming polymers.
- Y 0 or S.
- X 1 O or S
- X 2 O, S, CH 2 , or NR
- X 3 O, S, CH 2 , or NR 2 .
- X A 0, S, or NR,.
- X 5 0, S, CH 2 , NR 2 , or S0 2 .
- When n 1, X 5 is CH 2 or S0 2 .
- FIG. 1 shows a repeating subunit segment of exemplary morpholino-based polymers, designated A-A through G-G, constructed using subunits A-G, respectively, of Figure 3.
- Y, X,, X 2 , X 3 , X 4 , X 5 , n, R and R 2 are as in Figure 3.
- Figure 5 shows the steps in the synthesis of several types of morpholino subunits from a ribonucleoside.
- Figure 6 shows an alternative synthesis of the basic morpholino subunit.
- Figure 7 shows the steps in the synthesis of a mor- pholino subunit designed for construction of polymers with seven-atom repeating-unit backbones.
- Figure 8 shows the binding mode for 2-amine- containing purines to polar major-groove sites of respective target base-pairs (Figure 8a) and a representative base sequence of a duplex-binding polymer (Figure 8b) .
- a Adenine
- c cytosine
- g guanine
- t thymine
- u uracil
- D 2,6-Diaminopurine or 2-aminopurine
- G Guanine or thioguanine
- high specificity hydrogen bonding
- and : low specificity hydrogen bonding.
- Figure 9 shows the steps in linking two morpholino subunits through a carbamate linkage.
- Figure 10 shows the activation of sulfamic acid and coupling to form a sulfamide linkage.
- Figure 11 shows the activation of sulfonic acid and coupling to form a sulfonamide linkage.
- Figure 12 shows the steps in linking two morpholino subunits through a sulfamate linkage.
- Figure 13 shows the steps in linking two morpholino subunits through an amide linkage.
- Figure 14 shows a subunit coupling procedure which simultaneously generates the morpholino ring structure.
- Figure 15 shows thermal denaturation plots for poly(dC)/poly(dG) and. poly(C morpholino)/poly(dG) duplexes where the poly(C morpholino) was constructed according to the present invention.
- Figure 16 illustrates a diagnostic solid-support particle employing polymers of the present invention for use in a probe-diagnostic assay.
- the present invention includes a morpholino- based polymer which is designed for base-specific binding to a target sequence of a polynucleotide.
- the polymer is composed of morpholino-based ring structures which are linked together by uncharged, achiral linkages, one to three atoms long, joining the morpholino nitrogen of one structure to the 5' exocyclic carbon of an adjacent structure.
- Figure 1 shows the ⁇ -morpholino ring structures on which the polymer subunits are based, where the morpho ⁇ lino carbon atoms are numbered as in the parent ribose.
- the ring structure contains a 5' methylene attached to the A ' carbon in the ⁇ -orientation.
- Each ring structure includes a purine or pyrimidine or related hydrogen-bonding moiety, P A , attached to the backbone morpholine moiety through a linkage in the ⁇ - orientation.
- the purine hydrogen-bonding moieties or bases in ⁇ clude purines as well as purine-like planar ring struc ⁇ tures having a 5-6 fused ring in which one or more of the atoms, such as N3, N7, or N9 is replaced by a suitable atom, such as carbon.
- the pyrimidine moieties likewise include pyrimidines as well as pyrimidine-like planar 6- membered rings in which one or more of the atoms, such as NI, is replaced by a suitable atom, such as carbon.
- Preferred hydrogen-bonding moieties in the invention include the set of purines and pyrimidines shown in Figure 2.
- Each base includes at least two hydrogen- bonding sites specific for a polynucleotide base or base- pair.
- the purine 8 structures 1-3 are designed to bind to thymine or uracil bases; structures 7-8, to guanine bases; structures 4-6, to cytosine bases; and structure 9, to adenine bases.
- the polymers of the invention are also effective to bind to hydrogen-bonding sites accessible through the major-groove in duplex polynucleotides having mostly purine bases in one strand and mostly pyrimidine bases in the complementary strand, as discussed below.
- the H-bonding moiety of a duplex-binding polymer must hydrogen-bond to the N7 of its target base-pair in order to uniquely recognize a given base-pair in a target genetic duplex.
- the hydrogen-bonding moieties of the polymer preferably contain purines having an amine at the 2 position since that amine is suitably positioned for H- bonding to the N7 of the target base-pair.
- Structures 2 and 3 of Figure 2 provide for specific binding to a TA or UA base-pair, and Structures 4 and 6 provide for specific binding to a CG base-pair.
- Two bases which are parti ⁇ cularly useful in a duplex-binding polymer are 2,6-diami- nopurine (Structure 3) and guanine (Structure 4) .
- Figure 8 illustrates the binding of these two bases to the polar major-groove sites of their respective target base-pairs in duplex nucleic acids.
- the morpholino subunits of the instant invention are combined to form polymers by linking the subunits through stable, achiral, uncharged linkages.
- the linking group of a subunit usually includes a carbonyl or sulfonyl electrophile for reaction with a nucleophile of the subunit to which it is to be linked.
- duplex DNA and RNA duplexes are constructed according to parameters deter- mined by x-ray diffraction of oligodeoxyribonucleotides in the B-form and oligoribonucleotide-containing duplexes in the A-form.
- each of these constructed duplexes one of the two sugar phosphate backbones is removed, and the pro- spective backbone, including the morpholino ring and intersubunit linkage, is replaced, if possible, on the sites of the bases from which the original sugar-phos ⁇ phate backbone has been removed.
- Each resulting poly- nucleotide/polymer duplex is then examined for coplana- rity of the Watson/Crick base pairs, torsional and angle strain in the prospective binding polymer backbone, degree of distortion imposed on the nucleic acid strand, and interstrand and intrastrand nonbonded interactions.
- the linkages in the five-atom, six-atom, and seven-atom repeating-unit backbone contribute one, two, and three atoms to the backbone length, respectively.
- the linkage between the ring structures is (a) uncharged, (b) achi- ral, (c) stable, and (d) must permit adoption of a con ⁇ formation suitable for binding to the target polynucleo ⁇ tide.
- Figure 3 shows several preferred ⁇ -morpholino sub- unit types, including linkage groups, which meet the constraints and requirements outlined above. It will be appreciated that a polymer may contain more than one linkage type.
- Subunit A in Figure 3 contains a 1-atom sulfonyl linkage which forms the five atom repeating-unit backbone shown at A-A in Figure 4, where the morpholino rings are linked by a 1-atom sulfonamide linkage. It is noted here that the corresponding amide linkage (substituting a carbonyl for sulfonyl linkage) is not acceptable due to lack of rotational freedom about the carbon-nitrogen 11 tertiary amide bond.
- Subunits B and C in Figure 3 are designed for 6-atom repeating-unit backbones, as shown at B-B and C-C, re ⁇ spectively, in Figure 4.
- the atom X linking the 5' morpholino carbon to the carbonyl group may be oxygen or sulfur, but not nitrogen or carbon, due to lack of free rotation about the resultant intersubunit linkage.
- the nitrogen may be secondary (NH) , or tertiary (NR) , where R is a methyl or other group which does not interfere with polymer binding to the target polynucleotide (as can be easily determined from molecular modeling studies such as those outlined above) .
- Subunits D-G in Figure 3 are designed for 7-atom repeating-unit backbones, as shown at D-D through G-G, respectively, in Figure 4.
- the X can be a secondary nitrogen (NH) , or a tertiary nitrogen (NR) where R is a is a methyl or other group which does not interfere with polymer binding to the target polynucleo ⁇ tide, as can be determined from molecular modeling stu- dies.
- X in Structure E can be an oxygen since the 5'' methylene in such morpholino structures is surprisingly resistant to nucleophilic attack.
- morpholino-subunits are generally ribon- ucleosides.
- ribonucleosides containing hydro ⁇ gen-bonding moieties or bases are transformed to their morpholino derivatives to provide a complete set of subunits for polymer synthesis.
- a 1-haloribose or, preferably, a l ⁇ -bromoglucose derivative can be linked to a suitable base and this nucleoside analog then converted to the desired ⁇ -morpholino structure via peri- odate cleavage, and closing the resultant dialdehyde on a suitable amine.
- Example 1 Methods for base protecting a number of the more common ribonucleosides are given in Example 1.
- the methods detailed in the example are generally applicable for forming nucleosides with amine-protective groups.
- Standard base- protective groups used for nucleic acid chemistry are often suitable including the following groups: benzoyl for the N4 of cytosine (C) ; benzoyl or p-nitrobenzoyl for the N6 of adenine (A) ; acetyl, phenyl- acetyl or isobutyryl for the N2 of guanine (G) ; and N2,N6-bisisobutyryl for 2, 6-diaminopurine residues.
- These protective groups can be removed after polymer assembly by treatment with ammonium hydroxide.
- Suitable base protective groups removable by a strong non-nucleophilic base via a ⁇ -elimination mechanism in ⁇ clude: 2-(4-nitrophenyl)ethoxy carbonyl or 2- (phenyl sulfonyl)ethoxycarbonyl for both the N4 of C and the N6 of A; and the 9-fluorenyl methoxycarbonyl for the N2 of G and the N2 and N6 of 2, 6-diaminopurine.
- These groups can be removed after polymer assembly by treatment with the strong nonnucleophilic base 1,8-diazabicyclo[5.4.0]- undec-7-ene (DBU) , under stringently anhydrous condi ⁇ tions.
- a base-protected ribonucleoside is reacted with sodium periodate to form a transient 2', 3'-dialdehyde which then closes upon ammonia to form a morpholino-ring having 2' and 3' hydroxyl groups (numbered as in the parent ribose, see Figure 1) .
- the compound is then treated with sodium cyanoborohydride to reduce the ring hydroxyl groups.
- the ring nitrogen is preferably protected by trityl derivatization or by a benzhydraloxycarbonyl group for subsequent subunit coupling.
- the protective group can be added by reacting the morpholino subunit with trityl chloride or with nitrophenyl benzhydryl carbonate or by reacting the dialdehyde with a primary amine, as illustrated in Figure 6 and described in Example 3.
- the stereochemistry of the nucleoside starting material is retained as long as the pH of the reaction mixture at the iminium stage is not allowed to go above about 10.
- a variety of nitrogen sources can be used — including ammonia, ammo ⁇ nium hydroxide, ammonium carbonate, and ammonium bicar ⁇ bonate. Best results are obtained when the reaction solution is maintained near neutrality during the oxida ⁇ tion and morpholino ring closure reactions. This can be accomplished by continually titrating the reaction mix or, more conveniently, by using ammonium biborate as the ammonia source. When the solution is too acidic the yield of product is low and when it is too basic, side products (possibly due to epimerization of the 1' and/or 4' carbons) are produced which are difficult to separate from the desired product. It is also noted that the reducing agent can be added before, during, or after the 15 oxidation step with little noticeable effect on product yield.
- Ribonucleosides lacking base protection groups can also be successfully oxidized, ring closed, and reduced in aqueous solution to generate the morpholino ring.
- base protection the number and quantity of undesired side products frequently increases, par ⁇ ticularly in the case of cytidine.
- the subunits formed by the above methods contain a 5'-OH, SH, or amine which is modified, reacted with, and/or activated, to be suitable for coupling to a second morpholino subunit (see below) .
- Figure 5 shows the conversion of a 5'-OH of a morpholino subunit to a sulfonyl linking moiety to form a subunit (Structure 10) which is linked to form a 5-atom unit-length backbone polymer. Details of the subunit synthesis are given in Example 6.
- the subunits are designed to include a sulfonyl or carbonyl group attached directly or in- directly to the morpholino ring nitrogen, which is cou ⁇ pled to a 5' moiety of a second morpholino subunit (Fi ⁇ gures 12 and 13) .
- Subunits of this type are suitable for constructing morpholino polymers with 6-atom ( Figure 12) or 7-atom ( Figure 13) repeating-unit backbones.
- An example of the synthesis of a subunit suitable for 7-atom unit-length backbones having an amine at the 5'-carbon atom, and a sulfonyl group linked to the ring nitrogen through a methylene group is detailed in Example 9 (with reference to Figure 7) .
- Example 11 A similar synthesis, described in Example 10, is used to prepare morpholino subunits having a 5'-linked primary amine and an acetyl group linked to the ring nitrogen. This subunit is formed by coupling glycine, rather than AMSA, to the 5' ribonucleoside aldehyde 16 group. Examples 11 and 12 describe, with reference to Structure G of Figure 3, the preparation of non-morpho- lino subunits which are converted into morpholino struc ⁇ tures during polymer assembly.
- the subunits prepared as above are coupled, in a controlled, sequential manner, generally by activating the carbonyl or sulfonyl group on one subunit (having protected nitrogen groups) and contacting this activated subunit with another subunit having an unprotected nitro ⁇ gen.
- Different types of linkages such as those illust ⁇ rated below, may be employed in the construction of a single polymer.
- a number of closely related variations are possible for the carbonyl-containing linkages giving six-atom backbones, corresponding to Structure B-B in Figure 4.
- a typical activation and coupling reaction for forming a carbamate linkage (where X is 0 in Structure B-B) is illustrated in Figure 9.
- the simplest and most obvious morpholino-type bind ⁇ ing polymers are the carbamate-linked polymers (type B-B of Figure 4) where X is oxygen.
- the polymer has been found to effectively bind to its single-stranded DNA target sequence.
- the polymer exhibited unusual binding, as evi ⁇ denced by a highly atypical hypochromicity profile in the 320 to 230 nm spectral range and lack of a normal thermal denaturation.
- the sulfonyl group is activated with phosgene, and coupled to a second subunit having an unprotected ring nitrogen, as shown.
- the polymer assembly is con ⁇ tinued by deprotecting the morpholino ring nitrogen of the dimer, and reacting the dimer with a third activated subunit.
- the sulfamide linkage (corresponding to the linkage in structure C-C in Figure 4, where X is an amine) , is formed by sulfating the 5'-linked amine in a subunit having a protected morpholino ring nitrogen, and then activating with phosgene and reacting this subunit with a second subunit having an unprotected ring nitrogen, as illustrated in Figure 10. Details of the coupling reac ⁇ tion are given in Example 14.
- the sulfamate linkage (corresponding to the linkage in Structure C-C in Figure 4, wherein X is 0) is produced by sulfating the morpholino ring nitrogen of a 5' protec ⁇ ted subunit, then using phosgene to generate the sulf- amoyl chloride. This activated subunit is then mixed 19 with another subunit or oligomer having a free 5'OH. Coupling of the subunits is achieved either with a cata ⁇ lyst such as silver trifluoromethanesulfonate or use of a strong base to convert the 5' hydroxyl to the anionic form. Conversion of the 5' hydroxyl to the alkoxy can be achieved by KOH and a suitable phase transfer catalyst. This sulfamate coupling is illustrated in Figure 12 and details are given in Example 15.
- a number of 7-atom unit length backbones prepared from the morpholino-subunits allow even more flexibility in the construction of polymers which have specified distances between the base-pairing moieties.
- distances between the mor- pholino-subunits, and consequently between the base pairing moieties can be lengthened.
- Such lengthening of the intersubunit linkage is particularly useful when targeting duplex genetic sequences in a B conformation.
- the 7-atom backbone polymers can be readily syn- thesized from the subunits D-F constructed as above, employing the general coupling reactions described above.
- Structure D-D in Figure 4 can be produced by
- Structure E-E in Figure 4 can be produced by activating the sulfonyl group with phosgene, and coup ⁇ ling the activated subunit with a second subunit having an unprotected 5'-linked amine.
- Structure F-F in Figure 4 can be produced by a similar synthetic method in which the carboxyl group is activated with carbonyldiimidazole or a carbodiimide, and the activated compound is reacted with a second subunit 20 having an unprotected 5'-linked primary amine.
- a novel class of linkages corresponding to Structure G-G of Figure 4 can be produced by oxidizing vicinyl hydroxyls of one ribonucleoside subunit and closing the resultant dialdehyde on a primary amine of another sub- unit followed by reduction with cyanoborohydride.
- this same scheme could also be used to couple a secondary amine of one subunit and a mono-aldehyde of a second subunit; however, the coupling of a ribose-derived dialdehyde to a primary amine proceeds substantially faster and provides a. better yield.
- Examples 11 and 12 describe the synthesis of ribonucleosides containing a primary amine at the 5' . Their use in formation of mor ⁇ pholino polymers is illustrated in Figure 14.
- Example 18 outlines such a block assembly synthesis using monomers to form dimers, and dimers to form tetra ⁇ mers. The synthesis need not involve oligomers of equal size. A particular merit of this block assembly method is that each coupling product is roughly twice the length of its precursors, so purification of the product of each coupling is simplified. Example 18 details the assembly of a 4-subunit polymer formed by this method.
- the polymers may also be synthesized by stepwise subunit addition on a solid support.
- the op ⁇ timal synthetic approach often uses a combination of the solution and solid support assembly methods where dimers, trimers, or tetramers are synthesized by solution phase and subsequently assembled into the full-length polymer on a solid support, as described in Example 19.
- a solid support such as glass beads derivatized with acid-stable, long-chain cleavable lin- kers, are employed as the support material, and prepared for attachment of the first subunit, or block of sub- units, as described in Example 19.
- the glass beads are reacted with a subunit which generally has a readily cleavable protective group on a nitrogen. Whether the morpholino subunit is linked to the support via its morpholino nitrogen or a group at the 5' position depends on the direction of polymer synthesis, i.e., to which group the next subunit will be attached.
- any un- reacted nucleophilic sites can be capped by addition of a suitable capping reagent, such as p-nitrophenyl acetate or acetic anhydride, and thereafter the support is washed.
- a suitable capping reagent such as p-nitrophenyl acetate or acetic anhydride
- the protecting group on the nitrogen of the terminal subunit is removed, typically by acid treatment, and after neutralization, the support is reacted with an excess of the next-in- sequence subunit (or polymer unit) which is activated by one of the methods outlined above.
- One feature of the solid support assembly method is the need for high coupling efficiencies at each subunit addition step. This high coupling efficiency is general ⁇ ly achieved by addition of an excess of the activated subunit which maximizes the number of support-bound chains which are chain-elongated. 22
- Chain elongation is continued in this manner, with optional capping of failure sequences after each subunit addition, until the polymer of the desired length and sequence is achieved.
- the terminal backbone moiety may be reacted with a suitable charged or uncharged group, as described in Example 19.
- the polymer is then cleaved from the support, e.g., by treatment with either ammonium hydroxide or a non-nucleophilic base suitable for effecting ⁇ -elimination in the linker join ⁇ ing the polymer to the. support.
- the bases are deprotec ⁇ ted and the polymer is purified as described below and in Example 19.
- Binding polymers assembled in solution are typically base-deprotected by suspending in DMSO or DMF and layering on the suspension an equal volume of concentrated ammonium hydroxide. The prepara- tion is mixed with shaking and incubated at 30°C for 16 hrs. Workup includes removing the ammonia under reduced pressure. If a protective group (generally trityl or a related acid-labile moiety) is present, this group is cleaved and the crude polymer preparation is suspended in the appropriate buffer for purification (Example 19) .
- a protective group generally trityl or a related acid-labile moiety
- Binding polymers assembled by a solid-phase method (Example 19) wherein they are linked to the support via an ester linkage can be cleaved from the support by suspending the dried support in DMSO, layering on an equal volume of concentrated NH 4 OH, capping tightly, and slowly agitating for 16 hrs at 30°C. The solid support material is removed by filtration and the filtrate is treated as described above.
- binding polymers linked to the sup- 23 port via a ⁇ -elimination-sensitive linker can be cleaved from the support using a strong non-nucleophilic base 1,8 diazabicyclo(5.4.0.)undec-7-ene (DBU) in DMF.
- DBU diazabicyclo(5.4.0.)undec-7-ene
- Purification of the base-deprotected polymer is preferably carried out at pH 2.5 or pH 11, depending on the pKs of the base moieties in the polymer.
- pH 2.5 cytosine, adenine, and 2-6-diaminopurine moieties carry a positive charge and guanine carries a partial positive charge.
- pH 11 guanine, uracil and hypoxanthine carry a negative charge.
- the purification can be carried out by cation ex ⁇ change on a column of S-Sepharose fast-flow (Pharmacia) developed with a shallow NaCl gradient buffered at pH 2.5.
- the effluent is monitored at 254 nm and collected in a fraction collector.
- the full length polymer which elutes after the shorter failure sequences, can be fur ⁇ ther purified and desalted on a column of chromatogra ⁇ phic grade polypropylene (Polysciences Inc.), eluted with an aqueous gradient of acetonitrile adjusted to pH 2.5 with formic acid, with the eluant being monitored at 254 nm.
- the fractions containing the pure product are neutralized and dried under reduced pressure. Salts may be discarded by dissolving the polymer in trifluoroe- thanol, filtering, and evaporating the trifluoroethanol.
- the purification may be performed on an anion exchange column of Q Sepha- rose fast-flow (Pharmacia) developed with an aqueous pH 11 gradient of NaCl.
- the full-length polymer which 24 elutes after shorter failure sequences, is further puri ⁇ fied and desalted on a polypropylene column eluted with an aqueous pH 11 gradient of acetonitrile. Fractions containing the pure product are processed as above.
- the purification methods described above should be carried out so that polymers containing adenine base-pairing moieties are not exposed to pH 11 for more than a few hours at room temperature, to avoid potential base lability problems.
- the details of the purification methods are outlined in Example 19.
- polystyrene resin In neutral, aqueous solution, longer morpholino polymers may have solubilities only in the sub-micromolar range. Therefore, it may be advantageous to enhance polymer solubility by addition of one or more hydrophilic moieties, e.g., polyethylene glycol. For most of the polymer types disclosed herein, this can be accomplished by cleaving the terminal backbone protective group from the completed polymer, and reacting the polymer, with the bases still in the protected state, with excess of car- bonyldiimidazole-activated polyethylene glycol (PEG) . Thereafter the binding polymer is treated with ammonium hydroxide to remove the base-protected groups, and the polymer is purified as above.
- PEG car- bonyldiimidazole-activated polyethylene glycol
- solubiliza- tion is easily adjusted through proper selection of the PEG material.
- PEG fractions having average molecular weights of 200, 400, 600, 1,000, 1,540, 3,400, 4,000, 6,000, 7,500, and 18,500 daltons are commercially available (e.g., Polysciences, Inc.) with PEG1000 often providing the best solubilization.
- the solubilizing moiety may be linked to the polymer through a cleavable linkage, if desired, to allow the polymer to be released from the solubilizing agent, e.g., by esterase or pep- tidase enzymes. 25
- the polymer may be further derivatized or labeled according to known proce ⁇ dures.
- the polymer may be radiolabeled by preparing the polymer subunits from radiolabeled ribonu- cleosides or by attaching a radiolabeled amino acid at one terminus.
- the polymer may be readily derivatized, e.g., employing modifications of the above subunit cou ⁇ pling reactions, with enzymes, chromophoric groups, or the like, where the polymer is to be used as a diagnostic probe.
- the polymer may be derivatized with biomolecules which serve to target the polymers to speci ⁇ fic tissues or cell types.
- F. Structural Characterization Fully-protected binding polymers of moderate size (10 to 20 subunits) often give a strong molecular ion in FAB (Fast Atom Bombardment) mass spectroscopy, providing a key confirmation of the polymer length.
- FAB Fluor Atom Bombardment
- COSY-NMR two-dimensional correlated spec- troscopy
- Mobilities on ion exchange columns also provide information on the number of C + A base-pairing moieties in a polymer when purification is carried out at pH 2.5 and information on the number of G + U residues when the purification is run at pH 11. Structural verification is easiest when the polymers have been assembled from oligo- mer blocks, such as in Examples 18, 19 and 20, since any failure sequences then differ more substantially from the full-length sequences. 26
- the UV profiles of the polymers at pH 1, 7, and 13 can provide information about the relative nucleotide composition of the polymer.
- comparisons can be made between the melting curve of a regular nucleic acid duplex (such as p(dC) 6 /p(dG) 6 ) and the melting curve of a hybrid duplex containing a corresponding morpholino-based polymer (such as (morpholino-based C) 6 /p(dG) 6 ).
- Characterization of the synthetic intermediates and the full-length oligomer was achieved by proton NMR and negative ion FAB mass spec- troscopy. With these carbamates of the morpholino oligo ⁇ mers, the fragmentation of the oligomers is greatly suppressed so that little sequence information is avail ⁇ able.
- the parent ion signal is quite strong and allows confirmation of the composition of the morpholino oligomer (see Example 20) .
- High resolution mass spectro- metry of the morpholino-based poly C hexamer provided a satisfactory elemental analysis.
- the length of the oligomers could be ascertained by comparing the integration of the various signals. For example, in a dimer the two 2' protons were separated by 0.5 ppm and gave a 1.02/1 ratio of integrations and for the hexamer, this ratio was 4.65/1 against the expected value of 5/1.
- the bases of the above hexamer were deprotected by treatment with concentrated ammonia for 24 hours.
- the 4'- terminal morpholino ring nitrogen was liberated by treat ⁇ ment of the crude oligomer with 1% formic acid in tri- fluoroethanol.
- the hexamer was taken up in pH 2.5 buffer and puri ⁇ fied by cation exchange chromatography on S-Sepharose Fast FlowTM, eluting with potassium chloride gradients.
- the chromatograms showed one major peak comprising over 95% of the cytosine- containing materials in the mixture, and confirming that little or no cleavage of the oligomer occurs in the deprotection of the bases and the morpho- lino-amine.
- After neutralization the hexamer was desalted on a polypropylene column eluted with a water-acetonit- rile gradient.
- the purified hexamer was analyzed by ** H NMR.
- the assignment for the protons was made on the basis of a COSY plot.
- One cytosine base has signals that were found downfield relative to the other bases (8.04 to 7.65 and 6.78 to 5.85 ppm).
- the relative integrations of these peaks confirmed that the hexamer was deprotected and has been purified intact.
- the 5' protons were assigned to the signal at 4.35-4.15 downfield of the 1' proton signal at 4.14-3.90 ppm.
- the tailed hexamer was found to be freely soluble in pH 7.5 buffer in concentrations up to 2 mM. The characterization of the tailed hexamer by the 1 H NMR methods employed above was not possible. In the spectrum of the tailed hexamer there was no differentia ⁇ tion between the signals of the base protons, thus pre ⁇ cluding the assessment of the oligomer length. Addition- ally, the envelope containing the PEG tail signals ob ⁇ scured the majority of the signals of the morpholino rings. However, the ion exchange chromatography of the tailed hexamer gave one major peak indicating little or no cleavage of the oligomer during deprotection. The pattern of the chromatogram of the tailed hexamer was the same as found for the free hexamer, except that the tailed hexamer elutes faster than the free hexamer.
- the stability of complexes of the tailed hexamer with complementary nucleic acids was investigated by thermal denaturation experiments. Difference spectra between mixed and unmixed samples of the tailed hexamer and the selected phosphodiester complement were obtained from 14°C to 85°C and over the 320 to 260 nm range (see Example 20). As a control, the duplex of p)dC) 6 with 29 p(dG) 6 was thermally denatured.
- the difference UV spectrum of the tailed hexamer (morphC) 6 with p(dG) 6 was similar to that of the control DNA duplex, p(dC) 6 with p(dG) 6 , except that the amount of hypochromicity before denaturation of the (morphC) 6 /p(dG) 6 duplex was much greater than that of the control.
- the thermal denatura ⁇ tion of the p(morphC) 6 /p(dG) 6 duplex gave a T m value of 62.5°C (see Example 20 and Figure 15).
- the corresponding DNA/DNA duplex gave a Tm value of 26.5°C.
- the target-specific polymers of the invention can be used in a variety of diagnostic assays for detection of RNA or DNA having a given target sequence.
- the polymers are labeled with a suitable radiolabel or other detectable reporter group.
- Target polynucleotide typically a single stranded polynucleo ⁇ tide which is bound to a solid support, is reacted with the polymer under hybridization conditions, allowed to anneal, and then the sample is examined for the presence of polymer reporter group.
- the diagnostic assay can be carried out according to standard procedures, with suitable adjustment of the hybridization conditions to allow polymer hybridization with the target region.
- the polymer can be designed for hybridization with the target at a higher melting temperature than the comple ⁇ mentary polynucleotide strand, since polymer binding does not entail backbone charge repulsion effects. Therefore, the polymer can bind to the target at a temperature above ⁇ the normal polynucleotide melting temperature, an impor ⁇ tant advantage of the polymer over conventional oligo ⁇ nucleotide probes. This binding at elevated temperature minimizes the problem of competition for binding to the 30 target between the probe and any corresponding single- strand oligonucleotide which may be present in the diag ⁇ nostic mixture.
- the polymers are linked to a solid support, for capture of target RNA or DNA to the support.
- the solid support e.g., polymeric microparticles
- the solid support can be prepared by link ⁇ ing the polymers to the support according to the methods described above or by conventional derivatization proce- dures.
- this support may also serve as the assay support.
- the target polynucleotide molecules which are captured on the support by base-specific binding to the polymers can be detected on the basis of their backbone charge, since the support-bound polymers are themselves substantially uncharged.
- the assay system may also include polycationic reporter molecules which are designed to bind to the fully charged analyte back ⁇ bone, but not the uncharged (or substantially uncharged) polymer backbone, under selected binding conditions.
- the reporter molecules are com ⁇ posed of a polycationic moiety or tail designed to bind electrostatically to a fully charged polynucleotide, under conditions where the reporter does not bind to the less charged or uncharged binding polymer carried on the diagnostic reagent; one or more reporter groups may be attached to the tail, adapted to produce a signal by which the presence of the reporter can be detected.
- Methods for forming polycationic molecules and for at ⁇ taching reporter molecules to cationic compounds are known in the art. 31
- Each reporter molecule carries one or more reporter groups, and each polynucleotide can accommodate binding of typically several thousand or more reporter molecules.
- the system has an amplification factor, in terms of reporter signal per bound analyte molecule, of several orders of magnitude.
- the method has the advantage, noted above, that the polynucleotide binding reaction can be carried out under conditions in which binding competition with complementary nucleotide strands does not occur.
- the design considerations applied in preparing a polynucleotide binding polymer for use as a diagnostic reagent are governed by the nature of the target analyte and the reaction conditions under which the analyte is to be assayed.
- a first consideration there is selected a non-homopolymeric target base sequence against which the polymer is directed. This target sequence is gener ⁇ ally single-stranded and preferably unique to the ana ⁇ lyte being assayed.
- the probability of occurrence of a given n-base target sequence is approximately (1/4) n . Accordingly, a given n-base target sequence would be expected to occur approximately once in a polymer containing 4 n bases.
- the probability P that a 9-base target sequence will be found in a 20 kilobase polynucleotide is about 20xl0 3 /2xl0 5 or 0.08
- the probability that a 16-base target sequence will be present is about 20xl0 3 /4.3xl0 9 or 0.0000047.
- a polymer having 9-16 recognition moieties specific for a defined 9-16 base target sequence should have high speci ⁇ ficity for the target sequence in an assay mixture con- 32 taining only viral genomes, whose greatest complexities correspond to about 400K of unique-sequence bases.
- a 12 to 16 subunit polymer can provide adequate specificity for a viral or bacterial target sequence in an assay mixture containing viral and bacterial genomic material only; largest geno- mic sizes about 5,000 kilobases.
- a 16 to 22 subunit polymer can provide adequate specificity for a target sequence in a polynucleotide mixture containing mammalian genomic DNA material; genomic sizes of about 5 billion base pairs of unique-sequence DNA.
- the polymer/analyte binding affinity, and particu ⁇ larly the temperature at which the polymer just binds with the target sequence can be selectively varied according to the following criteria: (a) number of subunits in the polymer; (b) the number of hydrogen bonds that can be formed between the base-pairing moieties and the corresponding, complemen ⁇ tary bases of the analyte target sequence; (c) unit length of the polymer backbone; (d) the particular inter ⁇ subunit linkages; and (e) concentration of denaturants, such as formamide, which reduces the temperature of melting.
- the melting temperature of oligonucleotide duplexes in the 10 to 20 bp range in ⁇ creases roughly 3°C per additional base pair formed by two hydrogen bonds, and about 6°C per additional base pair formed by three hydrogen bonds. Therefore, the target sequence length originally selected to insure high binding specificity with the polymer may be extended to achieve a desired melting temperature under selected assay conditions.
- the target sequence may be selected to have a high per ⁇ centage of guanine plus cytosine bases to achieve a relatively high polymer/analyte melting temperature.
- a target sequence is selected which contains a relatively high percentage of adenine plus thymine bases.
- S the assay reagent
- the assay reagent is the. solid support having a number of binding polymers attached to its surface through spacer arms indicated by sawtooth lines.
- the target DNA in single strand form is reacted with the support-bound polymers under hybridization conditions, and the solid support is then washed to remove non-hybridized nucleic acid material.
- the washed support is then reacted with the repor ⁇ ter, under conditions which favor electrostatic binding of the reporter cationic moiety to the target DNA back ⁇ bone.
- the reporter shown in Figure 16 is a dicationic molecule having a reporter group R.
- the reagent After reaction with the reporter solution, typically at room temperature for 1-2 minutes, the reagent is washed to remove unbound reporter, and then the assay reagent is assessed for bound reporter.
- One approach in determining the amount of reporter associated with the reagent, particularly in the case of fluorescent or chromophoric reporter groups, is to elute the reporter from the reagent with a high salt solution and then assess the eluate for reporterhe polymer of the invention can undergo sequence-specific binding to duplex nucleic acids via base-pair-specific hydrogen bonding sites which are accessible through the major groove of 34 the double helix.
- the duplex binding polymer preferably includes 2-aminopurine or 2, 6-diamino ⁇ purine hydrogen bonding moieties for binding to T-A or U- A base pairs, and guanine or thioguanine hydrogen-bonding moieties for binding to C-G base pairs as illustrated in Figure 8A.
- the polymer of the invention can be .used for diagnostic assays of the types just described, but where the target nucleic acid is in nondenatured, duplex form.
- the polymers of the instant invention can be used in place of standard RNA or DNA oligomers for a number of standard laboratory procedures.
- mor ⁇ pholino-based polymers can be fixed to a solid support and used to isolate complementary nucleic acid sequences, for example, purification of a specific mRNA from a poly- A fraction (Goldberg et al) .
- the instant polymers are advantageous for such applications since they are inex ⁇ pensive and straightforward to prepare from activated subunits.
- Morpholino-based polymers can be easily and efficiently end-labelled by the inclusion in the last step of the polymer synthesis an activated and labelled morpholino- based subunit or, preferably, an 35 S-labelled methionine.
- the type of label to be used is dependent on the final application of the polymer, and includes radioactive ( 3 H, 1 C, 32 P, or 35 S) nucleosides and biotin. Labelled mor- 35 pholino-based oligonucleotide analogs can act as efficient probes in, for example, colony hybridization
- the polymers of the invention also have important potential use as therapeutic agents. Recently, uncharged anti-sense nucleic acid analogs, which are nearly iso- structural with DNA, have been used as anti-viral and anti-tumor agents.
- the polymers of the present invention provide several advantages over the more conventional anti-sense agents.
- the morpholino polymers are substantially less expensive to synthesize than oligonucleotides. This is due in part to the fact that the morpholino subunits used in polymer synthesis are derived from ribonucleo- sides, rather than the much more expensive deoxyribonu- cleosides. Also, as noted above, the coupling reaction between a phosphorous and an amine of a second subunit occurs under relatively mild conditions, so that protec ⁇ tion steps and other precautions needed to avoid unwanted reactions are simplified.
- the morpholino-based polymer is also more stable within the cell; the polymer backbone linkage is not susceptible to degradation by cellular nucleases.
- the uncharged morpholino polymer is more likely to efficiently enter cells than a charged oligonucleotide.
- the morpholino polymers of the present invention may be targeted against double-stranded genetic sequences in which one strand contains predominantly purines and the other strand contains predominantly pyrimidines (e.g., Figure 8B) .
- morpholino binding polymers targeted to the duplex have potential for also inactivating the mRNA.
- a polymer has the potential for inactivating key genetic sequences of a pathogen in both single-stranded and double-stranded forms.
- oligomers and oligomer combinations can perturb 37 protein synthesis in normal intact bacteria (where D is 2,6-Diaminopurine or adenine; G is Guanine; B is 5-Bromo- uracil, other 5-Halouracil or uracil; sequences are shown with their 5' end to the left) : DGG, BDDG, DDGG; DGGD; GGDG; GDGG; DGGB; GGBG; GGAGG; GGDGG; and the combinations BDD + GGDG; DDG + GDGG; DGG + DGGB; GGD + GGBG; BDDG + GDG; DDGG + DGG; DGGD + GGB GGDG + GBG; BDD + GGDG + GBG.
- RNA sequence which plays a key role in the metabolism of a target class of organisms but not a correspondingly important role in higher organisms should be broadly adaptable to a variety of pathogenic organisms (e.g., bacteria and fungi) having a cell wall which excludes the entrance of longer poly ⁇ mers.
- pathogenic organisms e.g., bacteria and fungi
- 1- ⁇ -D-ribofuranosyl)-2-pyrimidinone (2-hydroxy-pyri- midine riboside) is prepared by ..the procedure of Niedballa.
- 2-amino-9- ⁇ -D-ribofuranosyl) -1, 6-dihydro-6hpurine-6 -thione is prepared by the procedure of Fox. Dimethoxytrityl chloride, N-6-benzoyladeno- sine, N-4-benzoylcytidine, and N-2-benzoylguanosine are obtained from Sigma Chemicals. 9-fluorenylmethoxycar- bonyl chloride (FMOC chloride) , trimethylchlorosilane, isobutyric anhydride, 4-nitrobenzoyl chloride, naphthalic anhydride, and all organic solvents for reactions and chromatography were obtained from Aldrich Chemical Co.
- Suitable protective groups for this purpose include the naphthaloyl group (Dickshit) and the aminidine groups developed by McBride et al (1986) .
- dihalogenated electrophiles for subunit activation generally requires that the 06 of guanine moieties is protected; this protection is achieved using the diphenylcarboamoyl group
- N-2 9-fluorenylmethoxy- carbonyl derivative of guanosine is prepared by the procedure below which is general for the protection of nucleoside amino groups: guanosine (1 mmol) is suspended in pyridine (5 ml) and treated with tri'methyl- chlorosilane (5 mmol) .. After the solution is stirred for 15 minutes, 9-fluorenylmethoxycarbonyl chloride (5 mmol) is added and the solution is maintained at room temperature for 3 hours.
- N-2-acetylguanosine is obtained by the method of Reese.
- N-2-naphthaylguanosine is prepared by the method of Dikshit; this reference provides a general method for the protection of nucleoside amine groups.
- N-6 2-(4-nitrophenyl) -ethoxycarbonyl derivative is prepared by the method of Himmelsbach. 40
- N-6 (4-nitrobenzoyl)adenosine is prepared using the procedure above for FMOC-guanosine except that 4-nitro ⁇ benzoyl chloride is substituted for FMOC chloride.
- N- ⁇ 2-(phenylsulfonyl) -ethoxycarbonyl derivative is prepared by the procedure for FMOC guanosine except the 2- (phenylsulfonyl) -ethyl chloroformate (Balgobin) is used as the acylating agent and N-methylimidazole or pyridine is used as the solvent.
- N-6 naphthoyladenosine is prepared by the method of Dikshit; this reference provides a general method for the protection of nucleoside amine groups.
- N-2,N-6-bis (9-fluorenylmethoxycarbonyl) derivative of 2,6-diaminopurine riboside is prepared by the general procedure described for guanosine.
- N-2,N-6-bis (isobutyryl) derivative is prepared by the general procedure described for guanosine.
- N-2 (9-fluorenylmethoxycarbonyl) derivative of thioguanosine is prepared by the general procedure described for guanosine.
- N3 of the uracil moiety 5'0-tritylated uridine-2' ,3'-acetonide is converted to the N3 anisoyl derivative by the procedure of Kamimura et al (1983) . The product is then treated with hot 80% acetic acid or 0.1 N HC1 in THF to cleave the protective groups on the ribose moiety. 41
- Example 2 Synthesis of 5'-OH Morpholino Subunits The steps in the method are illustrated in Figure 5, with reference to structures shown in Figure 5.
- the base-protected ribonucleoside is oxidized with periodate to a 2'-3' dialdehyde (Structure 1).
- the dialdehyde is closed on ammonia or primary amine (Structure 2) and the 2' and 3' hydroxyls (numbered as in the parent ribose) are removed by reduction with cyanoborohydride (Structure 3) .
- the base-protected morpholino subunit is then pro ⁇ tected at the annular nitrogen of the morpholino ring using trityl chloride or benzyhydral nitrophenyl carbonate (Structure 4) .
- the 5' hydroxyl 42 can be protected with a trialkylsilyl group.
- a protection step to 2 liters of acetonitrile is added, with stirring, 0.1 mole of the tosylate salt from above followed by 0.26 mole of tri- ethylamine and 0.15 mole of trityl chloride. The mixture is covered and stirred for 1 hour at room temperature after which 100 ml methanol is added, followed by stir ⁇ ring for 15 minutes. After drying by rotovaping, 400 ml of methanol is added. After the solid is thoroughly sus- pended as a slurry, 5 liters of water is added, the mixture is stirred for 30 minutes and filtered. The solid is washed with 1 liter of water, filtered, and dried under vacuum.
- the solid is resuspended in 500 ml of dichloromethane, filtered, and rotovaped until precipitation just begins, after which 1 liter of hexane is added and stirred for 15 minutes. The solid is removed by filtering, and dried under vacuum.
- Example 3 Alternative Synthesis of Morpholino Subunits This example describes an alternative preparation of a morpholino subunit containing an acid-labile moiety linked to the morpholino ring nitrogen. The steps are described with respect to Figure 6.
- the subunit is prepared by oxidizing a ribonucleoside with periodate, as in Example 2, and closing the resultant dialdehyde (Structure 1) on the primary amine 4,4'-dimethoxybenzhydrylamine (which can be prepared by the method of Greenlee, 1984) buffered with benzotriazole, or p-nitrophenol. Reduction with sodium cyanoborohydride, carried out as in Example 2, gives a 43 morpholino subunit (Structure 2) having a 4,4'- dimethoxybenzhydryl group on the morpholino nitrogen.
- This procedure is particularly useful for preparing morpholino subunits from ribonucleosides which do not have a protective group on the base (e.g., uridine) .
- Structure 3 of Figure 5 is silylated with t-butyldi- methlsilyl chloride to give Structure 1 of Figure 12.
- salts of sulfamic acids e.g., Structure 7 of Figure 5, and Structure 2 of Figure 12
- salts of sulfonic acids e.g., Structure 10 of Figure 5, and Structure 5 of Figure 7
- silica gel using triethylamine/methanol/chloroform mixtures if the silica is first pre-eluted with 2% triethylamine in chloroform.
- the 5'hydroxyl of the doubly-protected morpholino subunit (Structure 4, Figure 5) can be converted to the amine as follows. To 500 ml of DMSO is added 1.0 mole of 44 pyridine (Pyr) , 0.5 mole of triflouroacetic acid (TFA) , and 0.1 mole of the morpholino subunit. The mixture is stirred until dissolved, and then 0.5 mole of diisopro- pylcarbodiimide (DIC) or dicyclohexylcarbodiimide (DCC) is added. After 2 hours the reaction mixture is added to 8 liters of rapidly stirred brine, which is stirred for 30 minutes and filtered.
- DIC diisopro- pylcarbodiimide
- DCC dicyclohexylcarbodiimide
- the solid is dried briefly, washed with 1 liter of ice cold hexanes, filtered, and the solid is added to 0.2 mole of sodium cyanoborohydride in 1 liter of methanol, stirred for 10 minutes, 0.4 mole of benzotriazole or p-nitrophenol is added, followed by 0.2 mole of methylamine (40% in H 2 0) and the preparation is stirred four hours at room temperature [Note: the benzotriazole or p-nitrophenol buffers the reaction mixture to prevent racemization at the 4' carbon of the subunit at the iminium stage of the reductive alkyla- tion] .
- reaction mixture is poured into 5 liters of water, stirred until a good precipitate forms, and the solid (Structure 6, Figure 5) is collected and dried.
- This dried product is next suspended in DMF and 4 equivalents of S0 3 /pyridine complex is added. Over a period of several hours, 8 equivalents of triethylamine is added dropwise with stirring. After an additional two hours the preparation is dumped into a large volume of brine and the solid collected by filtration and dried.
- This sulfamic acid preparation is then purified by silica gel chromatography.
- the morpholino nitrogen should be protected as a carbamate (e.g., Structure 4 of Figure 5) instead of with a trityl group.
- the 5' hydroxyl of the doubly-protected morpholino subunit is converted to a sulfhydral as follows. 0.1 mole of the 5'-hydroxyl subunit (Structure 4, Figure 5) is added to 1 liter of pyridine followed by 0.12 mole of toluenesulfonylchloride, and stirred for 3 hours at room temperature to give Structure 8 of Figure 5. After removing the pyridine by rotovapping, 0.5 mole of fresh sodium hydrosulfide in 1 liter of methanol/DMF containing Nal is added and the mixture is stirred at room temperature overnight.
- Example 7 Synthesis of 5' Methylenesulfonate Subunit This example describes the preparation of a subunit suitable for use in preparing polymers with 6-atom unit- length backbones having sulfonamide linkages.
- Example 8 Preparation of 5'-aminomethanesulfonate Subunit This example describes the preparation of a subunit suitable for use in preparing polymers with 7-atom unit- length backbones having sulfonamide linkages.
- Example 9 Synthesis of N-methanesulfonate Subunit This example describes the preparation of a subunit containing a sulfonate moiety linked to the morpholino ring nitrogen suitable for preparing polymers with 7-atom unit-length backbones. The steps are described with respect to structures shown in Figure 7.
- the subunit is prepared by oxidizing a ribonucleoside (Structure 1) with periodate in the 47 presence of aminomethanesulfonic acid (AMSA) and N-ethyl morpholine. The oxidation is followed by reduction with sodium cyanoborohydride in the presence of benzotriazole (used to buffer the reaction mix) to give a morpholino subunit having a methane sulfonic acid group on the morpholino nitrogen (Structure 2) .
- the 5'hydroxyl (numbered as in the parent ribose) is then oxidized to an aldehyde (Structure 3) and converted to a primary or secondary amine (Structure 4) by reductive alkylation as in Example 5, and tritylated to give the desired subunit of Structure 5.
- N-methanecarboxylate Subunit This example describes the preparation of a subunit containing a carboxylate moiety linked via a methylene to the morpholino ring nitrogen suitable for preparing polymers with 7-atom unit-length backbones.
- the subnit can be prepared essentially as in Example 9, but substituting glycine for aminomethanesulfonic acid. Alternatively, it is generally more convenient to prepare it starting with Structure 3 of Figure 5. This is readily alkylated on the morpholino ring nitrogen using chloroacetic acid or bromoacetic acid. The 5' hydroxyl is then converted to a primary amine and tritylated as in Example 9.
- N4-Benzoylcytidine-2',3'-acetonide (1 mmole) was converted to the 5'-Iodo derivative by reaction with methyltriphenoxyphosphonium iodide in DMF (20ml) under argon at room temperature for 20 hours. Methanol (5 ml) was added and after 30 minutes the mixture was evaporated in vacuo. The residue was dissolved in ethyl acetate and 48 the solution washed with aqueous sodium thiosulfate, then brine. After drying with sodium sulfate and evaporation of the solvent the product was purified by chromatography on silica using isopropanol/chloroform mixtures.
- the iodo compound (1 mmole) is reacted with potassium cyanide (5 mmol) in Dimethylsulfoxide for 12 hours under argon atmosphere.
- the nitrile is isolated by pouring the reaction mixture into saturated aqueous sodium dihydrogen phosphate. The mixture is extracted with ethyl acetate, the organic layer washed well with water, dried over sodium sulfate and evaporated in vacuo.
- the nitrile is purified by chromatography on silica using chloroform/ethylacetate mixtures.
- the nitrile from the previous paragraph is treated with a mixture of equal parts of DMF and aqueous ammonia at 25°C for 24 hours.
- the mixture is treated with rhodium on alumina and hydrogenated in a hydrogen atmosphere to provide the amine.
- the residue is dissolved in 0.2 N HC1 to cleave the acetonide.
- the amine diol may be purified by ion exchange on a cation exchange column.
- the amine moiety may be tritylated as in Example 2 to give the amine-protected 2',3'-diol.
- the sulfide from the previous paragraph was oxidized with excess perbenzoic acid in chloroform to the sulfone. This was immediately, treated with 0.2 N HCl/dioxane to cleave the acetonide group.
- the diol was purified by chromatography on silica using methanol/chloroform mixtures.
- the diol sulfone from above is reduced with hydrogen/ palladium on carbon in DMF/methanol in the presence of acetic acid to remove the carbobenzoxy group.
- One equivalent of tosic acid is added to the mix, the solution is filtered and the filtrate evaporated.
- the pendant amine is tritylated as in Example 2 to give the amine-protected 2',3'-diol.
- the benzoyl group on the base is removed by treatment with equal amounts of DMF and CMC aqueous ammonia at room temperature for 24 hours.
- Example 13 Activation and Coupling To Give Carbamate Linkage
- This example describes the activation of morpholino- subunits, such as prepared in Example 2, and their sub- sequent coupling via a carbamate linkage to yield a 6- atom unit-length backbone.
- the example is described with reference to the Structures in Figure 9. Activation Step
- the activated subunit (Structure 2) is added to the DMF solution of unprotected subunit and incubated at room temperature for 1 hour to give coupled product (Structure 4) .
- the activated subunit (Structure 2) is added to the DMF solution of deprotected subunit (Structure 3) and incubated at room temperature for 1 hour to give coupled product (Structure 4) .
- the activated subunit (Structure 2) is added to the DMF solution of deprotected subunit (Structure 3) and incubated at room temperature for 1 hour to give coupled product (Structure 4) .
- This example describes the oxidation of a ribonu ⁇ cleoside containing a protected amine linked through the 5' methylene, such as prepared in Example 11 or 12, and 54 coupling to the unprotected amine of another subunit to simultaneously form a morpholino ring structure and join the subunits.
- the example is described with reference to the structures in Figure 14.
- Tritylated subunit (Structure 2) in methanol, is reacted with 11 mmole of NaI0 4 to give the dialdehyde (Structure 3) .
- a weak acid is used to neutralize the amine component (Structure 1) and buffer the reaction in this coupling step.
- Weak acids which have been found suitable for this purpose are: carbonic, ortho and para nitrophenol, and benzotriazole. Accordingly, the dialdehyde (Structure 3) is combined with a suitable salt of Structure 1 in a water/methanol mixture to give the coupled product (Structure 4) .
- Oligomer of the Sequence 5'-CUGU This example describes the assembly of a short oligomer containing a sulfamide-linked backbone (Structure C-C of Figure 4, wherein X 2 is a nitrogen) coupled as in Example 14.
- This solution assembly method is particularly useful for large-scale synthesis of short oligomers suitable for subsequent assembly into longer oligomers using the solid-phase method (Example 19) .
- 5'Sulfamic acid subunits of C, U, and G tritylated on the morpholino ring nitrogen are prepared as in Example 5.
- the U subunit is then activated by conversion to the sulfamoyl chloride form as in Example 14.
- the C subunit and the G subunit are deprotected as in Example 14.
- the deprotected C component (1.1 m mole) is dissolved in 5 ml DMF and 0.3 ml TEA, followed by addition of 1.0 m mole of the activated U component.
- the deprotected G component is reacted with the activated U component.
- the CU dimer is deprotected as in Example 14. Better yields of tetramer are obtained when the dimer, after the initial ether precipitation, is thoroughly resuspended in about 2 ml of trifluoroethanol, reprecipitated with 30 ml of ether, and then resuspended in DMF and TEA for subsequent coupling.
- Coupling to form the desired tetramer entails simply adding 1 m mole of activated GU dimer to the DMF/TEA 56 solution containing 1.1 m mole of deprotected CU dimer.
- Example 19 Solid-Phase Assembly of Sulfamide-Linked Morpholino Polymer This example describes the use of tetramer blocks, prepared as per Example 18, for solid-phase assembly of a morpholino polymer containing sulfamide intersubunit linkages. Solid-phase assembly provides a rapid method for assembly of longer binding polymers. The use of short oligomer blocks instead of monomers greatly simplifies separation of the final product from failure sequences.
- This product is purified by silica gel chromatography and then added to a suitable solid support containing primary amine functions (e.g., Long Chain Alkyl Amine Controlled Pore Glass, from Pierce of Rockford, Illinois) .
- This procedure links the first tritylated subunit to the synthesis support via a linker which is stable to the acidic conditions used for detritylations, but which can be readily cleaved via a beta elimination mechanism using a strong non- nucleophilic base, such as a 1, 8- Diazabicyclo[5.4.0]undec-7-ene (DBU) .
- a linker which is stable to the acidic conditions used for detritylations, but which can be readily cleaved via a beta elimination mechanism using a strong non- nucleophilic base, such as a 1, 8- Diazabicyclo[5.4.0]undec-7-ene (DBU) .
- DBU 1, 8- Diazabicyclo[5.4.0]undec-7-ene
- the coupling cycle for addition of each subunit or oligomer block generally includes deprotection of the terminal backbone moiety, a thorough wash, addition of the next activated subunit or oligomer block, and a thorough wash.
- the coupling efficiency for each addition can be determined by collecting each detritylation solu ⁇ tion and subsequent wash and quantitating the trityl therein.
- Detritylation in the present sufamide-linked polymer is achieved by slowly passing through the column a solu- tion of 2% formic acid in trifluoroethanol (or 2% dichlo- roacetic acid in dicloromethane) until the eluant no longer tests positive for trityl (readily determined by adding a drop of eluant to 100 ⁇ l methanesulfonic acid and inspecting for the visible yellow color characteris- tic of the trityl carbonium ion) . Thereafter the support is thoroughly washed to remove excess acid and then washed with DMF containing 1% by volume of N-ethylmor- pholine (NEM) .
- NEM N-ethylmor- pholine
- Coupling of the next subunit or oligomer block in the desired polymer sequence entails addition of 58 a concentrated DMF solution containing the activated monomer or oligomer and a molar equivalent of NEM. Since the rate of coupling is a function of concentration it is desirable to add a substantial molar excess of monomer or oligomer relative to the concentration of support-bound growing chains. A 5-fold molar excess of activated monomer or oligomer over that of the growing chains often gives acceptable coupling efficiencies.
- Required cou ⁇ pling times can be determined by removing at specified time intervals small defined quantities of the support material, thoroughly washing, treating the support with methanesulfonic acid, and then spectrophotometrically quantitating the released trityl carbonium ion (molar absorbance at 409 nm is 45,000 in methane sulfonic acid).
- the unreacted subunit or oligomer is washed from the support with DMF.
- the un ⁇ reacted subunit is generally recovered, purified by chromatography, and reused for later synthesis.
- the sup ⁇ port is thoroughly washed with the solvent trifluoro- ethanol, without added acid. Washing is complete when addition of a drop of the wash eluant to 100 ⁇ l methane ⁇ sulfonic acid shows no yellow color.
- the synthesis support is treated with 20% DBU in DMF for two hours at room temperature in the presence of 2% diethylmalonate, to tie up the vinylsulfone generated during cleavage of the linker.
- the released morpholino polymer is washed from the support with DMF and precipi ⁇ tated by adding ethylacetate.
- the precipitate contains full-length polymer having a 5' methylamine, the bases 59 still protected and a trityl moiety on the terminal morpholino nitrogen.
- the precipitate con ⁇ tains small amounts of failure sequences.
- the polymer size can be confirmed by positive ion fast atom mass spectrometry.
- solubilizing groups to the morpholino polymer this can be done conveniently by detritylting the N-terminal morpholino nitrogen using 2% formic acid in trifluoroethanol.
- solubilizing moiet is to be added, then the 5'me- thylamine is acetylated with acetic anhydride before the detritylation step.
- Polyethylene glycol 1000 (from Polysciences Inc., Warrington, Pennsylvania, USA) is thoroughly dried by dissolving in dry DMF and then evaporating the solvent under vacuum. The solid is resuspended in a minimal volume of pure dry DMF and 0.5 mole equivalent (relative to PEG 1000) of bis (p-nitrophenyl)carbonate and 1 mole equivalent of TEA is added and the preparation sealed and incubated overnight at 30°C to give p-nitrophenyl car ⁇ bonate-activated PEG 1000.
- the full-length morpholino polymer which has been detritylated is added to a substantial molar excess (generally 10- to 20-fold) of activated PEG 1000 and incubated two hours at room temperature. Unreacted PEG 1000 is removed by precipitation of the tailed polymer with ether.
- Purification at pH 2.5 is general for binding poly- ers wherein about half or more of the base-pairing moieties are of types 1, 2, 3, and 7 of Figure 2.
- the eluant containing the polymer is desalted by loading on an equivalent-sized column packed with 35 micron chromatographic polypropylene (Cat. No. 4342 from Polysciences, Inc.) and washing thoroughly with solvent A. If baseline separation was achieved in the foregoing cation exchange chromatography, then pure product is obtained simply by eluting with solvent C; otherwise, the product is eluted with a linear gradient ranging from 100% solvent A to 100% solvent C. When the product is somewhat acid sensitive the solution is neutralized with dilute NaOH before drying under reduced pressure. Purification at high pH Purification at pH 11 is generally used for binding polymers wherein above half or more of the base-pairing moieties are at type 4, 5, 6 and 9 of Figure 2.
- N,N-diethylethanolamine (Aldrich) is added to degas ⁇ sed water to adjust the pH to 11.0 (solvent D) .
- a cor- responding pH 11 solution 2 N in KC1 (solvent E) is prepared.
- a third pH 11 solution is prepared by mixing Solvent D 1:1 by volume with chromatographic grade aceto ⁇ nitrile (solvent F) .
- the fully-deprotected binding polymer, prepared as above, is suspended in solvent D at a concentration of about 1 mg/ml.
- the pH is adjusted, if necessary, to pH 11 with N,N-diethylethanol-amine.
- About 10 ml of this polymer solution is placed on a chromatography column 1 cm in diameter and 10 to 20 cm in length which is packed with anion-exchange support Q-Sepharose Fast Flow (Phar ⁇ macia) . After washing the column thoroughly with solvent D, the column is eluted with a linear gradient ranging from 100% solvent D to 100% solvent E and the eluant is monitored at 254 nm. 62
- the eluant containing the polymer is desalted by loading on an equivalent-sized column of polypropylene and washing thoroughly with solvent D. If baseline separation is achieved in the foregoing anion exchange chromatography then pure product is obtained simply by eluting with solvent F; otherwise, the product is eluted with a linear gradient ranging from 100% solvent D to 100% solvent F. Fractions containing the product are dried under reduced pressure. H. Sequence confirmation
- One method for confirming the sequence of the poly- mer is to take a small portion of the growing polymer after coupling each oligomer block and use mass spectral analysis to follow the elongation of the polymer. This method is applicable except for those rare cases where two blocks used in the synthesis happen to have exactly the same mass.
- An indirect method to help verify the correctness of the polymer subunit sequence is to pair the morpholino polymer with its complementary DNA (whose sequence can be confirmed by established methods) and with DNA sequences 63 which might have resulted if the blocks were assembled in the wrong order. Pairing between the polymer and DNA can be evaluated by the occurrence of a hypochromic shift in the 240 to 290 nm wavelength region; such a shift occurs only between the polymer and its complementary sequence.
- the polymer/DNA duplex can also be distinguished from any partially-mismatched duplex by slowly raising the temper ⁇ ature while monitoring the absorbance in the 240 to 290 nm wavelength region.
- the perfect duplex will have a melting temperature (corresponding to a 50% reduction in the hypochromicity) generally 10 degrees or more above that of any mismatched duplex.
- This example describes the preparation, structural confirmation, and assessment of target binding affinity of a simple carbamate-linked morpholino polymer.
- a carbamate-linked morpholino hexamer wherein all P x moieties are cytosines is assembled from dimer prepared as in Example 13.
- One third of that dimer preparation is detritylated (as in Example 13) and the remaining two thirds is activated (again as in Example 13) .
- Half of the activated dimer is reacted with the detritylated dimer to give tetramer, which is purified by silica gel chromatography developed with 6% methanol/94%chloroform.
- the tetramer is detritylated and reacted with the remain ⁇ ing activated dimer to give hexamer, which is purified by silica gel chromatography developed with 10% methanol/90% 64 chloroform.
- a 260 units of DNA target p(dG) 6 purchased from Pharmacia LKB, is dis ⁇ solved in 50 microliters of deionized water and 200 65 microliters of DMSO (spectrophotometric grade from Aid- rich Chem. Co.) is added (stock solution A).
- DMSO spectrophotometric grade from Aid- rich Chem. Co.
- stock solution B 1.8 mg of the tailed morpholino hexamer, c(mC) 6 -PEG1000, is dis ⁇ solved in 0.36 ml of spectrophotometric grade DMSO (stock solution B) .
- Phosphate buffer is prepared by adjusting the pH of 0.05 N NaOH to 7.4 using phosphoric acid, followed by addition of EDTA to a final concentration of 0.001 N (Buffer C) .
- Stock solutions A and B are assayed for the actual concentration of polymer by UV; the absorbance of stock solution A is measured in 0.1 N NaOH and stock solution B is measured in 0.1 N HC1. Measurements at these pH extremes minimize base stacking and other polymer inter ⁇ actions which can give absorbance values not proportional to the component monomers.
- Stock solutions A and B are diluted with Buffer C to give solutions of a final con ⁇ centration of 10 micromolar in polymer. The required dilutions are calculated using molar absorbencies of 65,000 for solution A, p(dG)6, and 77,100 for solution B, c(mC * ) 6 -PEG1000.
- Using four matched quartz cuvettes one is filled with 0.5 ml of 10 micromolar p(dG) 6 and 0.5 ml of Buffer C and a second is filled with 0.5 ml of 10 micromolar c(mC * ) 6 -PEG1000 and 0.5 ml of Buffer C. These two cu- vettes are placed in the reference beam of the tempera ⁇ ture-controlled cell housing. Next, a third cuvette is filled with 1 ml of Buffer C and a fourth is filled with 0.5 ml of 10 micromolar p(dG) 6 and 0.5 ml of 10 micromo ⁇ lar c(mC * ) 6 -PEG1000.
- Example 21 Solution-phase Assembly of Simple Prototype Sulfamide-linked Morpholino Polymer and Assessment of Binding to RNA and DNA Target Sequences This example describes the preparation and target binding of a simple sulfamide-linked morpholino polymer.
- a sulfamide-linked morpholino hexamer, wherein all P ⁇ moieties are cytosines, is assembled from 5'sulfated 67 methylamine subunit (R is methyl) prepared as in Example 5 and activated as in Example 14. Activated monomer is reacted in DMF with an excess of 5'OH subunit lacking a protective group on the morpholino nitrogen, prepared as in Example 2. The resultant dimer is purified by silica gel chromatography developed with methanol/chloroform mixtures and then deprotected as in Example 14. This product is then reacted with more activated monomer, the chain-extended product purified, and deprotected as above. This cycle is repeated until hexamer is obtained. Before the last .detritylation, the mass of the hexamer was confirmed by negative ion FAB mass spectro ⁇ scopy, which showed M-l 2598.9 (100).
- the sulfamide-linked hexamer is tailed with PEG-1000, deprotected, purified, and tested for binding to its DNA target, p(dG) 6 , and its RNA tar ⁇ get, poly(G) .
- the target-binding affinities, expressed in T m values, for this sulfamide-linked hexamer, referred to as s (mC) 6 are tabulated below, along with the cor- responding target-binding affinities for the analogous DNA oligomer, p(dC) ⁇ .
- T_ value (° C.) s (mC) 6 /p(dG) 6 25 p(dC) 6 /p(dG) ⁇ 29
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE69032167T DE69032167T2 (en) | 1989-12-20 | 1990-12-20 | UNCHARGED POLYMERS WITH MORPHOLINO UNITS AND WITH ACHIRAL BINDINGS BETWEEN THESE UNITS |
EP91902401A EP0506845B1 (en) | 1989-12-20 | 1990-12-20 | Uncharged morpholino-based polymers having achiral intersubunit linkages |
KR1019920701480A KR0154317B1 (en) | 1989-12-20 | 1990-12-20 | Uncharged morpholino-based polymers having achiral intersubunit linkages |
JP50289391A JP3172174B2 (en) | 1989-12-20 | 1990-12-20 | Uncharged morpholino-based polymerase with achiral internal subunit linkage |
AU71587/91A AU654473B2 (en) | 1989-12-20 | 1990-12-20 | Uncharged morpholino-based polymers having achiral intersubunit linkages |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US07/454,055 US5034506A (en) | 1985-03-15 | 1989-12-20 | Uncharged morpholino-based polymers having achiral intersubunit linkages |
US454,055 | 1989-12-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1991009073A1 true WO1991009073A1 (en) | 1991-06-27 |
Family
ID=23803109
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1990/007565 WO1991009073A1 (en) | 1989-12-20 | 1990-12-20 | Uncharged morpholino-based polymers having achiral intersubunit linkages |
Country Status (9)
Country | Link |
---|---|
US (1) | US5034506A (en) |
EP (1) | EP0506845B1 (en) |
JP (1) | JP3172174B2 (en) |
KR (1) | KR0154317B1 (en) |
AT (1) | ATE164081T1 (en) |
AU (1) | AU654473B2 (en) |
CA (1) | CA2069906C (en) |
DE (1) | DE69032167T2 (en) |
WO (1) | WO1991009073A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993020236A1 (en) * | 1992-04-03 | 1993-10-14 | Applied Biosystems, Inc. | Probe composition and method |
WO1996003417A1 (en) * | 1994-07-25 | 1996-02-08 | Hybridon, Inc. | Improved methods of detritylation for oligonucleotide synthesis |
EP0773950A1 (en) * | 1994-07-15 | 1997-05-21 | Isis Pharmaceuticals, Inc. | Linked peptide nucleic acids |
WO1998032467A2 (en) * | 1997-01-24 | 1998-07-30 | Antivirals, Inc. | Method and conjugate for treating h. pylori infection |
WO2000044897A1 (en) * | 1999-01-29 | 2000-08-03 | Avi Biopharma, Inc. | Method of treating restenosis by antisense targeting of c-myc |
EP2002018A2 (en) * | 2006-03-07 | 2008-12-17 | AVI BioPharm, Inc. | Antisense antiviral compound and method for treating arenavirus infection |
Families Citing this family (1825)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5521063A (en) * | 1985-03-15 | 1996-05-28 | Antivirals Inc. | Polynucleotide reagent containing chiral subunits and methods of use |
US5217866A (en) * | 1985-03-15 | 1993-06-08 | Anti-Gene Development Group | Polynucleotide assay reagent and method |
US5506337A (en) * | 1985-03-15 | 1996-04-09 | Antivirals Inc. | Morpholino-subunit combinatorial library and method |
US5235033A (en) * | 1985-03-15 | 1993-08-10 | Anti-Gene Development Group | Alpha-morpholino ribonucleoside derivatives and polymers thereof |
US5470974A (en) * | 1985-03-15 | 1995-11-28 | Neu-Gene Development Group | Uncharged polynucleotide-binding polymers |
US5185444A (en) * | 1985-03-15 | 1993-02-09 | Anti-Gene Deveopment Group | Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages |
US5378841A (en) * | 1989-12-20 | 1995-01-03 | Antivirals Inc. | Alpha-morpholino ribonucleoside derivatives and polymers thereof |
US5955589A (en) * | 1991-12-24 | 1999-09-21 | Isis Pharmaceuticals Inc. | Gapped 2' modified oligonucleotides |
US5623065A (en) * | 1990-08-13 | 1997-04-22 | Isis Pharmaceuticals, Inc. | Gapped 2' modified oligonucleotides |
US6753423B1 (en) | 1990-01-11 | 2004-06-22 | Isis Pharmaceuticals, Inc. | Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals |
US5514788A (en) * | 1993-05-17 | 1996-05-07 | Isis Pharmaceuticals, Inc. | Oligonucleotide modulation of cell adhesion |
US6339066B1 (en) | 1990-01-11 | 2002-01-15 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotides which have phosphorothioate linkages of high chiral purity and which modulate βI, βII, γ, δ, Ε, ζ and η isoforms of human protein kinase C |
US5591623A (en) * | 1990-08-14 | 1997-01-07 | Isis Pharmaceuticals, Inc. | Oligonucleotide modulation of cell adhesion |
US5914396A (en) * | 1990-01-11 | 1999-06-22 | Isis Pharmaceuticals, Inc. | 2'-O-modified nucleosides and phosphoramidites |
US6399754B1 (en) * | 1991-12-24 | 2002-06-04 | Isis Pharmaceuticals, Inc. | Sugar modified oligonucleotides |
US20040142899A1 (en) * | 1990-01-11 | 2004-07-22 | Isis Pharmaceuticals, Inc. | Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals |
US5959096A (en) * | 1992-03-16 | 1999-09-28 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotides against human protein kinase C |
US5514577A (en) * | 1990-02-26 | 1996-05-07 | Isis Pharmaceuticals, Inc. | Oligonucleotide therapies for modulating the effects of herpes viruses |
US5834607A (en) * | 1990-07-27 | 1998-11-10 | Isis Pharmaceuticals, Inc. | Amines and methods of making and using the same |
US5789573A (en) * | 1990-08-14 | 1998-08-04 | Isis Pharmaceuticals, Inc. | Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2 |
US5442049A (en) * | 1992-11-19 | 1995-08-15 | Isis Pharmaceuticals, Inc. | Oligonucleotides for modulating the effects of cytomegalovirus infections |
US6153595A (en) * | 1990-08-16 | 2000-11-28 | Isis Pharmaceuticals Inc. | Composition and method for treatment of CMV infections |
US5595978A (en) * | 1990-08-16 | 1997-01-21 | Isis Pharmaceuticals, Inc. | Composition and method for treatment of CMV retinites |
US5965722A (en) * | 1991-05-21 | 1999-10-12 | Isis Pharmaceuticals, Inc. | Antisense inhibition of ras gene with chimeric and alternating oligonucleotides |
WO1994008003A1 (en) * | 1991-06-14 | 1994-04-14 | Isis Pharmaceuticals, Inc. | ANTISENSE OLIGONUCLEOTIDE INHIBITION OF THE ras GENE |
US7015315B1 (en) | 1991-12-24 | 2006-03-21 | Isis Pharmaceuticals, Inc. | Gapped oligonucleotides |
US6713602B1 (en) * | 1991-05-24 | 2004-03-30 | Ole Buchardt | Synthetic procedures for peptide nucleic acids |
US5719262A (en) * | 1993-11-22 | 1998-02-17 | Buchardt, Deceased; Ole | Peptide nucleic acids having amino acid side chains |
US5766855A (en) * | 1991-05-24 | 1998-06-16 | Buchardt, Deceased; Ole | Peptide nucleic acids having enhanced binding affinity and sequence specificity |
US6441130B1 (en) | 1991-05-24 | 2002-08-27 | Isis Pharmaceuticals, Inc. | Linked peptide nucleic acids |
US5714331A (en) * | 1991-05-24 | 1998-02-03 | Buchardt, Deceased; Ole | Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility |
DK51092D0 (en) * | 1991-05-24 | 1992-04-15 | Ole Buchardt | OLIGONUCLEOTIDE ANALOGUE DESCRIBED BY PEN, MONOMERIC SYNTHONES AND PROCEDURES FOR PREPARING THEREOF, AND APPLICATIONS THEREOF |
US6414112B1 (en) | 1991-05-24 | 2002-07-02 | Ole Buchardt | Peptide nucleic acids having 2,6-diaminopurine nucleobases |
BR9206156A (en) * | 1991-06-14 | 1995-10-17 | Isis Pharmaceuticals Inc | Oligonucleotide or aligonucleotide analogue process of modulating the expression of the human H-RAS gene process of detecting the presence of the H-RAS gene in cells or tissues process of detecting activated H-RAS based on the differential affinity of particular oligonucleotides by activated H-RAS VS, like, process of treating conditions that arise from the activation of the H-RAS oncogene |
US5747253A (en) * | 1991-08-23 | 1998-05-05 | Isis Pharmaceuticals, Inc. | Combinatorial oligomer immunoabsorbant screening assay for transcription factors and other biomolecule binding |
US6335434B1 (en) | 1998-06-16 | 2002-01-01 | Isis Pharmaceuticals, Inc., | Nucleosidic and non-nucleosidic folate conjugates |
US8153602B1 (en) | 1991-11-19 | 2012-04-10 | Isis Pharmaceuticals, Inc. | Composition and methods for the pulmonary delivery of nucleic acids |
US6235887B1 (en) * | 1991-11-26 | 2001-05-22 | Isis Pharmaceuticals, Inc. | Enhanced triple-helix and double-helix formation directed by oligonucleotides containing modified pyrimidines |
TW393513B (en) * | 1991-11-26 | 2000-06-11 | Isis Pharmaceuticals Inc | Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines |
AU3250093A (en) | 1991-12-12 | 1993-07-19 | Gilead Sciences, Inc. | Nuclease stable and binding competent oligomers and methods for their use |
US5359044A (en) * | 1991-12-13 | 1994-10-25 | Isis Pharmaceuticals | Cyclobutyl oligonucleotide surrogates |
US20070032446A1 (en) * | 1991-12-24 | 2007-02-08 | Isis Pharmaceuticals, Inc. | Gapped 2' modified oligonucleotides |
US5856455A (en) * | 1991-12-24 | 1999-01-05 | Isis Pharmaceuticals, Inc. | Gapped 2'-modified oligonucleotides |
JP3131222B2 (en) | 1991-12-24 | 2001-01-31 | アイシス・ファーマシューティカルス・インコーポレーテッド | 2 'modified oligonucleotide having a gap |
CA2126451A1 (en) * | 1991-12-24 | 1993-07-08 | Brett P. Monia | Compositions and methods for modulating .beta.-amyloid |
EP1126025A3 (en) * | 1992-03-16 | 2002-02-13 | Isis Pharmaceuticals, Inc. | Oligonucleotide modulation of protein kinase C |
US5885970A (en) * | 1992-03-16 | 1999-03-23 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotides against human protein kinase C |
US6153599A (en) * | 1992-03-16 | 2000-11-28 | Isis Pharmaceuticals, Inc. | Methoxyethoxy oligonucleotides for modulation of protein kinase C expression |
US5681747A (en) * | 1992-03-16 | 1997-10-28 | Isis Pharmaceuticals, Inc. | Nucleic acid sequences encoding protein kinase C and antisense inhibition of expression thereof |
US5922686A (en) * | 1992-03-16 | 1999-07-13 | Isis Pharmaceuticals, Inc. | Oligonucleotide modulation of protein kinase C |
US6537973B1 (en) | 1992-03-16 | 2003-03-25 | Isis Pharmaceuticals, Inc. | Oligonucleotide inhibition of protein kinase C |
US5882927A (en) * | 1992-03-16 | 1999-03-16 | Isis Pharmaceuticals, Inc. | Oligonucleotide inhibition of protein kinase C |
US5916807A (en) * | 1992-03-16 | 1999-06-29 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotides against human protein kinase C |
US5948898A (en) * | 1992-03-16 | 1999-09-07 | Isis Pharmaceuticals, Inc. | Methoxyethoxy oligonucleotides for modulation of protein kinase C expression |
US6117847A (en) * | 1992-03-16 | 2000-09-12 | Isis Pharmaceuticals, Inc. | Oligonucleotides for enhanced modulation of protein kinase C expression |
US5643780A (en) * | 1992-04-03 | 1997-07-01 | Isis Pharmaceuticals, Inc. | Compositions and methods for modulating RNA activity through modification of the 5' cap structure of RNA |
US5817781A (en) * | 1992-06-01 | 1998-10-06 | Gilead Sciences, Inc. | Modified internucleoside linkages (II) |
US5434257A (en) * | 1992-06-01 | 1995-07-18 | Gilead Sciences, Inc. | Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages |
ATE282695T1 (en) * | 1992-07-20 | 2004-12-15 | Isis Pharmaceuticals Inc | PSEUDO HALF-KNOT FORMING RNA THROUGH HYBRIDIZATION OF ANTISESEOLIGON NUCLEOTIDES TO TARGETED RNA SECONDARY STRUCTURES |
US6284458B1 (en) * | 1992-09-10 | 2001-09-04 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of hepatitis C virus-associated diseases |
US6995146B2 (en) | 1992-09-10 | 2006-02-07 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of hepatitis C virus-associated diseases |
US6423489B1 (en) | 1992-09-10 | 2002-07-23 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of Hepatitis C virus-associated diseases |
US6433159B1 (en) | 1992-09-10 | 2002-08-13 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of Hepatitis C virus associated diseases |
US6174868B1 (en) | 1992-09-10 | 2001-01-16 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of hepatitis C virus-associated diseases |
US20040049021A1 (en) * | 1992-09-10 | 2004-03-11 | Anderson Kevin P. | Compositions and mehtods for treatment of Hepatitis C virus-associated diseases |
US6391542B1 (en) | 1992-09-10 | 2002-05-21 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of Hepatitis C virus-associated diseases |
US6235886B1 (en) | 1993-09-03 | 2001-05-22 | Isis Pharmaceuticals, Inc. | Methods of synthesis and use |
WO1994006815A1 (en) | 1992-09-11 | 1994-03-31 | Isis Pharmaceuticals, Inc. | Oligonucleotide and nucleotide amine analogs, methods of synthesis and use |
IL107150A0 (en) * | 1992-09-29 | 1993-12-28 | Isis Pharmaceuticals Inc | Oligonucleotides having a conserved g4 core sequence |
US6784290B1 (en) | 1992-10-05 | 2004-08-31 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide inhibition of ras |
KR100199247B1 (en) * | 1992-10-05 | 1999-06-15 | 파샬 비. 린네 | Antisense oligonucleotide inhibition of the ras gene |
US5872242A (en) * | 1992-10-05 | 1999-02-16 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide inhibition of ras |
US20030013670A1 (en) * | 1992-10-05 | 2003-01-16 | Monia Brett P. | Antisense oligonucleotide inhibition of ras |
CA2170869C (en) | 1993-09-03 | 1999-09-14 | Phillip Dan Cook | Amine-derivatized nucleosides and oligonucleosides |
US5510239A (en) * | 1993-10-18 | 1996-04-23 | Isis Pharmaceuticals, Inc. | Oligonucleotide modulation of multidrug resistance-associated protein |
US5801154A (en) * | 1993-10-18 | 1998-09-01 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of multidrug resistance-associated protein |
US6399376B1 (en) | 1993-11-05 | 2002-06-04 | Isis Pharmaceuticals, Inc. | Modulation of vascular cell adhesive molecule expression through oligonucleotide interactions |
US6710164B1 (en) | 1993-11-22 | 2004-03-23 | Peter E. Nielsen | Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility |
US5656612A (en) * | 1994-05-31 | 1997-08-12 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of raf gene expression |
US5563255A (en) * | 1994-05-31 | 1996-10-08 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of raf gene expression |
US6410518B1 (en) | 1994-05-31 | 2002-06-25 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide inhibition of raf gene expression |
US6090626A (en) * | 1994-05-31 | 2000-07-18 | Isis Pharmaceuticals Inc. | Antisense oligonucleotide modulation of raf gene expression |
US20060142236A1 (en) * | 1994-05-31 | 2006-06-29 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of raf gene expression |
US20030119769A1 (en) * | 1994-05-31 | 2003-06-26 | Monia Brett P | Antisense oligonucleotide modulation of raf gene expression |
US5981731A (en) * | 1994-05-31 | 1999-11-09 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of B-raf gene expression |
KR100211178B1 (en) * | 1994-05-31 | 1999-07-15 | 파샬 비. 린네 | Antisense oligonucleotide modulation of raf gene expression |
US6391636B1 (en) | 1994-05-31 | 2002-05-21 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of raf gene expression |
US5665873A (en) * | 1995-02-09 | 1997-09-09 | Dana Farber Cancer Institute | Glucocorticoid response elements |
US6420549B1 (en) | 1995-06-06 | 2002-07-16 | Isis Pharmaceuticals, Inc. | Oligonucleotide analogs having modified dimers |
JPH11511128A (en) * | 1995-08-01 | 1999-09-28 | ノバルティス・アクチエンゲゼルシャフト | Liposome oligonucleotide composition |
US5854033A (en) | 1995-11-21 | 1998-12-29 | Yale University | Rolling circle replication reporter systems |
US7244622B2 (en) * | 1996-04-03 | 2007-07-17 | Applera Corporation | Device and method for multiple analyte detection |
US20050118605A9 (en) * | 1996-06-06 | 2005-06-02 | Baker Brenda F. | Oligomeric compounds having modified bases for binding to adenine and guanine and their use in gene modulation |
US20040171030A1 (en) * | 1996-06-06 | 2004-09-02 | Baker Brenda F. | Oligomeric compounds having modified bases for binding to cytosine and uracil or thymine and their use in gene modulation |
US20070275921A1 (en) * | 1996-06-06 | 2007-11-29 | Isis Pharmaceuticals, Inc. | Oligomeric Compounds That Facilitate Risc Loading |
US20050032068A1 (en) * | 2002-11-05 | 2005-02-10 | Prakash Thazha P. | Sugar and backbone-surrogate-containing oligomeric compounds and compositions for use in gene modulation |
US20030044941A1 (en) | 1996-06-06 | 2003-03-06 | Crooke Stanley T. | Human RNase III and compositions and uses thereof |
US5898031A (en) * | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
US20040266706A1 (en) * | 2002-11-05 | 2004-12-30 | Muthiah Manoharan | Cross-linked oligomeric compounds and their use in gene modulation |
US7812149B2 (en) | 1996-06-06 | 2010-10-12 | Isis Pharmaceuticals, Inc. | 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations |
US9096636B2 (en) * | 1996-06-06 | 2015-08-04 | Isis Pharmaceuticals, Inc. | Chimeric oligomeric compounds and their use in gene modulation |
US6593305B1 (en) * | 1996-08-02 | 2003-07-15 | Genesense Technologies Inc. | Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase |
US5948681A (en) * | 1996-08-14 | 1999-09-07 | Children's Hospital Of Philadelphia | Non-viral vehicles for use in gene transfer |
US6111085A (en) | 1996-09-13 | 2000-08-29 | Isis Pharmaceuticals, Inc. | Carbamate-derivatized nucleosides and oligonucleosides |
WO1998014592A2 (en) | 1996-10-01 | 1998-04-09 | Geron Corporation | Telomerase reverse transcriptase |
US6001991A (en) * | 1996-10-04 | 1999-12-14 | Isis Pharmaceuticals Inc. | Antisense oligonucleotide modulation of MDR P-glycoprotein gene expression |
US5919638A (en) * | 1996-10-08 | 1999-07-06 | Abbott Laboratories | Reagents and methods useful for detecting prostate tumors |
US20030165971A1 (en) * | 1996-10-31 | 2003-09-04 | Billing-Medel Patricia A. | Reagents and methods useful for detecting diseases of the breast |
US20050202499A1 (en) | 1996-10-31 | 2005-09-15 | Billing-Medel Patricia A. | Reagents and methods useful for detecting diseases of the breast |
US7235653B2 (en) * | 1996-12-31 | 2007-06-26 | Isis Pharmaceuticals, Inc. | Oligonucleotide compositions and methods for the modulation of the expression of B7 protein |
US6077833A (en) * | 1996-12-31 | 2000-06-20 | Isis Pharmaceuticals, Inc. | Oligonucleotide compositions and methods for the modulation of the expression of B7 protein |
US6319906B1 (en) | 1996-12-31 | 2001-11-20 | Isis Pharmaceuticals | Oligonucleotide compositions and methods for the modulation of the expression of B7 protein |
US20040023917A1 (en) * | 1996-12-31 | 2004-02-05 | Bennett C. Frank | Oligonucleotide compositions and methods for the modulation of the expression of B7 protein |
US6172209B1 (en) | 1997-02-14 | 2001-01-09 | Isis Pharmaceuticals Inc. | Aminooxy-modified oligonucleotides and methods for making same |
US6127533A (en) | 1997-02-14 | 2000-10-03 | Isis Pharmaceuticals, Inc. | 2'-O-aminooxy-modified oligonucleotides |
US6576752B1 (en) | 1997-02-14 | 2003-06-10 | Isis Pharmaceuticals, Inc. | Aminooxy functionalized oligomers |
US20020137904A1 (en) * | 1998-03-27 | 2002-09-26 | Patricia A. Billing-Medel | Reagents and methods useful for detecting diseases of the gastrointestinal tract |
US6716625B1 (en) | 1997-04-16 | 2004-04-06 | Claude Selitrennikoff | Histidine kinases of Aspergillus and other fungal species, related compositions, and methods of use |
US20050208567A1 (en) * | 1997-04-25 | 2005-09-22 | Billing-Medel Patricia A | Reagents and methods useful for detecting diseases of the prostate |
US7541151B2 (en) | 1997-06-05 | 2009-06-02 | Duke University | Single-cell biosensor for the measurement of GPCR ligands in a test sample |
US5891646A (en) * | 1997-06-05 | 1999-04-06 | Duke University | Methods of assaying receptor activity and constructs useful in such methods |
US6528271B1 (en) | 1997-06-05 | 2003-03-04 | Duke University | Inhibition of βarrestin mediated effects prolongs and potentiates opioid receptor-mediated analgesia |
US5962665A (en) | 1997-06-16 | 1999-10-05 | Abbott Laboratories | Nucleic acid primers and probes for detecting HIV-1 and HIV-2 |
EP1012331B1 (en) | 1997-07-01 | 2006-03-29 | Isis Pharmaceuticals, Inc. | Compositions and methods for the delivery of oligonucleotides via the alimentary canal |
AU8280798A (en) | 1997-07-03 | 1999-01-25 | Thomas Jefferson University | An improved method for design and selection of efficacious antisense oligonucleotides |
US7105496B2 (en) | 1998-07-23 | 2006-09-12 | Northwestern University | Methods and compositions for inhibiting angiogenesis |
US6797691B1 (en) | 1997-07-23 | 2004-09-28 | Northwestern University | Methods and compositions for inhibiting angiogenesis |
US6809193B2 (en) | 1997-08-13 | 2004-10-26 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide compositions and methods for the modulation of JNK proteins |
US6133246A (en) * | 1997-08-13 | 2000-10-17 | Isis Pharmaceuticals Inc. | Antisense oligonucleotide compositions and methods for the modulation of JNK proteins |
US6383808B1 (en) | 2000-09-11 | 2002-05-07 | Isis Pharmaceuticals, Inc. | Antisense inhibition of clusterin expression |
US5877309A (en) | 1997-08-13 | 1999-03-02 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotides against JNK |
US20070149472A1 (en) * | 1997-08-13 | 2007-06-28 | Mckay Robert | Antisense oligonucleotide compositions and methods for the modulation of jnk proteins |
US7252950B1 (en) | 1997-09-04 | 2007-08-07 | The Regents Of The University Of California | Assays for detecting modulators of cytoskeletal function |
US7115884B1 (en) | 1997-10-06 | 2006-10-03 | Trustees Of Tufts College | Self-encoding fiber optic sensor |
US5948902A (en) * | 1997-11-20 | 1999-09-07 | South Alabama Medical Science Foundation | Antisense oligonucleotides to human serine/threonine protein phosphatase genes |
US20040171564A1 (en) * | 1997-11-20 | 2004-09-02 | Honkanen Richard E. | Antisense oligonucleotide modulation of human serine/threonine protein phosphatase gene expression |
EP1049475A4 (en) | 1998-01-08 | 2003-06-04 | Univ California | KINESIN MOTOR MODULATORS DERIVED FROM THE MARINE SPONGE $i(ADOCIA) |
US7189703B2 (en) * | 1998-01-09 | 2007-03-13 | Intracell, Llc | Treatment and diagnosis of alzheimer's disease |
US6764830B1 (en) | 1998-01-23 | 2004-07-20 | The Regents Of The University Of California | Thermomyces lanuginosus kinesin motor protein and methods of screening for modulators of kinesin proteins |
US6326479B1 (en) | 1998-01-27 | 2001-12-04 | Boston Probes, Inc. | Synthetic polymers and methods, kits or compositions for modulating the solubility of same |
CA2319710A1 (en) | 1998-01-30 | 1999-08-05 | Jim A. Wright | Oligonucleotide sequences complementary to thioredoxin or thioredoxin reductase genes and methods of using same to modulate cell growth |
US5968748A (en) * | 1998-03-26 | 1999-10-19 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of human HER-2 expression |
US20040186071A1 (en) | 1998-04-13 | 2004-09-23 | Bennett C. Frank | Antisense modulation of CD40 expression |
US7321828B2 (en) | 1998-04-13 | 2008-01-22 | Isis Pharmaceuticals, Inc. | System of components for preparing oligonucleotides |
US6417169B1 (en) | 1998-04-23 | 2002-07-09 | Genesense Technologies Inc. | Insulin-like growth factor II antisense oligonucleotide sequences and methods of using same to inhibit cell growth |
CA2329252A1 (en) | 1998-05-21 | 1999-11-25 | Isis Pharmaceuticals Inc. | Compositions and methods for topical delivery of oligonucleotides |
JP2003524586A (en) | 1998-05-21 | 2003-08-19 | アイシス・ファーマシューティカルス・インコーポレーテッド | Compositions and methods for parenteral administration of oligonucleotides |
EP1084227A4 (en) | 1998-05-29 | 2002-06-12 | Univ Jefferson | Compositions and methods for use in affecting hematopoietic stem cell populations in mammals |
EP2045334A1 (en) | 1998-06-24 | 2009-04-08 | Illumina, Inc. | Decoding of array sensors with microspheres |
US6242589B1 (en) | 1998-07-14 | 2001-06-05 | Isis Pharmaceuticals, Inc. | Phosphorothioate oligonucleotides having modified internucleoside linkages |
US6867294B1 (en) * | 1998-07-14 | 2005-03-15 | Isis Pharmaceuticals, Inc. | Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages |
AU5329599A (en) * | 1998-07-30 | 2000-02-21 | University Of South Florida | Method for the modulation of function of transcription factors |
US6043352A (en) | 1998-08-07 | 2000-03-28 | Isis Pharmaceuticals, Inc. | 2'-O-Dimethylaminoethyloxyethyl-modified oligonucleotides |
US20040009938A1 (en) * | 1998-08-07 | 2004-01-15 | Muthiah Manoharan | Methods of enhancing renal uptake of oligonucleotides |
US6673912B1 (en) | 1998-08-07 | 2004-01-06 | Isis Pharmaceuticals, Inc. | 2′-O-aminoethyloxyethyl-modified oligonucleotides |
US20020172678A1 (en) | 2000-06-23 | 2002-11-21 | Napoleone Ferrara | EG-VEGF nucleic acids and polypeptides and methods of use |
US6175004B1 (en) | 1998-09-01 | 2001-01-16 | Isis Pharmaceuticals, Inc. | Process for the synthesis of oligonucleotides incorporating 2-aminoadenosine |
US6225293B1 (en) | 1998-09-02 | 2001-05-01 | Isis Pharmaceuticals, Inc. | Methods and compounds for tracking the biodistribution of macromolecule-carrier combinations |
US6335194B1 (en) | 1998-09-29 | 2002-01-01 | Isis Pharmaceuticals, Inc. | Antisense modulation of survivin expression |
US6077709A (en) | 1998-09-29 | 2000-06-20 | Isis Pharmaceuticals Inc. | Antisense modulation of Survivin expression |
IL142094A0 (en) | 1998-09-29 | 2002-03-10 | Gamida Cell Ltd | Methods of controlling proliferation and differentiation of stem and progenitor cells |
US6069243A (en) * | 1998-10-06 | 2000-05-30 | Isis Pharmaceuticals, Inc. | Process for oligonucleotide synthesis |
US6214986B1 (en) * | 1998-10-07 | 2001-04-10 | Isis Pharmaceuticals, Inc. | Antisense modulation of bcl-x expression |
US6172216B1 (en) * | 1998-10-07 | 2001-01-09 | Isis Pharmaceuticals Inc. | Antisense modulation of BCL-X expression |
US20020138856A1 (en) * | 1998-10-23 | 2002-09-26 | Northwestern University | Compositions and methods useful for treatment of depressive disorder based on an animal model |
US6429027B1 (en) | 1998-12-28 | 2002-08-06 | Illumina, Inc. | Composite arrays utilizing microspheres |
US6300320B1 (en) | 1999-01-05 | 2001-10-09 | Isis Pharmaceuticals, Inc. | Modulation of c-jun using inhibitors of protein kinase C |
WO2000041731A1 (en) | 1999-01-19 | 2000-07-20 | The Children's Hospital Of Philadelphia | Reverse gene therapy |
US6395029B1 (en) | 1999-01-19 | 2002-05-28 | The Children's Hospital Of Philadelphia | Sustained delivery of polyionic bioactive agents |
AU3347000A (en) | 1999-01-19 | 2000-08-01 | Children's Hospital Of Philadelphia, The | Hydrogel compositions for controlled delivery of virus vectors and methods of use thereof |
US7282489B2 (en) * | 2000-01-19 | 2007-10-16 | The Children's Hospital Of Philadelphia | Compositions and methods for performing reverse gene therapy |
US6127124A (en) * | 1999-01-20 | 2000-10-03 | Isis Pharmaceuticals, Inc. | Fluorescence based nuclease assay |
US6121000A (en) * | 1999-02-11 | 2000-09-19 | Genesense Technologies, Inc. | Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase |
ES2296613T3 (en) * | 1999-03-18 | 2008-05-01 | Queen Mary And Westfield College | INHIBITORS OF ENDOTHELINE SYNTHESIS-1. |
US6235891B1 (en) | 1999-03-31 | 2001-05-22 | South Alabama Medical Science Foundation | Glucocorticoid receptor agonist and decreased PP5 |
EP1165787A2 (en) | 1999-03-31 | 2002-01-02 | The University of North Carolina at Chapel Hill | Isolated dna encoding cullin regulators roc1 and roc2, isolated proteins encoded by the same, and methods utilizing the same |
US7098192B2 (en) | 1999-04-08 | 2006-08-29 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide modulation of STAT3 expression |
US20030207295A1 (en) * | 1999-04-20 | 2003-11-06 | Kevin Gunderson | Detection of nucleic acid reactions on bead arrays |
ATE413467T1 (en) | 1999-04-20 | 2008-11-15 | Illumina Inc | DETECTION OF NUCLEIC ACID REACTIONS ON BEAD ARRAYS |
US20060275782A1 (en) | 1999-04-20 | 2006-12-07 | Illumina, Inc. | Detection of nucleic acid reactions on bead arrays |
US6331618B1 (en) | 1999-05-13 | 2001-12-18 | Pe Corporation (Ny) | Compositions of solvents and high concentrations of nucleic acid analogs |
EP2360270B1 (en) | 1999-05-20 | 2016-11-09 | Illumina, Inc. | Combinatorial decoding of random nucleic acid arrays |
US8481268B2 (en) | 1999-05-21 | 2013-07-09 | Illumina, Inc. | Use of microfluidic systems in the detection of target analytes using microsphere arrays |
US8080380B2 (en) * | 1999-05-21 | 2011-12-20 | Illumina, Inc. | Use of microfluidic systems in the detection of target analytes using microsphere arrays |
US7534605B2 (en) * | 1999-06-08 | 2009-05-19 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | CD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases |
US6656730B1 (en) | 1999-06-15 | 2003-12-02 | Isis Pharmaceuticals, Inc. | Oligonucleotides conjugated to protein-binding drugs |
US6593466B1 (en) | 1999-07-07 | 2003-07-15 | Isis Pharmaceuticals, Inc. | Guanidinium functionalized nucleotides and precursors thereof |
US6147200A (en) * | 1999-08-19 | 2000-11-14 | Isis Pharmaceuticals, Inc. | 2'-O-acetamido modified monomers and oligomers |
US7668658B2 (en) | 1999-10-13 | 2010-02-23 | Sequenom, Inc. | Methods for generating databases and databases for identifying polymorphic genetic markers |
US20020165188A1 (en) * | 1999-10-14 | 2002-11-07 | Meenhard Herlyn | Methods for inhibition of tumorigenic properties of melanoma cells |
ATE322493T1 (en) * | 1999-12-30 | 2006-04-15 | Leuven K U Res & Dev | CYCLOHEXENE NUCLEIC ACIDS |
US20020055479A1 (en) | 2000-01-18 | 2002-05-09 | Cowsert Lex M. | Antisense modulation of PTP1B expression |
US6261840B1 (en) | 2000-01-18 | 2001-07-17 | Isis Pharmaceuticals, Inc. | Antisense modulation of PTP1B expression |
US6559128B1 (en) * | 2000-01-21 | 2003-05-06 | Northwestern University | Inhibitors of G protein-mediated signaling, methods of making them, and uses thereof |
WO2001061043A2 (en) | 2000-02-16 | 2001-08-23 | Illumina, Inc. | Parallel genotyping of multiple patient samples |
US6846486B1 (en) | 2000-02-24 | 2005-01-25 | Advanced Biotherapy Concepts, Inc. | Method of treating allergy by administering an anti-histamine antibody |
AU2001242190A1 (en) * | 2000-03-31 | 2001-10-15 | Aventis Pasteur Limited | Immunogenic peptides derived from prostate-specific membrane antigen (psma) and uses thereof |
EP2202241A3 (en) * | 2000-04-13 | 2010-07-28 | Thomas N. Wight | Therapeutic compounds and methods for modulating V3, a versican isoform |
JP2003531149A (en) | 2000-04-13 | 2003-10-21 | ザ・ロツクフエラー・ユニバーシテイ | Enhancement of antibody-derived immune response |
AU5752601A (en) | 2000-05-04 | 2001-11-12 | Avi Biopharma Inc | Splice-region antisense composition and method |
US6680172B1 (en) | 2000-05-16 | 2004-01-20 | Regents Of The University Of Michigan | Treatments and markers for cancers of the central nervous system |
US6686188B2 (en) * | 2000-05-26 | 2004-02-03 | Amersham Plc | Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle |
US6656700B2 (en) * | 2000-05-26 | 2003-12-02 | Amersham Plc | Isoforms of human pregnancy-associated protein-E |
CA2410950A1 (en) * | 2000-05-30 | 2001-12-06 | Hans-Michael Wenz | Methods for detecting target nucleic acids using coupled ligation and amplification |
US20060166227A1 (en) * | 2000-06-20 | 2006-07-27 | Stephen Kingsmore | Protein expression profiling |
AU2001271873A1 (en) | 2000-07-06 | 2002-01-21 | Avi Biopharma, Inc. | Transforming growth factor beta (TGF-beta) blocking agent-treated stem cell composition and method |
FR2811323B1 (en) * | 2000-07-07 | 2006-10-06 | Fuma Tech Gmbh | HYBRID MATERIAL, USE OF SAID HYBRID MATERIAL, AND METHOD OF MANUFACTURING THE SAME |
US6958214B2 (en) | 2000-07-10 | 2005-10-25 | Sequenom, Inc. | Polymorphic kinase anchor proteins and nucleic acids encoding the same |
US20080194022A1 (en) * | 2000-08-03 | 2008-08-14 | Clarke Michael F | Isolation and use of solid tumor stem cells |
US6984522B2 (en) * | 2000-08-03 | 2006-01-10 | Regents Of The University Of Michigan | Isolation and use of solid tumor stem cells |
CN1274072C (en) * | 2000-08-03 | 2006-09-06 | 松下电器产业株式会社 | Brushless motor and method of Manufacturing the brushless motor |
US8044259B2 (en) | 2000-08-03 | 2011-10-25 | The Regents Of The University Of Michigan | Determining the capability of a test compound to affect solid tumor stem cells |
US8568766B2 (en) | 2000-08-24 | 2013-10-29 | Gattadahalli M. Anantharamaiah | Peptides and peptide mimetics to treat pathologies associated with eye disease |
KR100916949B1 (en) * | 2000-08-30 | 2009-09-14 | 에이브이아이 바이오파마 인코포레이티드 | Method for analysis of oligonucleotide analogs |
AU2001290629A1 (en) * | 2000-09-07 | 2002-03-22 | Boehringer Ingelheim International G.M.B.H | Heat shock response and virus replication |
DE60129719T2 (en) * | 2000-09-14 | 2008-06-05 | The Mount Sinai School Of Medicine | SCREENING METHOD FOR IDENTIFYING G-PROTEINS AND OTHER COMPOUNDS WHICH INFLUENCE THE PHOSPHODIESTERASE (PDE) ACTIVITY |
EP1191097A1 (en) * | 2000-09-21 | 2002-03-27 | Leids Universitair Medisch Centrum | Induction of exon skipping in eukaryotic cells |
US20030044803A1 (en) * | 2000-09-22 | 2003-03-06 | Pedersen Finn Skou | Methods for diagnosis and treatment of diseases associated with altered expression of JAK1 |
US20020164576A1 (en) * | 2000-09-22 | 2002-11-07 | Pedersen Finn Skou | Methods for diagnosis and treatment of diseases associated with altered expression of Nrf2 |
US20020115058A1 (en) * | 2000-09-22 | 2002-08-22 | Pedersen Finn Skou | Methods for diagnosis and treatment of diseases associated with altered expression of Pik3r1 |
US20020123474A1 (en) * | 2000-10-04 | 2002-09-05 | Shannon Mark E. | Human GTP-Rho binding protein2 |
EP2336166A1 (en) | 2000-10-12 | 2011-06-22 | University Of Rochester | Compositions that inhibit proliferation of cancer cells |
US7045283B2 (en) | 2000-10-18 | 2006-05-16 | The Regents Of The University Of California | Methods of high-throughput screening for internalizing antibodies |
EP1736760A3 (en) | 2000-12-11 | 2008-06-18 | President And Fellows Of Harvard College | Nanosensors |
US7645441B2 (en) | 2000-12-22 | 2010-01-12 | Sagres Discovery Inc. | Compositions and methods in cancer associated with altered expression of PRLR |
US7820447B2 (en) * | 2000-12-22 | 2010-10-26 | Sagres Discovery Inc. | Compositions and methods for cancer |
US20030087252A1 (en) * | 2000-12-22 | 2003-05-08 | Morris David W. | Novel compositions and methods in cancer associated with altered expression of PRDM11 |
US20030165878A1 (en) * | 2000-12-22 | 2003-09-04 | Morris David W. | Novel compositions and methods in cancer associated with altered expression of MCM3AP |
US20030232334A1 (en) * | 2000-12-22 | 2003-12-18 | Morris David W. | Novel compositions and methods for cancer |
US7700274B2 (en) * | 2000-12-22 | 2010-04-20 | Sagres Discovery, Inc. | Compositions and methods in cancer associated with altered expression of KCNJ9 |
US7892730B2 (en) * | 2000-12-22 | 2011-02-22 | Sagres Discovery, Inc. | Compositions and methods for cancer |
US20030099963A1 (en) * | 2000-12-22 | 2003-05-29 | Morris David W. | Novel compositions and methods in cancer associated with altered expression of TBX21 |
US7767802B2 (en) | 2001-01-09 | 2010-08-03 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of anti-apoptotic genes |
US7279324B2 (en) * | 2001-01-23 | 2007-10-09 | Duke University | Nucleic acid encoding G-protein coupled receptor with modified DRY motif |
US20030036854A1 (en) * | 2001-02-06 | 2003-02-20 | The Penn State Research Foundation | Apparatus and method for designing proteins and protein libraries |
US6573051B2 (en) * | 2001-03-09 | 2003-06-03 | Molecular Staging, Inc. | Open circle probes with intramolecular stem structures |
US7294472B2 (en) * | 2001-03-14 | 2007-11-13 | Caden Biosciences | Method for identifying modulators of G protein coupled receptor signaling |
ES2328796T3 (en) | 2001-03-14 | 2009-11-18 | Myriad Genetics, Inc. | TSG101-GAG INTERACTION AND USE OF THE SAME. |
US7208279B2 (en) * | 2001-03-14 | 2007-04-24 | Caden Biosciences, Inc. | Method for identifying inhibitors of G protein coupled receptor signaling |
US7803982B2 (en) | 2001-04-20 | 2010-09-28 | The Mount Sinai School Of Medicine Of New York University | T1R3 transgenic animals, cells and related methods |
EP1572871A4 (en) * | 2001-04-20 | 2007-11-14 | Sinai School Medicine | T1r3 a novel taste receptor |
WO2002086147A2 (en) * | 2001-04-24 | 2002-10-31 | Pharmacia & Upjohn Company | Single nucleotide polymorphisms diagnostic for schizophrenia |
CA2446619C (en) | 2001-05-11 | 2011-04-26 | Elan Corporation, Plc | Permeation enhancers |
US7803915B2 (en) | 2001-06-20 | 2010-09-28 | Genentech, Inc. | Antibody compositions for the diagnosis and treatment of tumor |
DK2000545T3 (en) | 2001-06-20 | 2011-11-28 | Genentech Inc | Compositions and methods for diagnosis and treatment of lung tumor |
CA2451643C (en) | 2001-06-21 | 2012-11-13 | Isis Pharmaceuticals, Inc. | Antisense modulation of superoxide dismutase 1, soluble expression |
EP1925672A1 (en) | 2001-06-22 | 2008-05-28 | Syngeta Participations AG | Abiotic stress responsive polynucleotides and polypeptides |
US20040241683A1 (en) * | 2001-07-06 | 2004-12-02 | Ekker Stephen C | Hsst and angiogenesis |
US7393656B2 (en) * | 2001-07-10 | 2008-07-01 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for risk stratification |
US7381535B2 (en) | 2002-07-10 | 2008-06-03 | The Board Of Trustees Of The Leland Stanford Junior | Methods and compositions for detecting receptor-ligand interactions in single cells |
WO2003067210A2 (en) | 2001-07-10 | 2003-08-14 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for detecting the activation state of the multiple proteins in single cells |
EP2246438B1 (en) | 2001-07-12 | 2019-11-27 | Illumina, Inc. | Multiplex nucleic acid reactions |
US7425545B2 (en) | 2001-07-25 | 2008-09-16 | Isis Pharmaceuticals, Inc. | Modulation of C-reactive protein expression |
US6964950B2 (en) | 2001-07-25 | 2005-11-15 | Isis Pharmaceuticals, Inc. | Antisense modulation of C-reactive protein expression |
US20030096772A1 (en) | 2001-07-30 | 2003-05-22 | Crooke Rosanne M. | Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression |
US7407943B2 (en) | 2001-08-01 | 2008-08-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein B expression |
US7229774B2 (en) | 2001-08-02 | 2007-06-12 | Regents Of The University Of Michigan | Expression profile of prostate cancer |
US20040096880A1 (en) * | 2001-08-07 | 2004-05-20 | Kmiec Eric B. | Compositions and methods for the treatment of diseases exhibiting protein misassembly and aggregation |
US7227014B2 (en) | 2001-08-07 | 2007-06-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein (a) expression |
WO2003013437A2 (en) * | 2001-08-07 | 2003-02-20 | University Of Delaware | Compositions and methods for the prevention and treatment of huntington's disease |
DE60220804D1 (en) * | 2001-08-20 | 2007-08-02 | Regenesis Bioremediation Produ | BIOSENSOR FOR SMALL MOLECULAR ANALYTES |
WO2003020980A2 (en) * | 2001-08-28 | 2003-03-13 | Pharmacia & Upjohn Company | Single nucleotide polymorphisms diagnostic for schizophrenia |
US20040115699A1 (en) * | 2001-08-28 | 2004-06-17 | Kaytes Paul S. | Single nucleotide polymorphisms diagnostic for schizophrenia |
US6852491B2 (en) | 2001-09-04 | 2005-02-08 | Abbott Laboratories | Amplification and detection reagents for HIV-1 |
US7205048B2 (en) * | 2001-09-17 | 2007-04-17 | Invitrogen Corporation | Functionalized fluorescent nanocrystal compositions and methods of making |
EP2159044B1 (en) | 2001-09-17 | 2012-05-16 | Life Technologies Corporation | Nanocrystals |
US7214428B2 (en) * | 2001-09-17 | 2007-05-08 | Invitrogen Corporation | Highly luminescent functionalized semiconductor nanocrystals for biological and physical applications |
EP1721977A3 (en) | 2001-09-17 | 2008-10-15 | PDL BioPharma, Inc. | Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer |
CA2460120A1 (en) | 2001-09-18 | 2003-03-27 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
US20070098728A1 (en) * | 2001-09-24 | 2007-05-03 | Pedersen Finn S | Novel compositions and methods in cancer |
ATE441727T1 (en) | 2001-10-01 | 2009-09-15 | Sinai School Medicine | NOONANIC SYNDROME GENE |
ATE516364T1 (en) | 2001-10-09 | 2011-07-15 | Isis Pharmaceuticals Inc | ANTISENSE MODULATION OF EXPRESSION OF THE INSULIN-LIKE GROWTH FACTOR BINDING PROTEY S 5 |
US6750019B2 (en) | 2001-10-09 | 2004-06-15 | Isis Pharmaceuticals, Inc. | Antisense modulation of insulin-like growth factor binding protein 5 expression |
AU2004236174B2 (en) | 2001-10-10 | 2011-06-02 | Novo Nordisk A/S | Glycopegylation methods and proteins/peptides produced by the methods |
ES2538342T3 (en) | 2001-10-10 | 2015-06-19 | Ratiopharm Gmbh | Remodeling and glycoconjugation of follicle stimulating hormone (FSH) |
EP2305311A3 (en) | 2001-10-10 | 2011-07-20 | BioGeneriX AG | Glycoconjugation of peptides |
US8323903B2 (en) * | 2001-10-12 | 2012-12-04 | Life Technologies Corporation | Antibody complexes and methods for immunolabeling |
US20050069962A1 (en) | 2001-10-12 | 2005-03-31 | Archer Robert M | Antibody complexes and methods for immunolabeling |
US20040166490A1 (en) * | 2002-12-17 | 2004-08-26 | Morris David W. | Novel therapeutic targets in cancer |
US20040126762A1 (en) * | 2002-12-17 | 2004-07-01 | Morris David W. | Novel compositions and methods in cancer |
EP1436426A4 (en) * | 2001-10-24 | 2005-11-02 | Singulex Inc | Methods for detecting genetic haplotypes by interaction with probes |
US20030224380A1 (en) * | 2001-10-25 | 2003-12-04 | The General Hospital Corporation | Genes and polymorphisms on chromosome 10 associated with Alzheimer's disease and other neurodegenerative diseases |
AU2002364945A1 (en) * | 2001-10-25 | 2003-07-09 | Neurogenetics, Inc. | Genes and polymorphisms on chromosome 10 associated with alzheimer's disease and other neurodegenerative diseases |
US20030170678A1 (en) * | 2001-10-25 | 2003-09-11 | Neurogenetics, Inc. | Genetic markers for Alzheimer's disease and methods using the same |
EP1438417B1 (en) * | 2001-10-26 | 2014-05-14 | Danisco US Inc. | Phytase enzymes, nucleic acid sequences encoding phytase enzymes and vectors and host cells incorporating same |
US7510831B2 (en) * | 2001-10-26 | 2009-03-31 | Genencor International, Inc. | Trichoderma reesei phytase enzymes, nucleic acids encoding such phytase enzymes, vectors and host cells incorporating same and methods of making and using same |
WO2003042226A2 (en) * | 2001-11-09 | 2003-05-22 | Pharmacia & Upjohn Company | Single nucleotide polymorphisms in gh-1 |
US20060040262A1 (en) * | 2002-12-27 | 2006-02-23 | Morris David W | Novel compositions and methods in cancer |
US20040180344A1 (en) * | 2003-03-14 | 2004-09-16 | Morris David W. | Novel therapeutic targets in cancer |
US20040197778A1 (en) * | 2002-12-26 | 2004-10-07 | Sagres Discovery, Inc. | Novel compositions and methods in cancer |
US6965025B2 (en) | 2001-12-10 | 2005-11-15 | Isis Pharmaceuticals, Inc. | Antisense modulation of connective tissue growth factor expression |
JP2005525095A (en) | 2002-01-02 | 2005-08-25 | ジェネンテック・インコーポレーテッド | Compositions and methods for tumor diagnosis and treatment |
EP1953244A1 (en) | 2002-01-09 | 2008-08-06 | Nakamura, Yusuke | Cancer profiles |
IL152904A0 (en) | 2002-01-24 | 2003-06-24 | Gamida Cell Ltd | Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations |
WO2003062404A1 (en) * | 2002-01-25 | 2003-07-31 | Gamida-Cell Ltd. | Methods of expanding stem and progenitor cells and expanded cell populations obtained thereby |
US7553619B2 (en) | 2002-02-08 | 2009-06-30 | Qiagen Gmbh | Detection method using dissociated rolling circle amplification |
US7499806B2 (en) * | 2002-02-14 | 2009-03-03 | Illumina, Inc. | Image processing in microsphere arrays |
US20030191075A1 (en) * | 2002-02-22 | 2003-10-09 | Cook Phillip Dan | Method of using modified oligonucleotides for hepatic delivery |
JP2005518212A (en) | 2002-02-25 | 2005-06-23 | ジェネンテック・インコーポレーテッド | Novel type 1 cytokine receptor GLM-R |
US20030182669A1 (en) * | 2002-03-19 | 2003-09-25 | Rockman Howard A. | Phosphoinositide 3-kinase mediated inhibition of GPCRs |
US20030180712A1 (en) | 2002-03-20 | 2003-09-25 | Biostratum Ab | Inhibition of the beta3 subunit of L-type Ca2+ channels |
AU2003218350A1 (en) | 2002-03-21 | 2003-10-08 | Sagres Discovery, Inc. | Novel compositions and methods in cancer |
US7332585B2 (en) | 2002-04-05 | 2008-02-19 | The Regents Of The California University | Bispecific single chain Fv antibody molecules and methods of use thereof |
US7026120B2 (en) | 2002-04-15 | 2006-04-11 | Abbott Laboratories | Probes for detecting tumor cells |
AU2003230874A1 (en) | 2002-04-16 | 2003-11-03 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
US7622117B2 (en) * | 2002-04-17 | 2009-11-24 | Dynamis Therapeutics, Inc. | 3-deoxyglucosone and skin |
AU2003231121B2 (en) | 2002-04-26 | 2008-08-07 | University Of Utah Research Foundation | Characterization of single stranded nucleic acids by melting analysis using a double strand specific nucleic acid dye |
US7015317B2 (en) * | 2002-05-02 | 2006-03-21 | Abbott Laboratories | Polynucleotides for the detection and quantification of hepatitis B virus nucleic acids |
AU2003221575B2 (en) | 2002-05-02 | 2010-06-10 | Dalia Barsyte | Teneurin C-terminal associated peptides (TCAP) and uses thereof |
CA2484676A1 (en) | 2002-05-03 | 2003-11-13 | Sequenom, Inc. | Kinase anchor protein muteins, peptides thereof, and related methods |
US7351542B2 (en) | 2002-05-20 | 2008-04-01 | The Regents Of The University Of California | Methods of modulating tubulin deacetylase activity |
US7176181B2 (en) * | 2002-05-21 | 2007-02-13 | Yeda Research And Development Co. Ltd. | Compositions and methods of using galectin-8 as an inhibitor of tumor cell growth |
US7199107B2 (en) | 2002-05-23 | 2007-04-03 | Isis Pharmaceuticals, Inc. | Antisense modulation of kinesin-like 1 expression |
CA2488048A1 (en) | 2002-05-30 | 2003-12-11 | Memorial Sloan-Kettering Cancer Center | Kinase suppressor of ras inactivation for therapy of ras mediated tumorigenesis |
US7290215B2 (en) * | 2002-06-03 | 2007-10-30 | Microsoft Corporation | Dynamic wizard interface system and method |
WO2003106617A2 (en) * | 2002-06-12 | 2003-12-24 | Tel Aviv Medical Center Research Development Fund | Oligonucleotides antibodies and kits including same for treating prostate cancer and determining predisposition thereto |
AU2003276131A1 (en) * | 2002-06-18 | 2003-12-31 | Epigenesis Pharmaceuticals, Inc. | A dry powder oligonucleotide formulation, preparation and its uses |
WO2004013160A2 (en) | 2002-08-05 | 2004-02-12 | University Of Rochester | Protein transducing domain/deaminase chimeric proteins, related compounds, and uses thereof |
ATE490309T1 (en) * | 2002-08-12 | 2010-12-15 | Danisco Us Inc | MUTANT E. COLI-APPA PHYTASE ZYMES AND NATURAL VARIANTS THEREOF, NUCLEIC ACIDS ENCODING SUCH PHYTASE ZYMES, VECTORS AND HOST CELLS CONTAINING THE SAME, AND METHODS FOR THE PRODUCTION AND USE THEREOF |
AU2003270582A1 (en) * | 2002-09-12 | 2004-04-30 | Massachusetts Institute Of Technology | Rb pahtway and chromatin remodeling genes that antagonize let-60 ras signaling |
BR0314236A (en) | 2002-09-13 | 2005-08-09 | Replicor Inc | Oligonucleotide formulation, pharmaceutical composition, kit, antiviral compound, preparation of oligonucleotide and methods for selection of an antiviral oligonucleotide for use as an antiviral agent, for prophylaxis or treatment of a viral infection in a patient, for prophylactic treatment of cancer caused by oncoviruses. for identifying a compound that alters the binding of an oligonucleotide to at least one viral component, for purifying oligonucleotide binding to at least one viral component and for enriching oligonucleotides from an oligonucleotide cluster |
EP1546170A4 (en) * | 2002-09-20 | 2007-08-29 | Univ Yale | Riboswitches, methods for their use, and compositions for use with riboswitches |
EP2272958A1 (en) | 2002-09-26 | 2011-01-12 | ISIS Pharmaceuticals, Inc. | Modulation of forkhead box O1A expression |
US20040235005A1 (en) * | 2002-10-23 | 2004-11-25 | Ernest Friedlander | Methods and composition for detecting targets |
CA2504929C (en) | 2002-11-05 | 2014-07-22 | Charles Allerson | Compositions comprising alternating 2'-modified nucleosides for use in gene modulation |
WO2004044138A2 (en) | 2002-11-05 | 2004-05-27 | Isis Pharmaceuticals, Inc. | Chimeric oligomeric compounds and their use in gene modulation |
US9150605B2 (en) * | 2002-11-05 | 2015-10-06 | Isis Pharmaceuticals, Inc. | Compositions comprising alternating 2′-modified nucleosides for use in gene modulation |
US9150606B2 (en) * | 2002-11-05 | 2015-10-06 | Isis Pharmaceuticals, Inc. | Compositions comprising alternating 2'-modified nucleosides for use in gene modulation |
US7696345B2 (en) * | 2002-11-05 | 2010-04-13 | Isis Pharmaceuticals, Inc. | Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation |
US7807802B2 (en) | 2002-11-12 | 2010-10-05 | Abbott Lab | Polynucleotides for the amplification and detection of Chlamydia trachomatis and Neisseria gonorrhoeae |
DK1569695T3 (en) | 2002-11-13 | 2013-08-05 | Genzyme Corp | ANTISENSE MODULATION OF APOLIPOPROTEIN-B EXPRESSION |
JP4986109B2 (en) | 2002-11-13 | 2012-07-25 | ジェンザイム・コーポレーション | Antisense regulation of apolipoprotein B expression |
US20060009378A1 (en) * | 2002-11-14 | 2006-01-12 | Itshak Golan | Novel galectin sequences and compositions and methods utilizing same for treating or diagnosing arthritis and other chronic inflammatory diseases |
CA2506127C (en) | 2002-11-15 | 2013-07-09 | Morphotek, Inc. | Methods of generating high-production of antibodies from hybridomas created by in vitro immunization |
AU2003298650B2 (en) | 2002-11-15 | 2010-03-11 | Musc Foundation For Research Development | Complement receptor 2 targeted complement modulators |
AU2003298672A1 (en) * | 2002-11-19 | 2005-01-28 | Singulex, Inc. | Detection of target molecules through interaction with probes |
EP1624753B1 (en) | 2002-11-21 | 2012-01-25 | The University of Utah Research Foundation | Purinergic modulation of smell |
US7144999B2 (en) | 2002-11-23 | 2006-12-05 | Isis Pharmaceuticals, Inc. | Modulation of hypoxia-inducible factor 1 alpha expression |
AU2003299441A1 (en) * | 2002-12-19 | 2004-07-14 | Centre National De La Recherche Scientifique - Cnrs | Nf-hev compositions and methods of use |
US9487823B2 (en) | 2002-12-20 | 2016-11-08 | Qiagen Gmbh | Nucleic acid amplification |
AU2003299694A1 (en) | 2002-12-20 | 2004-07-22 | Qiagen Gmbh | Nucleic acid amplification |
US6977153B2 (en) * | 2002-12-31 | 2005-12-20 | Qiagen Gmbh | Rolling circle amplification of RNA |
JP4177123B2 (en) * | 2003-01-10 | 2008-11-05 | 富士通株式会社 | Wiring pattern verification method, program and apparatus |
US9169516B2 (en) | 2003-01-24 | 2015-10-27 | University Of Utah Research Foundation | Methods of predicting mortality risk by determining telomere length |
DK1597366T3 (en) | 2003-02-11 | 2013-02-25 | Antisense Therapeutics Ltd | Modulation of expression of insulin-like growth factor receptor I |
US7002006B2 (en) * | 2003-02-12 | 2006-02-21 | Isis Pharmaceuticals, Inc. | Protection of nucleosides |
US7767387B2 (en) * | 2003-06-13 | 2010-08-03 | Sagres Discovery, Inc. | Therapeutic targets in cancer |
EP2058408A3 (en) | 2003-02-14 | 2009-09-09 | Sagres Discovery, Inc. | Therapeutic GPCR targets in cancer |
US20040170982A1 (en) | 2003-02-14 | 2004-09-02 | Morris David W. | Novel therapeutic targets in cancer |
US6943768B2 (en) | 2003-02-21 | 2005-09-13 | Xtellus Inc. | Thermal control system for liquid crystal cell |
CA2517074A1 (en) | 2003-02-27 | 2004-09-10 | Yeda Research And Development Co., Ltd. | Nucleic acid molecules, polypeptides, antibodies and compositions containing same useful for treating and detecting influenza virus infection |
US7803781B2 (en) | 2003-02-28 | 2010-09-28 | Isis Pharmaceuticals, Inc. | Modulation of growth hormone receptor expression and insulin-like growth factor expression |
US20040185559A1 (en) | 2003-03-21 | 2004-09-23 | Isis Pharmaceuticals Inc. | Modulation of diacylglycerol acyltransferase 1 expression |
CA2524255C (en) | 2003-03-21 | 2014-02-11 | Academisch Ziekenhuis Leiden | Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure |
US8043834B2 (en) | 2003-03-31 | 2011-10-25 | Qiagen Gmbh | Universal reagents for rolling circle amplification and methods of use |
JP2007521791A (en) | 2003-04-01 | 2007-08-09 | ジェネンテック・インコーポレーテッド | Compositions and methods for tumor diagnosis and treatment |
US20050043510A1 (en) * | 2003-04-10 | 2005-02-24 | Moeckli Randolph A. | Affinity purification system using troponin molecules as affinity ligands |
US7598227B2 (en) | 2003-04-16 | 2009-10-06 | Isis Pharmaceuticals Inc. | Modulation of apolipoprotein C-III expression |
US7399853B2 (en) | 2003-04-28 | 2008-07-15 | Isis Pharmaceuticals | Modulation of glucagon receptor expression |
US20040219533A1 (en) * | 2003-04-29 | 2004-11-04 | Jim Davis | Biological bar code |
EP1629105B1 (en) | 2003-04-29 | 2010-09-01 | AVI BioPharma, Inc. | Compositions for enhancing transport and antisense efficacy of nucleic acid analog into cells |
US7709610B2 (en) | 2003-05-08 | 2010-05-04 | Facet Biotech Corporation | Therapeutic use of anti-CS1 antibodies |
US20050025763A1 (en) | 2003-05-08 | 2005-02-03 | Protein Design Laboratories, Inc. | Therapeutic use of anti-CS1 antibodies |
ATE446791T1 (en) * | 2003-05-16 | 2009-11-15 | Univ Laval | CNS CHLORIDE MODULATION AND USE THEREOF |
US7960355B2 (en) * | 2003-05-23 | 2011-06-14 | Isis Pharmaceuticals, Inc. | Compositions and methods for the modulation of the expression of B7 protein |
WO2004106360A2 (en) * | 2003-05-23 | 2004-12-09 | Mount Sinai School Of Medicine Of New York University | Viral vectors with improved properties |
US7897582B2 (en) * | 2003-05-23 | 2011-03-01 | Isis Pharmaceuticals, Inc. | Oligonucleotide compositions and methods for the modulation of the expression of B7 protein |
US7276599B2 (en) * | 2003-06-02 | 2007-10-02 | Isis Pharmaceuticals, Inc. | Oligonucleotide synthesis with alternative solvents |
AU2004253455B2 (en) | 2003-06-03 | 2011-03-03 | Eli Lilly And Company | Modulation of survivin expression |
US20050239089A1 (en) * | 2003-06-06 | 2005-10-27 | Johnson Martin D | Mobility cassettes |
US20060019256A1 (en) * | 2003-06-09 | 2006-01-26 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
GB2417727B (en) | 2003-06-13 | 2008-01-16 | Alnylam Europe Ag | Double-stranded ribonucleic acid with increased effectiveness in an organism |
US20040259100A1 (en) | 2003-06-20 | 2004-12-23 | Illumina, Inc. | Methods and compositions for whole genome amplification and genotyping |
US7572581B2 (en) * | 2003-06-30 | 2009-08-11 | Roche Molecular Systems, Inc. | 2′-terminator nucleotide-related methods and systems |
US7947817B2 (en) * | 2003-06-30 | 2011-05-24 | Roche Molecular Systems, Inc. | Synthesis and compositions of 2'-terminator nucleotides |
WO2005017109A2 (en) * | 2003-06-30 | 2005-02-24 | Massachusetts Institute Of Technology | Nucleic acids and polypeptides required for cell survival in the absence of rb |
US20090088982A1 (en) * | 2003-07-31 | 2009-04-02 | Fukushima Noelle H | Co-detection of single polypeptide and polynucleotide molecules |
CA2533701A1 (en) | 2003-07-31 | 2005-02-17 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding rnas |
CA2534382C (en) | 2003-08-04 | 2018-12-11 | The Hospital For Sick Children | Epm2b gene mutations associated with lafora's disease |
US7825235B2 (en) | 2003-08-18 | 2010-11-02 | Isis Pharmaceuticals, Inc. | Modulation of diacylglycerol acyltransferase 2 expression |
CA2903196A1 (en) | 2003-08-27 | 2005-03-10 | Ophthotech Corporation | Combination therapy for the treatment of ocular neovascular disorders |
US20050053981A1 (en) * | 2003-09-09 | 2005-03-10 | Swayze Eric E. | Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini |
US20070123480A1 (en) * | 2003-09-11 | 2007-05-31 | Replicor Inc. | Oligonucleotides targeting prion diseases |
SG146682A1 (en) | 2003-09-18 | 2008-10-30 | Isis Pharmaceuticals Inc | Modulation of eif4e expression |
EP1677822B1 (en) * | 2003-09-18 | 2014-04-23 | Isis Pharmaceuticals, Inc. | 4'-thionucleosides and oligomeric compounds |
US7125945B2 (en) * | 2003-09-19 | 2006-10-24 | Varian, Inc. | Functionalized polymer for oligonucleotide purification |
US20050222068A1 (en) * | 2003-10-23 | 2005-10-06 | Mourich Dan V | Method and antisense composition for selective inhibition of HIV infection in hematopoietic cells |
US20070281896A1 (en) * | 2003-09-30 | 2007-12-06 | Morris David W | Novel compositions and methods in cancer |
US7662929B2 (en) | 2003-10-10 | 2010-02-16 | Alchemia Oncology Pty Limited | Antibody that specifically binds hyaluronan synthase |
US20050191653A1 (en) | 2003-11-03 | 2005-09-01 | Freier Susan M. | Modulation of SGLT2 expression |
CA2747871C (en) | 2003-11-17 | 2018-04-10 | Genentech, Inc. | Compositions and methods for the treatment of tumor of hematopoietic origin |
NZ548204A (en) | 2003-12-03 | 2009-08-28 | Coda Therapeutics Nz Ltd | Antisense compounds targeted to connexins and methods of use thereof |
US7259258B2 (en) * | 2003-12-17 | 2007-08-21 | Illumina, Inc. | Methods of attaching biological compounds to solid supports using triazine |
WO2005060675A2 (en) * | 2003-12-19 | 2005-07-07 | Philadelphia Health And Education Corporation(D/B/A Drexel University College Of Medicine (Ducom)) | Novel spliced 5-ht1a receptors and methods, kits, and uses relating thereto |
US20050136414A1 (en) * | 2003-12-23 | 2005-06-23 | Kevin Gunderson | Methods and compositions for making locus-specific arrays |
WO2005067646A2 (en) | 2004-01-07 | 2005-07-28 | Hitachi Chemical Research Center, Inc. | Primers and probes for the detection of hiv |
JP2007520474A (en) * | 2004-01-12 | 2007-07-26 | ジーンセンス テクノロジーズ インコーポレーテッド | Antisense oligonucleotides directed to ribonucleotide reductase R2 and its use in combination therapy for the treatment of cancer |
WO2006054296A2 (en) | 2004-11-17 | 2006-05-26 | Spectrum Dynamics Llc | Methods of detecting prostate cancer |
WO2005071080A2 (en) | 2004-01-20 | 2005-08-04 | Isis Pharmaceuticals, Inc. | Modulation of glucocorticoid receptor expression |
US8778900B2 (en) * | 2004-01-22 | 2014-07-15 | Isis Pharmaceuticals, Inc. | Modulation of eIF4E-BP1 expression |
US7468431B2 (en) * | 2004-01-22 | 2008-12-23 | Isis Pharmaceuticals, Inc. | Modulation of eIF4E-BP2 expression |
WO2005072527A2 (en) * | 2004-01-23 | 2005-08-11 | Avi Biopharma, Inc. | Antisense oligomers and methods for inducing immune tolerance and immunosuppression |
EP2816351A3 (en) * | 2004-01-27 | 2015-03-25 | Compugen Ltd. | Methods and systems for annotating biomolecular sequences |
US7842459B2 (en) * | 2004-01-27 | 2010-11-30 | Compugen Ltd. | Nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis |
WO2005074633A2 (en) * | 2004-02-03 | 2005-08-18 | The Regents Of The University Of Michigan | Compositions and methods for characterizing, regulating, diagnosing, and treating cancer |
US7481997B1 (en) | 2004-02-12 | 2009-01-27 | Montana State University | Snow mountain virus genome sequence, virus-like particles and methods of use |
WO2005082110A2 (en) * | 2004-02-26 | 2005-09-09 | Illumina Inc. | Haplotype markers for diagnosing susceptibility to immunological conditions |
US8569474B2 (en) | 2004-03-09 | 2013-10-29 | Isis Pharmaceuticals, Inc. | Double stranded constructs comprising one or more short strands hybridized to a longer strand |
EP2700720A3 (en) | 2004-03-15 | 2015-01-28 | Isis Pharmaceuticals, Inc. | Compositions and methods for optimizing cleavage of RNA by RNASE H |
AU2005230684B2 (en) | 2004-04-05 | 2011-10-06 | Alnylam Pharmaceuticals, Inc. | Process and reagents for oligonucleotide synthesis and purification |
US20050244869A1 (en) | 2004-04-05 | 2005-11-03 | Brown-Driver Vickie L | Modulation of transthyretin expression |
US20050260755A1 (en) * | 2004-04-06 | 2005-11-24 | Isis Pharmaceuticals, Inc. | Sequential delivery of oligomeric compounds |
US20050260652A1 (en) * | 2004-04-15 | 2005-11-24 | The General Hospital Corporation | Compositions and methods that modulate RNA interference |
CA2562151C (en) | 2004-04-30 | 2016-09-06 | Alnylam Pharmaceuticals, Inc. | Oligonucleotides comprising a c5-modified pyrimidine |
EP2322650A1 (en) | 2004-05-14 | 2011-05-18 | Rosetta Genomics Ltd | MicroRNAs and uses thereof |
EP2325331A1 (en) | 2004-05-14 | 2011-05-25 | Rosetta Genomics Ltd | MicroRNAs and Uses Thereof |
AU2005244036A1 (en) * | 2004-05-14 | 2005-11-24 | Universite De Laval | Phospholipase C gamma modulation and uses thereof for management of pain and nociception |
AU2005245996A1 (en) | 2004-05-21 | 2005-12-01 | Atonomics A/S | Surface acoustic wave sensor comprising a hydrogel |
EP3225633B1 (en) | 2004-05-21 | 2020-03-25 | The UAB Research Foundation | Variable lymphocyte receptors, related polypeptides and nucleic acids, and uses thereof |
WO2005116081A2 (en) | 2004-05-24 | 2005-12-08 | Genvault Corporation | Stable protein storage and stable nucleic acid storage in recoverable form |
US7524827B2 (en) | 2004-06-01 | 2009-04-28 | Pronai Therapeutics, Inc. | Methods and compositions for the inhibition of gene expression |
US20090048192A1 (en) * | 2004-06-03 | 2009-02-19 | Isis Pharmaceuticals, Inc. | Double Strand Compositions Comprising Differentially Modified Strands for Use in Gene Modulation |
US8394947B2 (en) | 2004-06-03 | 2013-03-12 | Isis Pharmaceuticals, Inc. | Positionally modified siRNA constructs |
JP2008509681A (en) * | 2004-06-09 | 2008-04-03 | マクギル・ユニバーシテイ | Polynucleotides encoding the acetylcholine-dependent chloride channel subunit of CENORHABDITISELEGANS |
US7858323B2 (en) | 2004-06-09 | 2010-12-28 | The Regents Of The University Of Michigan | Phage microarray profiling of the humoral response to disease |
US7745125B2 (en) * | 2004-06-28 | 2010-06-29 | Roche Molecular Systems, Inc. | 2′-terminator related pyrophosphorolysis activated polymerization |
USRE48960E1 (en) | 2004-06-28 | 2022-03-08 | The University Of Western Australia | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
EP2500430B1 (en) | 2004-06-28 | 2017-03-08 | The University Of Western Australia | Antisense oligonucleotides for inducing exon skipping and methods of use thereof |
US8314072B2 (en) | 2004-07-02 | 2012-11-20 | Avi Biopharma, Inc. | Antisense antibacterial method and compound |
US20060024677A1 (en) | 2004-07-20 | 2006-02-02 | Morris David W | Novel therapeutic targets in cancer |
WO2006033732A1 (en) * | 2004-08-17 | 2006-03-30 | Invitrogen Corporation | Synthesis of highly luminescent colloidal particles |
WO2006023880A2 (en) * | 2004-08-23 | 2006-03-02 | Isis Pharmaceuticals, Inc. | Compounds and methods for the characterization of oligonucleotides |
US7884086B2 (en) | 2004-09-08 | 2011-02-08 | Isis Pharmaceuticals, Inc. | Conjugates for use in hepatocyte free uptake assays |
US8129352B2 (en) * | 2004-09-16 | 2012-03-06 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating ssRNA viral infection |
WO2006030442A2 (en) | 2004-09-16 | 2006-03-23 | Gamida-Cell Ltd. | Methods of ex vivo progenitor and stem cell expansion by co-culture with mesenchymal cells |
DK1809303T3 (en) | 2004-09-23 | 2019-06-11 | Arc Medical Devices Inc | PHARMACEUTICAL COMPOSITION AND METHODS IN RELATION TO FIBROSE ADHESION OR INFLAMMATORIC DISEASE USING LOW SULPHATE FUCAN |
ATE435025T1 (en) * | 2004-10-18 | 2009-07-15 | Sinai School Medicine | INHIBITION OF TUMOR GROWTH AND METASTASIS FORMATION WITH PEPTIDES DERIVED FROM ATF2 |
US7368086B2 (en) * | 2004-10-29 | 2008-05-06 | Invitrogen Corporation | Functionalized fluorescent nanocrystals, and methods for their preparation and use |
US7524829B2 (en) * | 2004-11-01 | 2009-04-28 | Avi Biopharma, Inc. | Antisense antiviral compounds and methods for treating a filovirus infection |
US20090118132A1 (en) * | 2004-11-04 | 2009-05-07 | Roche Molecular Systems, Inc. | Classification of Acute Myeloid Leukemia |
US8440610B2 (en) * | 2004-11-12 | 2013-05-14 | Massachusetts Institute Of Technology | Mapkap kinase-2 as a specific target for blocking proliferation of P53-defective cells |
WO2006050999A2 (en) * | 2004-11-15 | 2006-05-18 | Obe Therapy Biotechnology S.A.S | Methods of reducing body fat |
US7842794B2 (en) | 2004-12-17 | 2010-11-30 | Roche Molecular Systems, Inc. | Reagents and methods for detecting Neisseria gonorrhoeae |
DE102004063599B4 (en) | 2004-12-30 | 2007-07-12 | Bayer Innovation Gmbh | Shortened wound healing processes by means of novel fiber fleeces |
KR20070104574A (en) * | 2004-12-30 | 2007-10-26 | 신벤션 아게 | Combination comprising an agent providing a signal, an implant material and a drug |
WO2006076650A2 (en) * | 2005-01-12 | 2006-07-20 | Applera Corporation | Compositions, methods, and kits for selective amplification of nucleic acids |
EP2014708A1 (en) * | 2005-01-13 | 2009-01-14 | Cinvention Ag | Shaped body made of a composite material |
KR20070102717A (en) * | 2005-01-24 | 2007-10-19 | 신벤션 아게 | Metal containing composite materials |
AU2006257283A1 (en) | 2005-02-03 | 2006-12-21 | Coda Therapeutics Limited | Anti-connexin compounds and uses thereof |
CA2596506C (en) | 2005-02-09 | 2021-04-06 | Avi Biopharma, Inc. | Antisense composition and method for treating muscle atrophy |
WO2006123246A2 (en) * | 2005-02-11 | 2006-11-23 | Aurelium Biopharma Inc. | Methods for identifying chemotherapeutic resistance in non-hematopoietic tumors |
RU2007137489A (en) | 2005-03-10 | 2009-04-20 | Дженентек, Инк. (Us) | METHODS AND COMPOSITIONS FOR MODULATION OF VESSEL INTEGRITY |
JP2008532913A (en) * | 2005-03-18 | 2008-08-21 | シンベンション アーゲー | Process for the preparation of porous sintered metal materials |
US20060256599A1 (en) * | 2005-03-22 | 2006-11-16 | Malin Patricia J | Database of electronically profiled cells and methods for generating and using same |
US7476733B2 (en) | 2005-03-25 | 2009-01-13 | The United States Of America As Represented By The Department Of Health And Human Services | Development of a real-time PCR assay for detection of pneumococcal DNA and diagnosis of pneumococccal disease |
US20060240032A1 (en) * | 2005-03-31 | 2006-10-26 | Hinrichs David J | Immunomodulating compositions and methods for use in the treatment of human autoimmune diseases |
US8309303B2 (en) | 2005-04-01 | 2012-11-13 | Qiagen Gmbh | Reverse transcription and amplification of RNA with simultaneous degradation of DNA |
CA2605512A1 (en) * | 2005-04-22 | 2006-10-26 | Academisch Ziekenhuis Leiden | Modulation of exon recognition in pre-mrna by interfering with the binding of sr proteins and by interfering with secondary rna structure. |
US7838502B2 (en) * | 2005-05-06 | 2010-11-23 | University Of Massachusetts Medical School | Compositions and methods to modulate H. influenzae pathogenesis |
EP2298829B1 (en) | 2005-05-31 | 2017-09-20 | École Polytechnique Fédérale de Lausanne (EPFL) | Triblock copolymers for cytoplasmic delivery of gene-based drugs |
EP1904111A4 (en) | 2005-06-03 | 2009-08-19 | Univ Johns Hopkins | Compositions and methods for decreasing microrna expression for the treatment of neoplasia |
US20070105133A1 (en) * | 2005-06-13 | 2007-05-10 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
WO2006135886A2 (en) * | 2005-06-13 | 2006-12-21 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
US8252756B2 (en) | 2005-06-14 | 2012-08-28 | Northwestern University | Nucleic acid functionalized nanoparticles for therapeutic applications |
US20090264299A1 (en) * | 2006-02-24 | 2009-10-22 | Complete Genomics, Inc. | High throughput genome sequencing on DNA arrays |
EP3492602A1 (en) | 2005-06-15 | 2019-06-05 | Complete Genomics, Inc. | Single molecule arrays for genetic and chemical analysis |
US8067208B2 (en) | 2005-06-30 | 2011-11-29 | Roche Molecular Systems, Inc. | Probes and methods for hepatitis C virus typing using multidimensional probe analysis |
MX2008000131A (en) * | 2005-07-01 | 2008-04-04 | Cinv Ag | Medical devices comprising a reticulated composite material. |
EP1902087A1 (en) * | 2005-07-01 | 2008-03-26 | Cinvention Ag | Process for the production of porous reticulated composite materials |
WO2007007317A1 (en) | 2005-07-07 | 2007-01-18 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Nucleic acid agents for downregulating h19, and methods of using same |
WO2007009094A2 (en) | 2005-07-13 | 2007-01-18 | Avi Biopharma, Inc. | Antisense antibacterial method and compound |
US8067571B2 (en) | 2005-07-13 | 2011-11-29 | Avi Biopharma, Inc. | Antibacterial antisense oligonucleotide and method |
US7790694B2 (en) * | 2005-07-13 | 2010-09-07 | Avi Biopharma Inc. | Antisense antibacterial method and compound |
US7776532B2 (en) | 2005-08-11 | 2010-08-17 | Synthetic Genomics, Inc. | Method for in vitro recombination |
US20100015604A1 (en) | 2005-08-17 | 2010-01-21 | Evriklia Lianidou | Composition and method for determination of ck19 expression |
EP2338991B1 (en) | 2005-08-29 | 2017-01-18 | Regulus Therapeutics Inc. | Methods for use in modulating MIR-122a |
WO2007030691A2 (en) * | 2005-09-08 | 2007-03-15 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating picornavirus infection |
US8329668B2 (en) | 2005-09-08 | 2012-12-11 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating picornavirus infection |
EP1762627A1 (en) | 2005-09-09 | 2007-03-14 | Qiagen GmbH | Method for the activation of a nucleic acid for performing a polymerase reaction |
EP2612870A1 (en) | 2005-09-12 | 2013-07-10 | The Regents of the University of Michigan | Recurrent gene fusions in prostate cancer |
US8906609B1 (en) | 2005-09-26 | 2014-12-09 | Arrowhead Center, Inc. | Label-free biomolecule sensor based on surface charge modulated ionic conductance |
CN101321877B (en) | 2005-10-03 | 2013-04-10 | 应用生物系统有限责任公司 | Compositions, methods, and kits for amplifying nucleic acids |
IL172297A (en) | 2005-10-03 | 2016-03-31 | Compugen Ltd | Soluble vegfr-1 variants for diagnosis of preeclamsia |
EP2392645A1 (en) | 2005-10-14 | 2011-12-07 | MUSC Foundation For Research Development | Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy |
US8080534B2 (en) | 2005-10-14 | 2011-12-20 | Phigenix, Inc | Targeting PAX2 for the treatment of breast cancer |
US8652467B2 (en) * | 2005-10-14 | 2014-02-18 | The Regents Of The University Of Michigan | Dek protein compositions and methods of using the same |
JP2009511727A (en) * | 2005-10-18 | 2009-03-19 | シンベンション アーゲー | Thermosetting particles and manufacturing method thereof |
US7794951B2 (en) * | 2005-10-18 | 2010-09-14 | University Of Massachusetts Medical School | SREBP2gc transcription factors and uses thereof |
JP5671206B2 (en) | 2005-10-21 | 2015-02-18 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Mutation of c-KIT oncogene in melanoma |
CA2627025A1 (en) | 2005-10-28 | 2007-05-03 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of huntingtin gene |
US7723112B2 (en) * | 2005-10-31 | 2010-05-25 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
EP1961065A4 (en) | 2005-10-31 | 2009-11-11 | Oncomed Pharm Inc | Compositions and methods for diagnosing and treating cancer |
US7723477B2 (en) * | 2005-10-31 | 2010-05-25 | Oncomed Pharmaceuticals, Inc. | Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth |
WO2007056326A2 (en) * | 2005-11-04 | 2007-05-18 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of nav1.8 gene |
US8501704B2 (en) | 2005-11-08 | 2013-08-06 | Sarepta Therapeutics, Inc. | Immunosuppression compound and treatment method |
WO2007056331A2 (en) | 2005-11-09 | 2007-05-18 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of factor v leiden mutant gene |
CA2630602A1 (en) | 2005-11-21 | 2007-05-31 | Isis Pharmaceuticals, Inc. | Modulation of eif4e-bp2 expression |
US8846393B2 (en) | 2005-11-29 | 2014-09-30 | Gamida-Cell Ltd. | Methods of improving stem cell homing and engraftment |
WO2007064945A2 (en) | 2005-12-01 | 2007-06-07 | Pronai Therapeutics, Inc. | Cancer therapies and pharmaceutical compositions used therein |
US20090215055A1 (en) * | 2005-12-13 | 2009-08-27 | Erasmus University Medical Center Rotterdam | Genetic Brain Tumor Markers |
ES2433669T3 (en) | 2005-12-13 | 2013-12-12 | The Trustees Of The University Of Pennsylvania | Methods for phototransfecting nucleic acid in living cells |
US9157066B2 (en) | 2005-12-13 | 2015-10-13 | The Trustees Of The University Of Pennsylvania | Transcriptome transfer produces cellular phenotype conversion |
US10647960B2 (en) * | 2005-12-13 | 2020-05-12 | The Trustees Of The University Of Pennsylvania | Transcriptome transfer produces cellular phenotype conversion |
US8313901B2 (en) * | 2005-12-21 | 2012-11-20 | Yale University | Methods and compositions related to the modulation of riboswitches |
EP1976567B1 (en) * | 2005-12-28 | 2020-05-13 | The Scripps Research Institute | Natural antisense and non-coding rna transcripts as drug targets |
EP2216339A1 (en) | 2006-01-16 | 2010-08-11 | Compugen Ltd. | Novel nucleotide and amino acid sequences, and methods of use thereof for diagnosis |
CN101426536A (en) | 2006-01-20 | 2009-05-06 | 妇女儿童健康研究院公司 | Method of treatment, prophylaxis and diagnosis of pathologies of the bone |
SI2161038T1 (en) | 2006-01-26 | 2014-05-30 | Isis Pharmaceuticals, Inc. | Compositions and their uses directed to Huntingtin |
DE602007009487D1 (en) * | 2006-01-27 | 2010-11-11 | Isis Pharmaceutical Inc | 6-MODIFIED BICYCLIC NUCLEIC ACID ANALOGUE |
US7569686B1 (en) | 2006-01-27 | 2009-08-04 | Isis Pharmaceuticals, Inc. | Compounds and methods for synthesis of bicyclic nucleic acid analogs |
US8129515B2 (en) | 2006-01-27 | 2012-03-06 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for the use in modulation of microRNAs |
US8229398B2 (en) * | 2006-01-30 | 2012-07-24 | Qualcomm Incorporated | GSM authentication in a CDMA network |
US20080019961A1 (en) * | 2006-02-21 | 2008-01-24 | Regents Of The University Of Michigan | Hedgehog signaling pathway antagonist cancer treatment |
EP2495337A1 (en) | 2006-02-24 | 2012-09-05 | Callida Genomics, Inc. | High throughput genome sequencing on DNA arrays |
EP2010677A4 (en) * | 2006-02-24 | 2010-04-14 | Investigen Inc | Methods and compositions for detecting polynucleotides |
NZ571791A (en) | 2006-03-08 | 2012-03-30 | Archemix Llc | Complement binding aptamers and anti-C5 agents useful in the treatment of ocular disorders |
US7914988B1 (en) * | 2006-03-31 | 2011-03-29 | Illumina, Inc. | Gene expression profiles to predict relapse of prostate cancer |
AU2007233109B2 (en) | 2006-03-31 | 2010-10-14 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of Eg5 gene |
US8007790B2 (en) | 2006-04-03 | 2011-08-30 | Stowers Institute For Medical Research | Methods for treating polycystic kidney disease (PKD) or other cyst forming diseases |
US20100055116A1 (en) | 2006-04-13 | 2010-03-04 | Liou Hsiou-Chi | Methods and Compositions for Targeting c-Rel |
WO2007123391A1 (en) * | 2006-04-20 | 2007-11-01 | Academisch Ziekenhuis Leiden | Therapeutic intervention in a genetic disease in an individual by modifying expression of an aberrantly expressed gene. |
CN101437943A (en) | 2006-05-03 | 2009-05-20 | 波罗的科技发展有限公司 | Antisense agents combining strongly bound base - modified oligonucleotide and artificial nuclease |
EP2015758B1 (en) | 2006-05-05 | 2014-04-02 | Isis Pharmaceuticals, Inc. | Compounds and methods for modulating expression apob |
HUE036995T2 (en) * | 2006-05-10 | 2018-08-28 | Sarepta Therapeutics Inc | Oligonucleotide analogs having cationic intersubunit linkages |
US8785407B2 (en) * | 2006-05-10 | 2014-07-22 | Sarepta Therapeutics, Inc. | Antisense antiviral agent and method for treating ssRNA viral infection |
CA2651815A1 (en) * | 2006-05-10 | 2007-11-22 | Dxterity Diagnostics | Detection of nucleic acid targets using chemically reactive oligonucleotide probes |
CN101490074B (en) * | 2006-05-11 | 2013-06-26 | Isis制药公司 | 5'-modified bicyclic nucleic acid analogs |
US20070265215A1 (en) * | 2006-05-11 | 2007-11-15 | Iversen Patrick L | Antisense restenosis composition and method |
PL2194128T3 (en) | 2006-05-11 | 2012-12-31 | Alnylam Pharmaceuticals Inc | Compositions and methods for inhibiting expression of the PCSK9 gene |
US7666854B2 (en) * | 2006-05-11 | 2010-02-23 | Isis Pharmaceuticals, Inc. | Bis-modified bicyclic nucleic acid analogs |
BRPI0712034A2 (en) * | 2006-05-19 | 2012-01-10 | Alnylam Pharmaceuticals Inc | aha rnai modulation and therapeutic uses thereof |
EP1857548A1 (en) * | 2006-05-19 | 2007-11-21 | Academisch Ziekenhuis Leiden | Means and method for inducing exon-skipping |
EP2192200B1 (en) | 2006-05-22 | 2012-10-24 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of IKK-B gene |
WO2007137301A2 (en) * | 2006-05-23 | 2007-11-29 | Isis Pharmaceuticals, Inc. | Modulation of chrebp expression |
US11001881B2 (en) | 2006-08-24 | 2021-05-11 | California Institute Of Technology | Methods for detecting analytes |
US8637436B2 (en) | 2006-08-24 | 2014-01-28 | California Institute Of Technology | Integrated semiconductor bioarray |
EP2489745B1 (en) | 2006-06-05 | 2017-01-11 | California Institute Of Technology | Real time micro arrays |
US9115389B2 (en) * | 2006-06-30 | 2015-08-25 | Rosetta Genomics Ltd. | Method for detecting a target nucleic acid comprising two portions using probes having a first portion complementary to the first portion of the target nucleic acid and a second portion substantially complementary to the second portion of the target nucleic acid |
WO2008011473A2 (en) | 2006-07-19 | 2008-01-24 | Isis Pharmaceuticals, Inc. | Compositions and their uses directed to hbxip |
US8048626B2 (en) | 2006-07-28 | 2011-11-01 | California Institute Of Technology | Multiplex Q-PCR arrays |
EP2412383A1 (en) | 2006-07-28 | 2012-02-01 | Children's Memorial Hospital | Methods of inhibiting tumor cell aggressiveness using the microenvironment of human embryonic stem cells |
US11525156B2 (en) | 2006-07-28 | 2022-12-13 | California Institute Of Technology | Multiplex Q-PCR arrays |
EP2049664B1 (en) | 2006-08-11 | 2011-09-14 | Prosensa Technologies B.V. | Single stranded oligonucleotides complementary to repetitive elements for treating DNA repeat instability associated genetic disorders |
US11560588B2 (en) | 2006-08-24 | 2023-01-24 | California Institute Of Technology | Multiplex Q-PCR arrays |
US20080261216A1 (en) * | 2006-09-08 | 2008-10-23 | The Regents Of The University Of Michigan | HERV Group II Viruses In Lymphoma And Cancer |
JP2010502752A (en) * | 2006-09-11 | 2010-01-28 | イェール ユニバーシティー | Lysine riboswitch, structure-based compound design using lysine riboswitch, and methods and compositions for use with lysine riboswitch |
WO2008073175A2 (en) | 2006-09-14 | 2008-06-19 | The Regents Of The University Of California | Nanoplasmonic molecular ruler for nuclease activity and dna footprinting |
WO2008036933A2 (en) | 2006-09-21 | 2008-03-27 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the hamp gene |
CA2927045A1 (en) | 2006-10-03 | 2008-04-10 | Muthiah Manoharan | Lipid containing formulations |
US20100166743A1 (en) | 2006-10-06 | 2010-07-01 | University Of Utah Research Foundation | Method of detecting ocular diseases and pathologic conditions and treatment of same |
EP1914303A1 (en) * | 2006-10-09 | 2008-04-23 | Qiagen GmbH | Thermus eggertssonii DNA polymerases |
US20080096193A1 (en) * | 2006-10-24 | 2008-04-24 | Charles Robert Bupp | Methods and compositions for detecting polynucleotides |
JP2010507595A (en) | 2006-10-27 | 2010-03-11 | ザ・ユニヴァーシティ・オヴ・ウェスタン・オンタリオ | Inhibition of SOX9 function in the treatment of pathophysiological conditions associated with proteoglycans |
US7910354B2 (en) | 2006-10-27 | 2011-03-22 | Complete Genomics, Inc. | Efficient arrays of amplified polynucleotides |
US8999317B2 (en) | 2006-11-01 | 2015-04-07 | University Of Rochester | Methods and compositions related to the structure and function of APOBEC3G |
US20090111705A1 (en) * | 2006-11-09 | 2009-04-30 | Complete Genomics, Inc. | Selection of dna adaptor orientation by hybrid capture |
CA2669832A1 (en) * | 2006-11-15 | 2008-05-22 | Coda Therapeutics, Inc. | Improved methods and compositions for wound healing |
US20080242560A1 (en) * | 2006-11-21 | 2008-10-02 | Gunderson Kevin L | Methods for generating amplified nucleic acid arrays |
AU2006351377A1 (en) * | 2006-11-30 | 2008-06-05 | University Of British Columbia | Poxviridae treatment comprising TAP-1 and/or TAP-2 as a molecular adjuvant |
WO2009024834A2 (en) * | 2006-12-05 | 2009-02-26 | Rosetta Genomics Ltd | Nucleic acids involved in viral infection |
CA2672297A1 (en) | 2006-12-11 | 2008-06-19 | University Of Utah Research Foundation | Compositions and methods for treating pathologic angiogenesis and vascular permeability |
US9938641B2 (en) * | 2006-12-18 | 2018-04-10 | Fluidigm Corporation | Selection of aptamers based on geometry |
US7858772B2 (en) * | 2006-12-22 | 2010-12-28 | Roche Molecular Systems, Inc. | Compounds and methods for synthesis and purification of oligonucleotides |
EP2097448A4 (en) | 2006-12-22 | 2010-07-21 | Univ Utah Res Found | Method of detecting ocular diseases and pathologic conditions and treatment of same |
US7820389B2 (en) * | 2007-01-10 | 2010-10-26 | Geneohm Sciences, Inc. | Inhibition of mismatch hybridization by a universal competitor DNA |
JP2010515464A (en) * | 2007-01-11 | 2010-05-13 | イエール・ユニバーシテイ | Compositions and methods for targeted inactivation of HIV cell surface receptors |
US20100086526A1 (en) * | 2007-01-16 | 2010-04-08 | Abraham Hochberg | Nucleic acid constructs and methods for specific silencing of h19 |
BRPI0806916A2 (en) * | 2007-01-19 | 2014-04-29 | Cinv Ag | NON-DEGRADABLE POROUS IMPLANT MADE BY DUST |
EP2106439B1 (en) | 2007-01-24 | 2014-11-12 | The Regents of the University of Michigan | Compositions and methods for treating and diagnosing pancreatic cancer |
WO2008092099A2 (en) * | 2007-01-26 | 2008-07-31 | Rosetta Genomics, Ltd. | Compositions and methods for treating hematopoietic malignancies |
US20100196403A1 (en) * | 2007-01-29 | 2010-08-05 | Jacob Hochman | Antibody conjugates for circumventing multi-drug resistance |
AU2008212820B2 (en) | 2007-02-09 | 2014-01-30 | Northwestern University | Particles for detecting intracellular targets |
US7771947B2 (en) * | 2007-02-23 | 2010-08-10 | Investigen, Inc. | Methods and compositions for rapid light-activated isolation and detection of analytes |
AU2008220438A1 (en) * | 2007-02-27 | 2008-09-04 | Rosetta Genomics Ltd. | Composition and methods for modulating cell proliferation and cell death |
US9006206B2 (en) | 2007-02-27 | 2015-04-14 | Rosetta Genomics Ltd. | Composition and methods for modulating cell proliferation and cell death |
EP2129803A4 (en) * | 2007-02-27 | 2010-11-03 | Univ Northwestern | Molecule attachment to nanoparticles |
US20080206862A1 (en) * | 2007-02-28 | 2008-08-28 | Cinvention Ag | High surface cultivation system bag |
EP2126040A1 (en) * | 2007-02-28 | 2009-12-02 | Cinvention Ag | High surface cultivation system |
EP2126115A2 (en) | 2007-03-01 | 2009-12-02 | Rosetta Genomics Ltd | Diagnosis and prognosis of various types of cancers |
EP2471925A1 (en) | 2007-03-22 | 2012-07-04 | Yale University | Methods and compositions related to riboswitches that control alternative splicing |
PE20090064A1 (en) | 2007-03-26 | 2009-03-02 | Novartis Ag | DOUBLE-CHAIN RIBONUCLEIC ACID TO INHIBIT THE EXPRESSION OF THE HUMAN E6AP GENE AND THE PHARMACEUTICAL COMPOSITION THAT INCLUDES IT |
WO2012070037A2 (en) | 2010-11-22 | 2012-05-31 | Rosetta Genomics Ltd. | Methods and materials for classification of tissue of origin of tumor samples |
US20100273172A1 (en) | 2007-03-27 | 2010-10-28 | Rosetta Genomics Ltd. | Micrornas expression signature for determination of tumors origin |
JP5350360B2 (en) | 2007-03-29 | 2013-11-27 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | Compositions and methods for inhibiting the expression of genes from Ebola |
CA2690281A1 (en) | 2007-05-11 | 2008-11-20 | The Johns Hopkins University | Biomarkers for melanoma |
WO2008141176A1 (en) * | 2007-05-11 | 2008-11-20 | The Trustees Of The University Of Pennsylvania | Methods of treatment of skin ulcers |
EA200971050A1 (en) | 2007-05-11 | 2010-06-30 | Томас Джефферсон Юниверсити | METHODS OF TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES AND DISORDERS |
EP3351270A1 (en) | 2007-05-23 | 2018-07-25 | The Trustees of the University of Pennsylvania | Targeted carriers for intracellular drug delivery |
KR20100017905A (en) | 2007-05-29 | 2010-02-16 | 예일 유니버시티 | Riboswitches and methods and compositions for use of and with riboswitches |
MX2009012647A (en) * | 2007-05-29 | 2009-12-14 | Univ Yale | Methods and compositions related to riboswitches that control alternative splicing and rna processing. |
EP2160464B1 (en) | 2007-05-30 | 2014-05-21 | Northwestern University | Nucleic acid functionalized nanoparticles for therapeutic applications |
CA2688321A1 (en) | 2007-05-30 | 2008-12-11 | Isis Pharmaceuticals, Inc. | N-substituted-aminomethylene bridged bicyclic nucleic acid analogs |
US7807372B2 (en) * | 2007-06-04 | 2010-10-05 | Northwestern University | Screening sequence selectivity of oligonucleotide-binding molecules using nanoparticle based colorimetric assay |
ES2798758T3 (en) | 2007-06-06 | 2020-12-14 | Sarepta Therapeutics Inc | Soluble her2 and her3 splice variant proteins, splice exchange oligonucleotides and their use in the treatment of disease |
EP2173760B2 (en) | 2007-06-08 | 2015-11-04 | Isis Pharmaceuticals, Inc. | Carbocyclic bicyclic nucleic acid analogs |
US20090324596A1 (en) * | 2008-06-30 | 2009-12-31 | The Trustees Of Princeton University | Methods of identifying and treating poor-prognosis cancers |
US10745701B2 (en) | 2007-06-28 | 2020-08-18 | The Trustees Of Princeton University | Methods of identifying and treating poor-prognosis cancers |
CA2691673A1 (en) | 2007-06-29 | 2009-01-08 | Avi Biopharma, Inc. | Tissue specific peptide conjugates and methods |
CA2692579C (en) * | 2007-07-05 | 2016-05-03 | Isis Pharmaceuticals, Inc. | 6-disubstituted bicyclic nucleic acid analogs |
EP2319926B1 (en) | 2007-07-05 | 2016-08-31 | Arrowhead Research Corporation | DSRNA for treating viral infection |
AU2008275304B2 (en) | 2007-07-06 | 2012-07-26 | The Regents Of The University Of Michigan | Recurrent gene fusions in prostate cancer |
WO2009008725A2 (en) * | 2007-07-12 | 2009-01-15 | Prosensa Technologies B.V. | Molecules for targeting compounds to various selected organs, tissues or tumor cells |
JP5706157B2 (en) * | 2007-07-12 | 2015-04-22 | プロセンサ テクノロジーズ ビー.ブイ.Prosensa Technologies B.V. | Molecules for targeting compounds to various selected organs or tissues |
CN101821277B (en) * | 2007-08-15 | 2014-05-07 | Isis制药公司 | Tetrahydropyran nucleic acid analogs |
CN101802182A (en) | 2007-08-21 | 2010-08-11 | 诺达利蒂公司 | Be used to diagnose, the method for prognosis and methods of treatment |
US9422363B2 (en) | 2007-08-28 | 2016-08-23 | Uab Research Foundation | Synthetic apolipoprotein E mimicking polypeptides and methods of use |
CA2697957A1 (en) | 2007-08-28 | 2009-03-12 | Uab Research Foundation | Synthetic apolipoprotein e mimicking polypeptides and methods of use |
LT2769729T (en) | 2007-09-04 | 2019-05-10 | Compugen Ltd. | Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics |
US8138318B2 (en) | 2007-09-13 | 2012-03-20 | Abbott Laboratories | Hepatitis B pre-S2 nucleic acid |
WO2009039192A2 (en) | 2007-09-17 | 2009-03-26 | The Regents Of The University Of Californina | Internalizing human monoclonal antibodies targeting prostate cancer cells in situ |
US8445217B2 (en) | 2007-09-20 | 2013-05-21 | Vanderbilt University | Free solution measurement of molecular interactions by backscattering interferometry |
US7951785B2 (en) * | 2007-09-21 | 2011-05-31 | California Institute Of Technology | NFIA in glial fate determination, glioma therapy and astrocytoma treatment |
JP2010539978A (en) | 2007-10-02 | 2010-12-24 | アムジェン インコーポレイテッド | Increased erythropoietin using nucleic acids that can hybridize to micro-RNA and its precursors |
JP5600064B2 (en) | 2007-10-26 | 2014-10-01 | アカデミシュ ジーケンハウス ライデン | Means and methods for offsetting myopathy |
USRE48468E1 (en) | 2007-10-26 | 2021-03-16 | Biomarin Technologies B.V. | Means and methods for counteracting muscle disorders |
US7820391B2 (en) | 2007-11-06 | 2010-10-26 | Osmetech Molecular Diagnostics | Baseless nucleotide analogues and uses thereof |
US8097712B2 (en) | 2007-11-07 | 2012-01-17 | Beelogics Inc. | Compositions for conferring tolerance to viral disease in social insects, and the use thereof |
USRE47320E1 (en) | 2007-11-20 | 2019-03-26 | Ionis Pharmaceuticals, Inc. | Modulation of CD40 expression |
US8546556B2 (en) * | 2007-11-21 | 2013-10-01 | Isis Pharmaceuticals, Inc | Carbocyclic alpha-L-bicyclic nucleic acid analogs |
DK2610351T3 (en) | 2007-12-05 | 2015-09-28 | Complete Genomics Inc | Base efficient provision of sequencing reactions |
EP2848688A1 (en) | 2007-12-10 | 2015-03-18 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of factor VII gene |
PT2231861E (en) * | 2007-12-13 | 2015-02-03 | Philip Morris Products Sa | Transgenic plants modified for reduced cadmium transport, derivative products, and related methods |
AU2008343841A1 (en) | 2007-12-21 | 2009-07-09 | Coda Therapeutics, Inc. | Use of inhibitors of connexin43 for treatment of fibrotic conditions |
JP2011507859A (en) * | 2007-12-21 | 2011-03-10 | コーダ セラピューティクス, インコーポレイテッド | Use of anti-connexin polynucleotides for the treatment of surgical adhesions |
JP2011507861A (en) * | 2007-12-21 | 2011-03-10 | コーダ セラピューティクス, インコーポレイテッド | Use of anti-connexin polypeptide agents in combination with anti-connexin polynucleotide agents for the treatment of fibrotic conditions |
AU2008345033B2 (en) | 2007-12-28 | 2014-04-03 | Sarepta Therapeutics, Inc. | Immunomodulatory agents and methods of use |
EP3100718B1 (en) | 2008-01-02 | 2019-11-27 | Arbutus Biopharma Corporation | Improved compositions and methods for the delivery of nucleic acids |
US20110038920A1 (en) * | 2008-01-07 | 2011-02-17 | Ryoichi Mori | Wound healing compositions and treatments |
AU2009208035B2 (en) | 2008-01-22 | 2014-04-03 | Dogenes Inc. | Compositions and methods for detecting Juvenile Renal Dysplasia or calcium oxalate stones in dogs |
CA2708661A1 (en) | 2008-01-27 | 2009-07-30 | Rosetta Genomics Ltd. | Methods and compositions for diagnosing complications of pregnancy |
CA2713667A1 (en) * | 2008-01-31 | 2009-08-06 | Compugen Ltd. | Cd55 isoform and uses therof in cancer detection, monitoring and therapy |
US8530640B2 (en) * | 2008-02-07 | 2013-09-10 | Isis Pharmaceuticals, Inc. | Bicyclic cyclohexitol nucleic acid analogs |
AU2009210872A1 (en) * | 2008-02-08 | 2009-08-13 | Prosensa Holding Bv | Methods and means for treating DNA repeat instability associated genetic disorders |
KR101397407B1 (en) | 2008-03-05 | 2014-06-19 | 알닐람 파마슈티칼스 인코포레이티드 | Compositions and methods for inhibiting expression of Eg5 and VEGF genes |
US8426378B2 (en) | 2008-03-21 | 2013-04-23 | Isis Pharmaceuticals, Inc. | Oligomeric compounds comprising tricyclic nucelosides and methods for their use |
WO2009124238A1 (en) * | 2008-04-04 | 2009-10-08 | Isis Pharmaceuticals, Inc. | Oligomeric compounds comprising neutrally linked terminal bicyclic nucleosides |
US8802923B2 (en) | 2008-04-10 | 2014-08-12 | A.B. Seeds Ltd. | Compositions and methods for enhancing oil content in plants |
DK2982753T3 (en) | 2008-04-18 | 2018-09-03 | Baxter Int | Microsphere-based composition to prevent and / or reverse newly started autoimmune diabetes |
US10150990B2 (en) | 2008-04-21 | 2018-12-11 | Roche Molecular Systems, Inc. | Ribonucleotide tag nucleic acid detection |
CA2722668A1 (en) * | 2008-04-29 | 2009-11-05 | Wyeth Llc | Methods for treating inflammation |
EP2119783A1 (en) | 2008-05-14 | 2009-11-18 | Prosensa Technologies B.V. | Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means |
US8082730B2 (en) * | 2008-05-20 | 2011-12-27 | Caterpillar Inc. | Engine system having particulate reduction device and method |
CA2725138A1 (en) | 2008-05-21 | 2009-11-26 | Kinemed, Inc. | Compositions and methods of treatment using modulators of motoneuron diseases |
CA2635187A1 (en) | 2008-06-05 | 2009-12-05 | The Royal Institution For The Advancement Of Learning/Mcgill University | Oligonucleotide duplexes and uses thereof |
US20100209957A1 (en) * | 2008-06-20 | 2010-08-19 | Genvault Corporation | Biosample storage devices and methods of use thereof |
KR20110017005A (en) * | 2008-07-15 | 2011-02-18 | 에프. 호프만-라 로슈 아게 | Compositions and methods for inhibiting expression of tgf-beta receptor genes |
WO2010007526A1 (en) | 2008-07-17 | 2010-01-21 | Andreas Pfuetzner | Biomarkers for cardiodiabetes |
ES2433691T3 (en) | 2008-07-17 | 2013-12-12 | Ikfe Institut Für Klinische Forschung Und Entwicklung Gmbh | Biomarkers for insulin resistance and beta cell dysfunction |
AU2009279682B2 (en) | 2008-08-04 | 2015-01-22 | University Of Miami | STING (stimulator of interferon genes), a regulator of innate immune responses |
JP5420668B2 (en) | 2008-08-25 | 2014-02-19 | エクスカリアード・ファーマシューティカルズ,インコーポレイテッド | Antisense oligonucleotides for connective tissue growth factor and uses thereof |
EP2331690B1 (en) | 2008-09-02 | 2016-01-13 | Alnylam Pharmaceuticals Inc. | Compositions and methods for inhibiting expression of mutant egfr gene |
ES2574137T3 (en) | 2008-09-03 | 2016-06-15 | Quantumdx Group Limited | Strategies and methods for detecting nucleic acids by biosensors |
JP5822726B2 (en) | 2008-09-03 | 2015-11-24 | クワンタムディーエックス・グループ・リミテッド | Design, synthesis and use of synthetic nucleotides containing charge tags |
EP2334792B1 (en) | 2008-09-12 | 2020-09-09 | GenTegra LLC | Matrices and media for storage and stabilization of biomolecules |
EP3067359A1 (en) | 2008-09-23 | 2016-09-14 | Scott G. Petersen | Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating rna interference |
EP2356129B1 (en) * | 2008-09-24 | 2013-04-03 | Isis Pharmaceuticals, Inc. | Substituted alpha-l-bicyclic nucleosides |
WO2010036696A1 (en) * | 2008-09-24 | 2010-04-01 | Isis Pharmaceuticals, Inc. | Cyclohexenyl nucleic acid analogs |
EP3109321B1 (en) | 2008-09-25 | 2019-05-01 | Alnylam Pharmaceuticals, Inc. | Lipid formulated compositions and methods for inhibiting expression of serum amyloid a gene |
CA2738485A1 (en) | 2008-09-26 | 2010-04-01 | Oncomed Pharmaceuticals, Inc. | Frizzled-binding agents and uses thereof |
US8551789B2 (en) | 2010-04-01 | 2013-10-08 | OncoMed Pharmaceuticals | Frizzled-binding agents and their use in screening for WNT inhibitors |
EP2568044B1 (en) | 2008-09-29 | 2015-04-08 | The Trustees of The University of Pennsylvania | Tumor vascular marker-targeted vaccines |
MX339820B (en) | 2008-10-03 | 2016-06-13 | Curna Inc | Treatment of apolipoprotein-a1 related diseases by inhibition of natural antisense transcript to apolipoprotein-a1. |
CA2740000C (en) | 2008-10-09 | 2017-12-12 | Tekmira Pharmaceuticals Corporation | Improved amino lipids and methods for the delivery of nucleic acids |
WO2010042933A2 (en) | 2008-10-10 | 2010-04-15 | Northwestern University | Inhibition and treatment of prostate cancer metastasis |
WO2010045509A2 (en) | 2008-10-15 | 2010-04-22 | Isis Pharmaceuticals, Inc. | Modulation of factor 11 expression |
EP3848461A1 (en) | 2008-10-20 | 2021-07-14 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of transthyretin |
ES2714787T3 (en) | 2008-10-24 | 2019-05-30 | Sarepta Therapeutics Inc | Exon skipping compositions for DMD |
US8987435B2 (en) | 2008-10-24 | 2015-03-24 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and methods |
CN102264374B (en) | 2008-10-24 | 2015-01-07 | Isis制药公司 | 5' and 2' bis-substituted nucleosides and oligomeric compounds prepared therefrom |
US8309306B2 (en) * | 2008-11-12 | 2012-11-13 | Nodality, Inc. | Detection composition |
RU2011124146A (en) * | 2008-11-17 | 2012-12-27 | Ф.Хоффманн-Ля Рош Аг | COMPOSITIONS AND METHODS OF SUPPRESSING EXPRESSION OF FACTOR VII GENES |
MX2011005429A (en) | 2008-11-24 | 2011-06-21 | Univ Northwestern | Polyvalent rna-nanoparticle compositions. |
WO2010061393A1 (en) | 2008-11-30 | 2010-06-03 | Compugen Ltd. | He4 variant nucleotide and amino acid sequences, and methods of use thereof |
RU2746478C2 (en) | 2008-12-04 | 2021-04-14 | КьюРНА, Инк. | Treatment of tumors of diseases related to the genom-suppressor by therapy of natural transcript inhibition in anti-significant orientation regarding this gene |
JP5971948B2 (en) | 2008-12-04 | 2016-08-17 | クルナ・インコーポレーテッド | Treatment of vascular endothelial growth factor (VEGF) -related diseases by suppression of natural antisense transcripts against VEGF |
WO2010065662A2 (en) | 2008-12-04 | 2010-06-10 | Curna, Inc. | Treatment of sirtuin 1 (sirt1) related diseases by inhibition of natural antisense transcript to sirtuin 1 |
US20100256196A1 (en) | 2008-12-04 | 2010-10-07 | Ikfe | Biomarkers for Atherosclerosis |
KR101829469B1 (en) | 2008-12-04 | 2018-03-30 | 큐알엔에이, 인크. | Treatment of erythropoietin (epo) related diseases by inhibition of natural antisense transcript to epo |
EP2633854B1 (en) | 2008-12-05 | 2015-09-16 | Yeda Research And Development Co. Ltd. | miRNA-9 or miRNA-9* for use in treating ALS |
JP5855462B2 (en) | 2008-12-10 | 2016-02-09 | アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. | DsRNA compositions targeting GNAQ and methods for inhibiting expression |
WO2010067207A1 (en) | 2008-12-11 | 2010-06-17 | Ikfe Gmbh | Biomarkers for insulin sensitizer drug response |
CA2746508A1 (en) | 2008-12-17 | 2010-07-15 | Avi Biopharma, Inc. | Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis |
CA2748265C (en) | 2008-12-22 | 2018-04-03 | University Of Utah Research Foundation | Monochrome multiplex quantitative pcr |
US8645115B2 (en) | 2008-12-22 | 2014-02-04 | Trustees Of Boston University | Modular nucleic acid-based circuits for counters, binary operations, memory and logic |
US20100209350A1 (en) | 2008-12-30 | 2010-08-19 | Andreas Pfuetzner | Biomarkers for Adipose Tissue Activity |
US8206929B2 (en) | 2009-01-07 | 2012-06-26 | Roche Molecular Systems, Inc. | Nucleic acid amplification with allele-specific suppression of sequence variants |
WO2010079428A2 (en) | 2009-01-07 | 2010-07-15 | Ikfe Gmbh | Biomarkers for appetite regulation |
US20100233270A1 (en) | 2009-01-08 | 2010-09-16 | Northwestern University | Delivery of Oligonucleotide-Functionalized Nanoparticles |
US20100294952A1 (en) * | 2009-01-15 | 2010-11-25 | Northwestern University | Controlled agent release and sequestration |
CA3036963A1 (en) | 2009-01-29 | 2010-08-05 | Arbutus Biopharma Corporation | Lipid formulations comprising cationic lipid and a targeting lipid comprising n-acetyl galactosamine for delivery of nucleic acid |
CN102307996A (en) * | 2009-02-03 | 2012-01-04 | 弗·哈夫曼-拉罗切有限公司 | Compositions and methods for inhibiting expression of PTP1B genes |
WO2010090762A1 (en) | 2009-02-04 | 2010-08-12 | Rxi Pharmaceuticals Corporation | Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality |
US8536320B2 (en) | 2009-02-06 | 2013-09-17 | Isis Pharmaceuticals, Inc. | Tetrahydropyran nucleic acid analogs |
US20100233733A1 (en) * | 2009-02-10 | 2010-09-16 | Nodality, Inc., A Delaware Corporation | Multiple mechanisms for modulation of the pi3 kinase pathway |
KR101682735B1 (en) | 2009-02-12 | 2016-12-06 | 큐알엔에이, 인크. | Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf |
ES2658626T3 (en) | 2009-02-12 | 2018-03-12 | Curna, Inc. | Treatment of diseases related to glial cell-derived neurotrophic factor (GDNF) by inhibition of natural antisense transcript to GDNF |
US7964355B2 (en) * | 2009-02-17 | 2011-06-21 | Investigen, Inc. | Assays based on detection of photobleaching reaction products from dye catalytic complex |
US20120041051A1 (en) | 2009-02-26 | 2012-02-16 | Kevin Fitzgerald | Compositions And Methods For Inhibiting Expression Of MIG-12 Gene |
EP2403863B1 (en) | 2009-03-02 | 2013-08-28 | Alnylam Pharmaceuticals Inc. | Nucleic acid chemical modifications |
JP6250263B2 (en) | 2009-03-04 | 2017-12-20 | クルナ・インコーポレーテッド | Treatment of SIRT1-related diseases by suppression of natural antisense transcripts against sirtuin 1 (SIRT1) |
EP2406376A1 (en) | 2009-03-12 | 2012-01-18 | Alnylam Pharmaceuticals, Inc. | LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 AND VEGF GENES |
ES2656290T3 (en) | 2009-03-16 | 2018-02-26 | Curna, Inc. | Treatment of diseases related to nuclear factor (derived from erythroid 2) similar to 2 (NRF2) by inhibition of natural antisense transcript to NRF2 |
EP2408920B1 (en) | 2009-03-17 | 2017-03-08 | CuRNA, Inc. | Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1 |
DK2414544T3 (en) * | 2009-04-01 | 2014-06-16 | Dxterity Diagnostics Inc | Probe amplification-dependent chemical ligation |
US8309356B2 (en) * | 2009-04-01 | 2012-11-13 | Yale University | Pseudocomplementary oligonucleotides for targeted gene therapy |
KR20120022938A (en) | 2009-04-15 | 2012-03-12 | 노오쓰웨스턴 유니버시티 | Delivery of oligonucleotide-functionalized nanoparticles |
EP3524275A1 (en) | 2009-04-22 | 2019-08-14 | Massachusetts Institute Of Technology | Innate immune supression enables repeated delivery of long rna molecules |
US8871494B2 (en) | 2009-04-24 | 2014-10-28 | Wisconsin Alumni Research Foundation | Over-production of secondary metabolites by over-expression of the VEA gene |
CA2759899A1 (en) | 2009-04-24 | 2010-10-28 | Prosensa Technologies B.V. | Oligonucleotide comprising an inosine for treating dmd |
EP2424987B1 (en) | 2009-05-01 | 2017-11-15 | CuRNA, Inc. | Treatment of hemoglobin (hbf/hbg) related diseases by inhibition of natural antisense transcript to hbf/hbg |
EP2427572B1 (en) * | 2009-05-01 | 2013-08-28 | Illumina, Inc. | Sequencing methods |
CA2760706C (en) | 2009-05-05 | 2019-08-06 | Alnylam Pharmaceuticals, Inc. | Methods of delivering oligonucleotides to immune cells |
KR20220150411A (en) | 2009-05-05 | 2022-11-10 | 알닐람 파마슈티칼스 인코포레이티드 | Lipid compositions |
JP5883782B2 (en) | 2009-05-06 | 2016-03-15 | クルナ・インコーポレーテッド | Treatment of lipid transport metabolism gene-related diseases by suppression of natural antisense transcripts on lipid transport metabolism genes |
WO2010129746A2 (en) | 2009-05-06 | 2010-11-11 | Curna, Inc. | Treatment of tristetraproline (ttp) related diseases by inhibition of natural antisense transcript to ttp |
KR101742334B1 (en) | 2009-05-08 | 2017-06-01 | 큐알엔에이, 인크. | Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to dmd family |
KR20120069610A (en) * | 2009-05-15 | 2012-06-28 | 에프. 호프만-라 로슈 아게 | Compositions and methods for inhibiting expression of glucocorticoid receptor (gcr) genes |
WO2010132665A1 (en) | 2009-05-15 | 2010-11-18 | Yale University | Gemm riboswitches, structure-based compound design with gemm riboswitches, and methods and compositions for use of and with gemm riboswitches |
DK2432881T3 (en) | 2009-05-18 | 2018-02-26 | Curna Inc | TREATMENT OF REPROGRAMMING FACTOR-RELATED DISEASES BY INHIBITING NATURAL ANTISENSE TRANSCRIPTS TO A REPROGRAMMING FACTOR |
CA2682429A1 (en) * | 2009-05-20 | 2010-11-20 | Gary Levy | An assay for measuring plasma fgl-2 and methods and uses thereof |
KR101703695B1 (en) | 2009-05-22 | 2017-02-08 | 큐알엔에이, 인크. | Treatment of transcription factor e3 (tfe3) and insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to tfe3 |
CN103221541B (en) | 2009-05-28 | 2017-03-01 | 库尔纳公司 | Antiviral gene relevant disease is treated by the natural antisense transcript suppressing antiviral gene |
US9200276B2 (en) | 2009-06-01 | 2015-12-01 | Halo-Bio Rnai Therapeutics, Inc. | Polynucleotides for multivalent RNA interference, compositions and methods of use thereof |
PL3431076T3 (en) | 2009-06-10 | 2022-01-31 | Arbutus Biopharma Corporation | Improved lipid formulation |
DK2977455T3 (en) | 2009-06-15 | 2020-07-13 | Complete Genomics Inc | PROGRESS FOR LONG-FRAGMENT READING SEQUENCE |
JP6128846B2 (en) | 2009-06-16 | 2017-05-17 | クルナ・インコーポレーテッド | Treatment of PON1 gene-related diseases by suppression of natural antisense transcripts against paraoxonase (PON1) |
WO2010148050A2 (en) | 2009-06-16 | 2010-12-23 | Curna, Inc. | Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene |
US8859515B2 (en) | 2009-06-24 | 2014-10-14 | Curna, Inc. | Treatment of tumor necrosis factor receptor 2 (TNFR2) related diseases by inhibition of natural antisense transcript to TNFR2 |
EP2446037B1 (en) | 2009-06-26 | 2016-04-20 | CuRNA, Inc. | Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene |
WO2011005860A2 (en) | 2009-07-07 | 2011-01-13 | Alnylam Pharmaceuticals, Inc. | 5' phosphate mimics |
WO2011005861A1 (en) | 2009-07-07 | 2011-01-13 | Alnylam Pharmaceuticals, Inc. | Oligonucleotide end caps |
US20120252869A1 (en) | 2009-07-24 | 2012-10-04 | Opko Curna, Llc | Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt) |
GB0913258D0 (en) | 2009-07-29 | 2009-09-02 | Dynex Technologies Inc | Reagent dispenser |
US9523701B2 (en) | 2009-07-29 | 2016-12-20 | Dynex Technologies, Inc. | Sample plate systems and methods |
CA2769665A1 (en) | 2009-08-05 | 2011-02-10 | Opko Curna, Llc | Treatment of insulin gene (ins) related diseases by inhibition of natural antisense transcript to an insulin gene (ins) |
EP2462153B1 (en) | 2009-08-06 | 2015-07-29 | Isis Pharmaceuticals, Inc. | Bicyclic cyclohexose nucleic acid analogs |
CA2770071C (en) | 2009-08-07 | 2014-07-15 | Ohmx Corporation | Enzyme triggered redox altering chemical elimination (e-trace) immunoassay |
CN102625841A (en) | 2009-08-11 | 2012-08-01 | 欧科库尔纳有限责任公司 | Treatment of Adiponectin (ADIPOQ) related diseases by inhibition of natural antisense transcript to an Adiponectin (ADIPOQ) |
US8409802B2 (en) | 2009-08-14 | 2013-04-02 | Roche Molecular Systems, Inc. | Format of probes to detect nucleic acid differences |
US9029338B2 (en) | 2009-08-14 | 2015-05-12 | Alnylam Pharmaceuticals, Inc. | Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus |
US20120157324A1 (en) | 2009-08-17 | 2012-06-21 | Yale University | Methylation biomarkers and methods of use |
US8791087B2 (en) | 2009-08-21 | 2014-07-29 | Curna, Inc. | Treatment of ‘C terminus of HSP70-interacting protein’ (CHIP)related diseases by inhibition of natural antisense transcript to CHIP |
CN102482671B (en) | 2009-08-25 | 2017-12-01 | 库尔纳公司 | IQGAP relevant diseases are treated by suppressing the natural antisense transcript of ' gtpase activating protein containing IQ die bodys ' (IQGAP) |
CA2772715C (en) | 2009-09-02 | 2019-03-26 | Genentech, Inc. | Mutant smoothened and methods of using the same |
US10072287B2 (en) | 2009-09-10 | 2018-09-11 | Centrillion Technology Holdings Corporation | Methods of targeted sequencing |
US10174368B2 (en) | 2009-09-10 | 2019-01-08 | Centrillion Technology Holdings Corporation | Methods and systems for sequencing long nucleic acids |
WO2011038228A1 (en) | 2009-09-24 | 2011-03-31 | President And Fellows Of Harvard College | Bent nanowires and related probing of species |
ES2664591T3 (en) | 2009-09-25 | 2018-04-20 | Curna, Inc. | Treatment of phylagrin-related diseases (flg) by modulating the expression and activity of the FLG gene |
CA2780741C (en) | 2009-10-12 | 2023-04-04 | Smith Holdings, Llc | Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro |
CA2777448C (en) | 2009-10-14 | 2023-02-28 | Ilan Sela | Compositions for controlling varroa mites in bees |
US8962584B2 (en) | 2009-10-14 | 2015-02-24 | Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. | Compositions for controlling Varroa mites in bees |
WO2011050194A1 (en) | 2009-10-22 | 2011-04-28 | Genentech, Inc. | Methods and compositions for modulating hepsin activation of macrophage-stimulating protein |
US20110129832A1 (en) * | 2009-10-27 | 2011-06-02 | Swift Biosciences, Inc. | Polynucleotide Primers and Probes |
MX2012004905A (en) | 2009-10-30 | 2012-07-23 | Univ British Columbia | Gna11 mutations in melanoma. |
CA2779099C (en) | 2009-10-30 | 2021-08-10 | Northwestern University | Templated nanoconjugates |
KR102138780B1 (en) | 2009-11-02 | 2020-07-29 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | Foot and mouth disease virus (fmdv) consensus proteins, coding sequences therefor and vaccines made therefrom |
US20110268810A1 (en) | 2009-11-02 | 2011-11-03 | Yale University | Polymeric materials loaded with mutagenic and recombinagenic nucleic acids |
WO2011056215A1 (en) | 2009-11-03 | 2011-05-12 | Landers James P | Versatile, visible method for detecting polymeric analytes |
WO2011054939A2 (en) | 2009-11-09 | 2011-05-12 | F. Hoffmann-La Roche Ag | Compositions and methods for inhibiting expression of kif10 genes |
WO2011058555A1 (en) | 2009-11-12 | 2011-05-19 | Yeda Research And Development Co. Ltd. | A method of editing dna in a cell and constructs capable of same |
BR122023023194A2 (en) | 2009-11-12 | 2023-12-26 | The University Of Western Australia | ANTISENSE OLIGONUCLEOTIDE, COMPOSITION AND RESPECTIVE USE |
JP5991922B2 (en) | 2009-11-13 | 2016-09-14 | サレプタ セラピューティクス, インコーポレイテッド | Antisense antiviral compounds and methods for treating influenza virus infection |
US8916362B2 (en) | 2009-11-23 | 2014-12-23 | Swift Biosciences, Inc. | Devices comprising a polynucleotide to extend single stranded target molecules |
TWI507524B (en) | 2009-11-30 | 2015-11-11 | Genentech Inc | Compositions and methods for the diagnosis and treatment of tumor |
US8614071B2 (en) | 2009-12-11 | 2013-12-24 | Roche Molecular Systems, Inc. | Preferential amplification of mRNA over DNA using chemically modified primers |
WO2011084455A2 (en) | 2009-12-16 | 2011-07-14 | Opko Curna, Llc. | Treatment of membrane bound transcription factor peptidase, site 1 (mbtps1) related diseases by inhibition of natural antisense transcript to mbtps1 |
US20110152349A1 (en) * | 2009-12-18 | 2011-06-23 | Anke Geick | Compositions and methods for inhibiting expression of il-18 genes |
RU2619185C2 (en) | 2009-12-23 | 2017-05-12 | Курна, Инк. | Treatment of diseases associated with uncoupling proteins 2 (ucp2), by inhibiting of natural antisense transcript to ucp2 |
KR101891352B1 (en) | 2009-12-23 | 2018-08-24 | 큐알엔에이, 인크. | Treatment of hepatocyte growth factor (hgf) related diseases by inhibition of natural antisense transcript to hgf |
CA2785451C (en) | 2009-12-24 | 2019-01-22 | Prosensa Technologies B.V. | Molecule for treating an inflammatory disorder |
EP2519633B1 (en) | 2009-12-29 | 2017-10-25 | CuRNA, Inc. | Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1 |
JP5982288B2 (en) | 2009-12-29 | 2016-08-31 | カッパーアールエヌエー,インコーポレイテッド | Treatment of tumor protein 63-related diseases by inhibition of natural antisense transcripts against tumor protein 63 (p63) |
US20120289583A1 (en) | 2009-12-31 | 2012-11-15 | Curna, Inc. | Treatment of insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to irs2 and transcription factor e3 (tfe3) |
NO2521784T3 (en) | 2010-01-04 | 2018-05-05 | ||
EP2521785B1 (en) | 2010-01-06 | 2022-03-09 | CuRNA, Inc. | Inhibition of natural antisense transcript to a pancreatic developmental gene for use in a treatment of pancreatic developmental gene related diseases |
ES2664866T3 (en) | 2010-01-11 | 2018-04-23 | Curna, Inc. | Treatment of diseases related to sex hormone binding globulin (shbg) by inhibition of the natural antisense transcript to shbg |
US8779118B2 (en) | 2010-01-11 | 2014-07-15 | Isis Pharmaceuticals, Inc. | Base modified bicyclic nucleosides and oligomeric compounds prepared therefrom |
TWI535445B (en) | 2010-01-12 | 2016-06-01 | 安可美德藥物股份有限公司 | Wnt antagonists and methods of treatment and screening |
WO2011088076A2 (en) | 2010-01-12 | 2011-07-21 | Yale University | Structured rna motifs and compounds and methods for their use |
US8883739B2 (en) | 2010-01-19 | 2014-11-11 | The Trustees Of Columbia University In The City Of New York | Osteocalcin as a treatment for male reproductive disorders |
WO2011090949A2 (en) | 2010-01-19 | 2011-07-28 | Illumina, Inc. | Methods and compositions for processing chemical reactions |
CA2786568A1 (en) | 2010-01-25 | 2011-07-28 | Curna, Inc. | Treatment of rnase h1 related diseases by inhibition of natural antisense transcript to rnase h1 |
WO2011097407A1 (en) | 2010-02-04 | 2011-08-11 | Ico Therapeutics Inc. | Dosing regimens for treating and preventing ocular disorders using c-raf antisense |
TW201129365A (en) * | 2010-02-05 | 2011-09-01 | Hoffmann La Roche | Compositions and methods for inhibiting expression of IKK2 genes |
JP5976548B2 (en) | 2010-02-22 | 2016-08-23 | カッパーアールエヌエー,インコーポレイテッド | Treatment of pyrroline-5-carboxylate reductase 1 (PYCR1) related diseases by inhibition of natural antisense transcripts against PYCR1 |
WO2011105902A2 (en) | 2010-02-23 | 2011-09-01 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Antagonists of complement component 8-beta (c8-beta) and uses thereof |
WO2011105900A2 (en) | 2010-02-23 | 2011-09-01 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Antagonists of complement component 8-alpha (c8-alpha) and uses thereof |
SG183335A1 (en) | 2010-02-23 | 2012-09-27 | Genentech Inc | Compositions and methods for the diagnosis and treatment of tumor |
WO2011105901A2 (en) | 2010-02-23 | 2011-09-01 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Antagonists of complement component 9 (c9) and uses thereof |
EP2539357B1 (en) | 2010-02-26 | 2017-06-14 | Memorial Sloan-Kettering Cancer Center | Methods and compositions for the detection and treatment of cancer involving mirnas and mirna inhibitors and targets |
EP2542249A4 (en) | 2010-03-05 | 2013-08-07 | Tissue Genesis Inc | Methods and compositions to support tissue integration and inosculation of transplanted tissue and transplanted engineered penile tissue with adipose stromal cells |
AU2011224570B2 (en) | 2010-03-08 | 2014-08-14 | Monsanto Technology Llc | Polynucleotide molecules for gene regulation in plants |
WO2011112516A1 (en) | 2010-03-08 | 2011-09-15 | Ico Therapeutics Inc. | Treating and preventing hepatitis c virus infection using c-raf kinase antisense oligonucleotides |
US9068185B2 (en) | 2010-03-12 | 2015-06-30 | Sarepta Therapeutics, Inc. | Antisense modulation of nuclear hormone receptors |
WO2011112732A2 (en) | 2010-03-12 | 2011-09-15 | The Brigham And Women's Hospital, Inc. | Methods of treating vascular inflammatory disorders |
US20130101512A1 (en) | 2010-03-12 | 2013-04-25 | Chad A. Mirkin | Crosslinked polynucleotide structure |
EP3450979A3 (en) | 2010-03-17 | 2019-04-24 | The Regents of The University of Michigan | Using phage epitopes to profile the immune response |
US9193752B2 (en) | 2010-03-17 | 2015-11-24 | Isis Pharmaceuticals, Inc. | 5′-substituted bicyclic nucleosides and oligomeric compounds prepared therefrom |
US8889350B2 (en) | 2010-03-26 | 2014-11-18 | Swift Biosciences, Inc. | Methods and compositions for isolating polynucleotides |
WO2011123468A1 (en) | 2010-03-29 | 2011-10-06 | Alnylam Pharmaceuticals, Inc. | Sirna therapy for transthyretin (ttr) related ocular amyloidosis |
US9102938B2 (en) | 2010-04-01 | 2015-08-11 | Alnylam Pharmaceuticals, Inc. | 2′ and 5′ modified monomers and oligonucleotides |
WO2011123745A2 (en) | 2010-04-02 | 2011-10-06 | Opko Curna Llc | Treatment of colony-stimulating factor 3 (csf3) related diseases by inhibition of natural antisense transcript to csf3 |
WO2011127337A2 (en) | 2010-04-09 | 2011-10-13 | Opko Curna Llc | Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21 |
WO2011133695A2 (en) | 2010-04-20 | 2011-10-27 | Swift Biosciences, Inc. | Materials and methods for nucleic acid fractionation by solid phase entrapment and enzyme-mediated detachment |
US20110262406A1 (en) | 2010-04-21 | 2011-10-27 | Yale University | Compositions and methods for targeted inactivation of hiv cell surface receptors |
US20110293585A1 (en) | 2010-04-21 | 2011-12-01 | Helix Therapeutics, Inc. | Compositions and methods for treatment of lysosomal storage disorders |
WO2011133871A2 (en) | 2010-04-22 | 2011-10-27 | Alnylam Pharmaceuticals, Inc. | 5'-end derivatives |
WO2011139714A2 (en) | 2010-04-26 | 2011-11-10 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-trna synthetase |
US8961960B2 (en) | 2010-04-27 | 2015-02-24 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl tRNA synthetases |
EP2625186B1 (en) | 2010-04-28 | 2016-07-27 | Ionis Pharmaceuticals, Inc. | 5' modified nucleosides and oligomeric compounds prepared therefrom |
EP2563911B1 (en) | 2010-04-28 | 2021-07-21 | aTyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl trna synthetases |
WO2011139702A2 (en) | 2010-04-28 | 2011-11-10 | Isis Pharmaceuticals, Inc. | Modified nucleosides and oligomeric compounds prepared therefrom |
AU2011248490B2 (en) | 2010-04-29 | 2016-11-10 | Pangu Biopharma Limited | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Asparaginyl tRNA synthetases |
SI2563920T1 (en) | 2010-04-29 | 2017-05-31 | Ionis Pharmaceuticals, Inc. | Modulation of transthyretin expression |
US9034320B2 (en) | 2010-04-29 | 2015-05-19 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Valyl-tRNA synthetases |
JP5976638B2 (en) | 2010-05-03 | 2016-08-23 | エータイアー ファーマ, インコーポレイテッド | Innovative discovery of therapeutic, diagnostic and antibody compositions related to protein fragments of arginyl tRNA synthetase |
US8981045B2 (en) | 2010-05-03 | 2015-03-17 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of methionyl-tRNA synthetases |
SG185027A1 (en) | 2010-05-03 | 2012-11-29 | Genentech Inc | Compositions and methods for the diagnosis and treatment of tumor |
EP2566495B1 (en) | 2010-05-03 | 2017-03-01 | aTyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-trna synthetases |
WO2011139387A1 (en) | 2010-05-03 | 2011-11-10 | Opko Curna, Llc | Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt) |
US9062302B2 (en) | 2010-05-04 | 2015-06-23 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-tRNA synthetase complex |
US10232374B2 (en) | 2010-05-05 | 2019-03-19 | Miroculus Inc. | Method of processing dried samples using digital microfluidic device |
WO2011143124A2 (en) | 2010-05-10 | 2011-11-17 | The Regents Of The University Of California | Endoribonuclease compositions and methods of use thereof |
JP5866106B2 (en) | 2010-05-12 | 2016-02-17 | コロンビア ユニヴァーシティ | Method for producing enteroendocrine cells that produce and secrete insulin |
US9050373B2 (en) | 2010-05-13 | 2015-06-09 | The Charlotte-Mecklenburg Hospital Authority | Pharmaceutical compositions comprising antisense oligonucleotides and methods of using same |
CA3090304A1 (en) | 2010-05-13 | 2011-11-17 | Sarepta Therapeutics, Inc. | Antisense modulation of interleukins 17 and 23 signaling |
EP2568996B1 (en) | 2010-05-14 | 2017-10-04 | aTyr Pharma, Inc. | Therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-trna synthetases |
TWI586356B (en) | 2010-05-14 | 2017-06-11 | 可娜公司 | Treatment of par4 related diseases by inhibition of natural antisense transcript to par4 |
US9034598B2 (en) | 2010-05-17 | 2015-05-19 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of leucyl-tRNA synthetases |
RU2620978C2 (en) | 2010-05-26 | 2017-05-30 | Курна, Инк. | Treatment of diseases associated with methionine sulfoxide reductase a (msra), by msra natural antisense transcript inhibition |
RU2585229C2 (en) | 2010-05-26 | 2016-05-27 | Курна, Инк. | Treatment of diseases associated with atonal homolog 1 (aton1) by inhibiting natural antisense transcript of gene aton1 |
US20130203045A1 (en) | 2010-05-26 | 2013-08-08 | University Of Virginia Patent Foundation | Method for detecting nucleic acids based on aggregate formation |
AU2011258106B2 (en) | 2010-05-27 | 2017-02-23 | Pangu Biopharma Limited | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-tRNA synthetases |
CA2799501C (en) | 2010-05-28 | 2022-02-15 | Sarepta Therapeutics, Inc. | Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups |
CA3102008A1 (en) | 2010-06-02 | 2011-12-08 | Alnylam Pharmaceuticals, Inc. | Compositions and methods directed to treating liver fibrosis |
US9228240B2 (en) | 2010-06-03 | 2016-01-05 | California Institute Of Technology | Methods for detecting and quantifying viable bacterial endo-spores |
WO2011156278A1 (en) | 2010-06-07 | 2011-12-15 | Isis Pharmaceuticals, Inc. | Bicyclic nucleosides and oligomeric compounds prepared therefrom |
US8846637B2 (en) | 2010-06-08 | 2014-09-30 | Isis Pharmaceuticals, Inc. | Substituted 2′-amino and 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom |
US9638632B2 (en) | 2010-06-11 | 2017-05-02 | Vanderbilt University | Multiplexed interferometric detection system and method |
WO2011163466A1 (en) | 2010-06-23 | 2011-12-29 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Regulation of skin pigmentation by neuregulin-1 (nrg-1) |
ES2863526T3 (en) | 2010-06-23 | 2021-10-11 | Curna Inc | Treatment of voltage-controlled sodium channel alpha subunit (SCNA) -related diseases by inhibiting natural antisense transcription to SCNA |
US20130209463A1 (en) | 2010-06-30 | 2013-08-15 | Compugen Ltd. | Polypeptides and uses thereof as a drug for treatment of multiple sclerosis, rheumatoid arthritis and other autoimmune disorders |
EP2593125B1 (en) | 2010-07-12 | 2017-11-01 | aTyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-trna synthetases |
RU2611190C2 (en) | 2010-07-14 | 2017-02-21 | Курна, Инк. | Treatment of diseases related with gene dlg by inhibition of natural antisense transcript of dlg gene |
AU2011280958B2 (en) | 2010-07-22 | 2014-10-09 | Massachusetts Institute Of Technology | Multiple input biologic classifier circuits for cells |
WO2012021554A1 (en) | 2010-08-09 | 2012-02-16 | Yale University | Cyclic di-gmp-ii riboswitches, motifs, and compounds, and methods for their use |
US8198429B2 (en) | 2010-08-09 | 2012-06-12 | Avi Biopharma, Inc. | Antisense antiviral compounds and methods for treating a filovirus infection |
EP2603607B1 (en) | 2010-08-11 | 2016-04-06 | Celula, Inc. | Genotyping dna |
US9029506B2 (en) | 2010-08-25 | 2015-05-12 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of tyrosyl-tRNA synthetases |
WO2012028697A1 (en) | 2010-09-01 | 2012-03-08 | Eth Zürich, Institute Of Molecular Biology And Biophysics | Affinity purification system based on donor strand complementation |
US10017763B2 (en) | 2010-09-03 | 2018-07-10 | Sarepta Therapeutics, Inc. | dsRNA molecules comprising oligonucleotide analogs having modified intersubunit linkages and/or terminal groups |
US20120070829A1 (en) | 2010-09-10 | 2012-03-22 | Bio-Rad Laboratories, Inc. | Size selection of dna for chromatin analysis |
US8483969B2 (en) | 2010-09-17 | 2013-07-09 | Illuminia, Inc. | Variation analysis for multiple templates on a solid support |
US20130210901A1 (en) | 2010-09-20 | 2013-08-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Method of treating neurodegenerative diseases |
JP5974012B2 (en) | 2010-10-05 | 2016-08-23 | ジェネンテック, インコーポレイテッド | Mutant smoothened and method of using the same |
ES2640755T3 (en) | 2010-10-06 | 2017-11-06 | Curna, Inc. | Treatment of diseases related to Sialidase 4 (neu4) by inhibition of the natural antisense transcript to the neu4 gene |
EP2625292B1 (en) | 2010-10-07 | 2018-12-05 | The General Hospital Corporation | Biomarkers of cancer |
WO2012052872A2 (en) | 2010-10-17 | 2012-04-26 | Yeda Research And Development Co. Ltd. | Methods and compositions for the treatment of insulin-associated medical conditions |
EP2851426B1 (en) | 2010-10-18 | 2018-08-22 | Arrowhead Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of RRM2 genes |
US8648053B2 (en) | 2010-10-20 | 2014-02-11 | Rosalind Franklin University Of Medicine And Science | Antisense oligonucleotides that target a cryptic splice site in Ush1c as a therapeutic for Usher syndrome |
WO2012054723A2 (en) | 2010-10-22 | 2012-04-26 | Opko Curna Llc | Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua |
US8753816B2 (en) | 2010-10-26 | 2014-06-17 | Illumina, Inc. | Sequencing methods |
RU2611195C2 (en) | 2010-10-27 | 2017-02-21 | Курна, Инк. | Treatment of interferon-related developmental regulator 1 (ifrd1) associated diseases by inhibition of natural antisense transcript to ifrd1 |
CN103270174B (en) | 2010-10-28 | 2016-08-24 | 生命技术公司 | Chemical reinforcing type Primer composition, method and test kit |
CA2821299C (en) | 2010-11-05 | 2019-02-12 | Frank J. Steemers | Linking sequence reads using paired code tags |
CN110123830A (en) | 2010-11-09 | 2019-08-16 | 阿尔尼拉姆医药品有限公司 | Composition and method for inhibiting the lipid of the expression of Eg5 and VEGF gene to prepare |
AU2011326364B2 (en) | 2010-11-12 | 2016-08-11 | Sarepta Therapeutics, Inc. | Antisense antibacterial compounds and methods |
AU2011325956B2 (en) | 2010-11-12 | 2016-07-14 | The General Hospital Corporation | Polycomb-associated non-coding RNAs |
CA3077910A1 (en) | 2010-11-17 | 2012-05-24 | Ionis Pharmaceuticals, Inc. | Modulation of alpha synuclein expression |
US10000752B2 (en) | 2010-11-18 | 2018-06-19 | Curna, Inc. | Antagonat compositions and methods of use |
CA2818824A1 (en) | 2010-11-23 | 2012-05-31 | Joseph Collard | Treatment of nanog related diseases by inhibition of natural antisense transcript to nanog |
US9150926B2 (en) | 2010-12-06 | 2015-10-06 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Diagnosis and treatment of adrenocortical tumors using human microRNA-483 |
EP2649182A4 (en) | 2010-12-10 | 2015-05-06 | Alnylam Pharmaceuticals Inc | Compositions and methods for increasing erythropoietin (epo) production |
WO2012079046A2 (en) | 2010-12-10 | 2012-06-14 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of klf-1 and bcl11a genes |
EP2663323B1 (en) | 2011-01-14 | 2017-08-16 | The General Hospital Corporation | Methods targeting mir-128 for regulating cholesterol/lipid metabolism |
EP2663639B1 (en) | 2011-01-14 | 2017-09-13 | Life Technologies Corporation | Methods for isolation, identification, and quantification of mirnas |
WO2012100078A1 (en) | 2011-01-19 | 2012-07-26 | Ohmx Corporation | Enzyme triggered redox altering chemical elimination (e-trace) immmunoassay |
DK3037536T3 (en) | 2011-01-28 | 2020-01-13 | Illumina Inc | OLIGONUCLEOTID REPLACEMENT FOR DI-TAGGED AND DIRECTORY LIBRARIES |
EP2670864B1 (en) | 2011-01-31 | 2017-03-08 | Illumina, Inc. | Methods for reducing nucleic acid damage |
KR101697396B1 (en) | 2011-02-02 | 2017-01-17 | 엑스칼리아드 파마슈티컬즈, 인코포레이티드 | Method of treating keloids or hypertrophic scars using antisense compounds targeting connective tissue growth factor (ctgf) |
EP2670404B1 (en) | 2011-02-02 | 2018-08-29 | The Trustees of Princeton University | Sirtuin modulators as virus production modulators |
CN103501793A (en) | 2011-02-08 | 2014-01-08 | 夏洛特-梅克伦堡医院(商业用名:卡罗来纳保健系统) | Antisense oligonucleotides |
US9365897B2 (en) | 2011-02-08 | 2016-06-14 | Illumina, Inc. | Selective enrichment of nucleic acids |
US9327037B2 (en) | 2011-02-08 | 2016-05-03 | The Johns Hopkins University | Mucus penetrating gene carriers |
WO2012109495A1 (en) | 2011-02-09 | 2012-08-16 | Metabolic Solutions Development Company, Llc | Cellular targets of thiazolidinediones |
EP3940084A1 (en) | 2011-02-09 | 2022-01-19 | Bio-Rad Laboratories, Inc. | Analysis of nucleic acids |
WO2012112606A1 (en) | 2011-02-15 | 2012-08-23 | Bio-Rad Laboratories, Inc. | Detecting methylati0n in a subpopulation of genomic dna |
US9562853B2 (en) | 2011-02-22 | 2017-02-07 | Vanderbilt University | Nonaqueous backscattering interferometric methods |
EP2689028B1 (en) | 2011-03-23 | 2017-08-30 | Pacific Biosciences Of California, Inc. | Isolation of polymerase-nucleic acid complexes and loading onto substrates |
EP3406267A1 (en) | 2011-03-25 | 2018-11-28 | Children's Medical Center Corporation | Lin28-mediated control of let-7 biogenesis |
SG193923A1 (en) | 2011-03-29 | 2013-11-29 | Alnylam Pharmaceuticals Inc | Compositions and methods for inhibiting expression of tmprss6 gene |
AU2012236099A1 (en) | 2011-03-31 | 2013-10-03 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
US20120252682A1 (en) | 2011-04-01 | 2012-10-04 | Maples Corporate Services Limited | Methods and systems for sequencing nucleic acids |
WO2012138453A1 (en) | 2011-04-03 | 2012-10-11 | The General Hospital Corporation | Efficient protein expression in vivo using modified rna (mod-rna) |
EP2697256A1 (en) | 2011-04-15 | 2014-02-19 | Compugen Ltd. | Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer |
JP2014512826A (en) | 2011-04-25 | 2014-05-29 | バイオ−ラド ラボラトリーズ インコーポレイテッド | Methods and compositions for nucleic acid analysis |
WO2012149154A1 (en) | 2011-04-26 | 2012-11-01 | Swift Biosciences, Inc. | Polynucleotide primers and probes |
US9353371B2 (en) | 2011-05-02 | 2016-05-31 | Ionis Pharmaceuticals, Inc. | Antisense compounds targeting genes associated with usher syndrome |
WO2012151268A1 (en) | 2011-05-02 | 2012-11-08 | University Of Virginia Patent Foundation | Method and system for high throughput optical and label free detection of analytes |
WO2012151289A2 (en) | 2011-05-02 | 2012-11-08 | University Of Virginia Patent Foundation | Method and system to detect aggregate formation on a substrate |
WO2012150960A1 (en) | 2011-05-05 | 2012-11-08 | Avi Biopharma, Inc. | Peptide oligonucleotide conjugates |
CN105132284B (en) | 2011-05-13 | 2018-04-03 | 加利福尼亚大学董事会 | Photo-thermal substrate for selective transfectional cell |
EP2710145B1 (en) | 2011-05-17 | 2015-12-09 | Dxterity Diagnostics Incorporated | Methods and compositions for detecting target nucleic acids |
ES2703133T3 (en) | 2011-05-24 | 2019-03-07 | Rosetta Genomics Ltd | Methods and compositions for determining heart failure or a risk of heart failure |
WO2012170347A1 (en) | 2011-06-09 | 2012-12-13 | Isis Pharmaceuticals, Inc. | Bicyclic nucleosides and oligomeric compounds prepared therefrom |
ES2653247T3 (en) | 2011-06-09 | 2018-02-06 | Curna, Inc. | Treatment of frataxin-related diseases (FXN) by inhibiting the natural antisense transcript to the FXN gene |
EP3320922A1 (en) | 2011-06-10 | 2018-05-16 | Ionis Pharmaceuticals, Inc. | Methods for modulating kallikrein (klkb1) expression |
CA3191066A1 (en) | 2011-06-21 | 2012-12-27 | Alnylam Pharmaceuticals Inc. | Compositions and methods for inhibition of expression of apolipoprotein c-iii (apoc3) genes |
CN103890000B (en) | 2011-06-21 | 2017-09-01 | 阿尔尼拉姆医药品有限公司 | (ANGPTL3) the iRNA compositions of angiopoietin-like 3 and its application method |
EP3388068A1 (en) | 2011-06-21 | 2018-10-17 | Alnylam Pharmaceuticals, Inc. | Composition and methods for inhibition of expression of protein c (proc) genes |
EP4134433A1 (en) | 2011-06-23 | 2023-02-15 | Alnylam Pharmaceuticals, Inc. | Serpina1 sirnas: compositions of matter and methods of treatment |
EP2726153B1 (en) | 2011-06-29 | 2018-03-28 | Ionis Pharmaceuticals, Inc. | Methods for modulating kallikrein (klkb1) expression |
CA2836855C (en) | 2011-06-30 | 2020-07-14 | Compugen Ltd. | Polypeptides and uses thereof for treatment of autoimmune disorders and infection |
WO2013001372A2 (en) | 2011-06-30 | 2013-01-03 | University Of Oslo | Methods and compositions for inhibition of activation of regulatory t cells |
TW202244278A (en) | 2011-06-30 | 2022-11-16 | 美商艾羅海德製藥公司 | Compositions and methods for inhibiting gene expression of hepatitis b virus |
JP6109165B2 (en) | 2011-07-01 | 2017-04-05 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Herpesvirus vaccines and methods of use |
AU2012284259A1 (en) | 2011-07-15 | 2014-03-06 | Sarepta Therapeutics, Inc. | Methods and compositions for manipulating translation of protein isoforms from alternative initiation start sites |
WO2013019857A2 (en) | 2011-08-01 | 2013-02-07 | Alnylam Pharmaceuticals, Inc. | Method for improving the success rate of hematopoietic stem cell transplants |
WO2013019960A1 (en) | 2011-08-03 | 2013-02-07 | Bio-Rad Laboratories, Inc. | Filtering small nucleic acids using permeabilized cells |
BR112014002737B1 (en) | 2011-08-04 | 2022-08-02 | Yeda Research And Development Co. Ltd. | MIR-135 |
US9040678B2 (en) | 2011-08-05 | 2015-05-26 | Illumina, Inc. | Functionalization and purification of molecules by reversible group exchange |
JP6125505B2 (en) | 2011-09-06 | 2017-05-10 | カッパーアールエヌエー,インコーポレイテッド | Treatment of voltage-gated sodium channel alpha subunit related diseases with small molecules |
US9840715B1 (en) | 2011-09-13 | 2017-12-12 | Monsanto Technology Llc | Methods and compositions for delaying senescence and improving disease tolerance and yield in plants |
CA2848695A1 (en) | 2011-09-13 | 2013-03-21 | Monsanto Technology Llc | Methods and composition for weed control comprising inhibiting ppg oxidase |
US10760086B2 (en) | 2011-09-13 | 2020-09-01 | Monsanto Technology Llc | Methods and compositions for weed control |
US10829828B2 (en) | 2011-09-13 | 2020-11-10 | Monsanto Technology Llc | Methods and compositions for weed control |
US10806146B2 (en) | 2011-09-13 | 2020-10-20 | Monsanto Technology Llc | Methods and compositions for weed control |
EP3382027A3 (en) | 2011-09-13 | 2018-10-31 | Monsanto Technology LLC | Methods and compositions for weed control |
EP2755466A4 (en) | 2011-09-13 | 2015-04-15 | Monsanto Technology Llc | Methods and compositions for weed control |
CN103957697B (en) | 2011-09-13 | 2017-10-24 | 孟山都技术公司 | Method and composition for Weeds distribution |
AU2012308320C1 (en) | 2011-09-14 | 2018-08-23 | Translate Bio Ma, Inc. | Multimeric oligonucleotide compounds |
EP2755692B1 (en) | 2011-09-14 | 2020-11-25 | Northwestern University | Nanoconjugates able to cross the blood-brain barrier |
US9920326B1 (en) | 2011-09-14 | 2018-03-20 | Monsanto Technology Llc | Methods and compositions for increasing invertase activity in plants |
US20140234373A1 (en) | 2011-09-16 | 2014-08-21 | Georfia Regents University | Methods of Promoting Immune Tolerance |
US9580713B2 (en) | 2011-09-17 | 2017-02-28 | Yale University | Fluoride-responsive riboswitches, fluoride transporters, and methods of use |
US9801948B2 (en) | 2011-09-21 | 2017-10-31 | Yale University | Antimicrobial compositions and methods of use thereof |
CA2847943C (en) | 2011-09-23 | 2017-08-29 | F.Hoffmann-La Roche Ag | Use of g-clamp for improved allele-specific pcr |
US20130085139A1 (en) | 2011-10-04 | 2013-04-04 | Royal Holloway And Bedford New College | Oligomers |
WO2013055865A1 (en) | 2011-10-11 | 2013-04-18 | The Brigham And Women's Hospital, Inc. | Micrornas in neurodegenerative disorders |
AU2012322618A1 (en) | 2011-10-14 | 2014-05-29 | Genentech, Inc. | Anti-HtrA1 antibodies and methods of use |
CN103998921B (en) | 2011-10-14 | 2016-04-20 | 贝克顿·迪金森公司 | Square wave thermal cycle |
EP2768967B1 (en) | 2011-10-17 | 2017-12-06 | Ohmx Corporation | Single, direct detection of hemoglobin a1c percentage using enzyme triggered redox altering chemical elimination (e-trace) immunoassay |
CN104080958A (en) | 2011-10-19 | 2014-10-01 | 纽亘技术公司 | Compositions and methods for directional nucleic acid amplification and sequencing |
US9145559B2 (en) | 2011-10-27 | 2015-09-29 | Yeda Research And Development Co. Ltd. | Methods of treating cancer |
WO2013063482A2 (en) | 2011-10-28 | 2013-05-02 | The Regents Of The University Of California | Flt3 mutations associated with drug resistance in aml patients having activating mutations in flt3 |
US9073851B2 (en) | 2011-10-28 | 2015-07-07 | Board Of Regents, The University Of Texas System | Compositions and methods for treating cancer |
US10837879B2 (en) | 2011-11-02 | 2020-11-17 | Complete Genomics, Inc. | Treatment for stabilizing nucleic acid arrays |
JP2014532720A (en) | 2011-11-04 | 2014-12-08 | オームクス コーポレイション | New chemistry used in biosensors |
EP2780299A4 (en) | 2011-11-18 | 2015-04-22 | Sarepta Therapeutics Inc | Functionally-modified oligonucleotides and subunits thereof |
ES2832531T3 (en) | 2011-11-30 | 2021-06-10 | Sarepta Therapeutics Inc | Oligonucleotides for the treatment of repeat expansion diseases |
JP6496549B2 (en) | 2011-11-30 | 2019-04-03 | サレプタ セラピューティクス, インコーポレイテッド | Induced exon inclusion in spinal muscular atrophy |
WO2013082529A1 (en) | 2011-12-02 | 2013-06-06 | Yale University | Enzymatic synthesis of poly(amine-co-esters) and methods of use thereof for gene delivery |
US9895451B2 (en) | 2011-12-02 | 2018-02-20 | Yale University | Formulations for targeted release of agents to low pH tissue environments or cellular compartments and methods of use thereof |
US10465042B2 (en) | 2011-12-02 | 2019-11-05 | Yale University | Poly(amine-co-ester) nanoparticles and methods of use thereof |
SI2788487T1 (en) | 2011-12-08 | 2018-09-28 | Sarepta Therapeutics, Inc. | Oligonucleotide analogues targeting human lmna |
CA2895077A1 (en) | 2011-12-12 | 2013-06-20 | Beverly Packard | In vivo delivery of oligonucleotides |
WO2013090804A2 (en) | 2011-12-14 | 2013-06-20 | The Johns Hopkins University | Nanoparticles with enhanced mucosal penetration or decreased inflammation |
AU2012354062B2 (en) | 2011-12-16 | 2017-09-07 | Targetgene Biotechnologies Ltd | Compositions and methods for modifying a predetermined target nucleic acid sequence |
WO2013090648A1 (en) | 2011-12-16 | 2013-06-20 | modeRNA Therapeutics | Modified nucleoside, nucleotide, and nucleic acid compositions |
WO2013096455A1 (en) | 2011-12-20 | 2013-06-27 | Dana-Farber Cancer Institute, Inc. | Methods for diagnosing and treating oncogenic kras-associated cancer |
US9115394B2 (en) | 2011-12-22 | 2015-08-25 | Roche Molecular Systems, Inc. | Methods and reagents for reducing non-specific amplification |
EP2794880B1 (en) | 2011-12-22 | 2018-05-02 | Ionis Pharmaceuticals, Inc. | Methods for modulating metastasis-associated-in-lung-adenocarcinoma-transcript-1(malat-1) expression |
EP2798089B1 (en) | 2011-12-30 | 2018-05-23 | Bio-rad Laboratories, Inc. | Methods and compositions for performing nucleic acid amplification reactions |
GB201122458D0 (en) | 2011-12-30 | 2012-02-08 | Univ Wageningen | Modified cascade ribonucleoproteins and uses thereof |
CA2860739A1 (en) | 2012-01-09 | 2013-07-18 | Ohmx Corporation | Enzyme cascade methods for e-trace assay signal amplification |
EP2802674B1 (en) | 2012-01-11 | 2020-12-16 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulation of ikbkap splicing |
US9415020B2 (en) | 2012-01-19 | 2016-08-16 | The Johns Hopkins University | Nanoparticle formulations with enhanced mucosal penetration |
GB2513793B (en) | 2012-01-26 | 2016-11-02 | Nugen Tech Inc | Compositions and methods for targeted nucleic acid sequence enrichment and high efficiency library generation |
WO2013112053A1 (en) | 2012-01-27 | 2013-08-01 | Prosensa Technologies B.V. | Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy |
JP2015512616A (en) | 2012-02-01 | 2015-04-30 | コンピュゲン エルティーディー. | C1ORF32 antibody and its use for the treatment of cancer |
WO2013120003A1 (en) | 2012-02-08 | 2013-08-15 | Isis Pharmaceuticals, Inc. | Modulation of rna by repeat targeting |
US9862994B2 (en) | 2012-02-09 | 2018-01-09 | Dana-Farber Cancer Institute, Inc. | Selective nucleic acid amplification from nucleic acid pools |
WO2013121426A1 (en) | 2012-02-13 | 2013-08-22 | Gamida-Cell Ltd. | Culturing of mesenchymal stem cells |
EP3222627B1 (en) | 2012-02-15 | 2019-08-07 | Pacific Biosciences of California, Inc. | Polymerase enzyme substrates with protein shield |
JP2015509366A (en) | 2012-02-22 | 2015-03-30 | ブレインステム バイオテック リミテッド | Generation of neural stem cells and motor neurons |
US10034902B2 (en) | 2012-02-22 | 2018-07-31 | Exostem Biotec Ltd. | MicroRNAs for the generation of astrocytes |
CA2866625C (en) | 2012-03-13 | 2020-12-08 | Swift Biosciences, Inc. | Methods and compositions for size-controlled homopolymer tailing of substrate polynucleotides by a nucleic acid polymerase |
CA2867262C (en) | 2012-03-15 | 2021-03-16 | Curna, Inc. | Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf |
EP2639238A1 (en) | 2012-03-15 | 2013-09-18 | Universität Bern | Tricyclic nucleosides and oligomeric compounds prepared therefrom |
US9610362B2 (en) | 2012-03-16 | 2017-04-04 | Valerion Therapeutics, Llc | Antisense conjugates for decreasing expression of DMPK |
US9340784B2 (en) | 2012-03-19 | 2016-05-17 | Ionis Pharmaceuticals, Inc. | Methods and compositions for modulating alpha-1-antitrypsin expression |
EA031110B1 (en) | 2012-03-20 | 2018-11-30 | Сарепта Терапьютикс, Инк. | Boronic acid conjugates of oligonucleotide analogues |
US20150086584A1 (en) | 2012-03-22 | 2015-03-26 | University Of Miami | Multi-specific binding agents |
EP2831232A4 (en) | 2012-03-30 | 2015-11-04 | Univ Washington | Methods for modulating tau expression for reducing seizure and modifying a neurodegenerative syndrome |
AU2013243948A1 (en) | 2012-04-02 | 2014-10-30 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins associated with human disease |
CN108949772A (en) | 2012-04-02 | 2018-12-07 | 现代泰克斯公司 | For generating the modification polynucleotides of biological agent relevant to human diseases and protein |
JP6375289B2 (en) | 2012-04-05 | 2018-08-15 | マサチューセッツ インスティテュート オブ テクノロジー | Immune stimulating composition and method of use thereof |
WO2013154799A1 (en) | 2012-04-09 | 2013-10-17 | Isis Pharmaceuticals, Inc. | Tricyclic nucleosides and oligomeric compounds prepared therefrom |
WO2013154798A1 (en) | 2012-04-09 | 2013-10-17 | Isis Pharmaceuticals, Inc. | Tricyclic nucleic acid analogs |
US9133461B2 (en) | 2012-04-10 | 2015-09-15 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the ALAS1 gene |
US20150087055A1 (en) | 2012-04-13 | 2015-03-26 | Massachusetts Institute Of Technology | Analog and mixed-signal computation and circuits in living cells |
WO2013159091A2 (en) | 2012-04-20 | 2013-10-24 | Aptamir Therapeutics, Inc. | Mirna modulators of thermogenesis |
US9127274B2 (en) | 2012-04-26 | 2015-09-08 | Alnylam Pharmaceuticals, Inc. | Serpinc1 iRNA compositions and methods of use thereof |
WO2013163628A2 (en) | 2012-04-27 | 2013-10-31 | Duke University | Genetic correction of mutated genes |
US9533068B2 (en) | 2012-05-04 | 2017-01-03 | The Johns Hopkins University | Drug loaded microfiber sutures for ophthalmic application |
JP6392209B2 (en) | 2012-05-04 | 2018-09-19 | ザ・ジョンズ・ホプキンス・ユニバーシティー | Lipid-based drug carriers for rapid permeation through the mucus lining |
US9273949B2 (en) | 2012-05-11 | 2016-03-01 | Vanderbilt University | Backscattering interferometric methods |
EP2850190B1 (en) | 2012-05-16 | 2020-07-08 | Translate Bio MA, Inc. | Compositions and methods for modulating mecp2 expression |
EP2850186B1 (en) | 2012-05-16 | 2018-12-19 | Translate Bio MA, Inc. | Compositions and methods for modulating smn gene family expression |
EP2850189B8 (en) | 2012-05-16 | 2019-01-23 | Translate Bio MA, Inc. | Compositions and methods for modulating gene expression |
US9574193B2 (en) | 2012-05-17 | 2017-02-21 | Ionis Pharmaceuticals, Inc. | Methods and compositions for modulating apolipoprotein (a) expression |
WO2013173789A2 (en) | 2012-05-17 | 2013-11-21 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide compositions |
EP2852606B1 (en) | 2012-05-22 | 2019-08-07 | Ionis Pharmaceuticals, Inc. | Modulation of enhancer rna mediated gene expression |
AU2013264742B2 (en) | 2012-05-24 | 2018-10-04 | A.B. Seeds Ltd. | Compositions and methods for silencing gene expression |
CA2874521A1 (en) | 2012-05-24 | 2013-11-28 | Dana-Farber Cancer Institute, Inc. | Targeting the glutamine to pyruvate pathway for treatment of oncogenic kras-associated cancer |
PT3241902T (en) | 2012-05-25 | 2018-05-28 | Univ California | Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription |
US9487780B2 (en) | 2012-06-01 | 2016-11-08 | Ionis Pharmaceuticals, Inc. | Antisense compounds targeting genes associated with fibronectin |
WO2013181665A1 (en) | 2012-06-01 | 2013-12-05 | Isis Pharmaceuticals, Inc. | Antisense compounds targeting genes associated with fibronectin |
WO2013184209A1 (en) | 2012-06-04 | 2013-12-12 | Ludwig Institute For Cancer Research Ltd. | Mif for use in methods of treating subjects with a neurodegenerative disorder |
EP2861787B1 (en) | 2012-06-18 | 2017-09-20 | Nugen Technologies, Inc. | Compositions and methods for negative selection of non-desired nucleic acid sequences |
EP3461895B1 (en) | 2012-06-25 | 2020-07-01 | Ionis Pharmaceuticals, Inc. | Modulation of ube3a-ats expression |
US20150011396A1 (en) | 2012-07-09 | 2015-01-08 | Benjamin G. Schroeder | Methods for creating directional bisulfite-converted nucleic acid libraries for next generation sequencing |
US20140038182A1 (en) | 2012-07-17 | 2014-02-06 | Dna Logix, Inc. | Cooperative primers, probes, and applications thereof |
WO2014014518A1 (en) | 2012-07-18 | 2014-01-23 | Dana-Farber Cancer Institute, Inc. | Methods for treating, preventing and predicting risk of developing breast cancer |
US9567569B2 (en) | 2012-07-23 | 2017-02-14 | Gamida Cell Ltd. | Methods of culturing and expanding mesenchymal stem cells |
US20150175979A1 (en) | 2012-07-23 | 2015-06-25 | La Jolla Institute For Allergy And Immunology | Ptprs and proteoglycans in autoimmune disease |
US9175266B2 (en) | 2012-07-23 | 2015-11-03 | Gamida Cell Ltd. | Enhancement of natural killer (NK) cell proliferation and activity |
US10870099B2 (en) | 2012-07-26 | 2020-12-22 | Illumina, Inc. | Compositions and methods for the amplification of nucleic acids |
ES2773489T3 (en) | 2012-07-27 | 2020-07-13 | Ionis Pharmaceuticals Inc | Modulation of diseases related to the renin-angiotensin system (RAS) using angiotensinogens |
CA2880833A1 (en) | 2012-08-03 | 2014-02-06 | Aptamir Therapeutics, Inc. | Cell-specific delivery of mirna modulators for the treatment of obesity and related disorders |
US8603470B1 (en) | 2012-08-07 | 2013-12-10 | National Cheng Kung University | Use of IL-20 antagonists for treating liver diseases |
WO2014028739A1 (en) | 2012-08-15 | 2014-02-20 | Isis Pharmaceuticals, Inc. | Method of preparing oligomeric compounds using modified capping protocols |
CN104781271B (en) | 2012-08-20 | 2018-07-06 | 加利福尼亚大学董事会 | The polynucleotides of group with bio-reversible |
US10111962B2 (en) | 2012-09-25 | 2018-10-30 | Genzyme Corporation | Peptide-linked morpholino antisense oligonucleotides for treatment of myotonic dystrophy |
AR092982A1 (en) | 2012-10-11 | 2015-05-13 | Isis Pharmaceuticals Inc | MODULATION OF THE EXPRESSION OF ANDROGEN RECEIVERS |
US9523094B2 (en) | 2012-10-11 | 2016-12-20 | Ionis Pharmaceuticals, Inc. | Methods of treating kennedy's disease |
EP2906255B1 (en) | 2012-10-12 | 2023-02-22 | Ionis Pharmaceuticals, Inc. | Antisense compounds and uses thereof |
EP3459549B1 (en) | 2012-10-12 | 2022-04-06 | Ionis Pharmaceuticals, Inc. | Selective antisense compounds and uses thereof |
US9029335B2 (en) | 2012-10-16 | 2015-05-12 | Isis Pharmaceuticals, Inc. | Substituted 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom |
WO2014062989A2 (en) | 2012-10-18 | 2014-04-24 | Monsanto Technology Llc | Methods and compositions for plant pest control |
US10548962B2 (en) | 2012-10-22 | 2020-02-04 | The Board Of Regents For Oklahoma State University | Use of the salmonella SPP type III secretion proteins as a protective vaccination |
US9266959B2 (en) | 2012-10-23 | 2016-02-23 | Oncomed Pharmaceuticals, Inc. | Methods of treating neuroendocrine tumors using frizzled-binding agents |
US20140322706A1 (en) | 2012-10-24 | 2014-10-30 | Jon Faiz Kayyem | Integrated multipelx target analysis |
JP1628115S (en) | 2012-10-24 | 2019-04-01 | ||
US20150299803A1 (en) | 2012-11-05 | 2015-10-22 | Pronai Therapeutics, Inc. | Methods of Using Biomarkers for the Treatment of Cancer by Modulation of BCL2 Expression |
CA2890207A1 (en) | 2012-11-05 | 2014-05-08 | Foundation Medicine, Inc. | Novel ntrk1 fusion molecules and uses thereof |
ES2921623T3 (en) | 2012-11-26 | 2022-08-30 | Modernatx Inc | terminally modified RNA |
WO2014093305A2 (en) | 2012-12-13 | 2014-06-19 | Ymir Genomics, Llc | Micrornas and uses thereof |
AU2013364158A1 (en) | 2012-12-20 | 2015-07-09 | Sarepta Therapeutics, Inc. | Improved exon skipping compositions for treating muscular dystrophy |
US10683505B2 (en) | 2013-01-01 | 2020-06-16 | Monsanto Technology Llc | Methods of introducing dsRNA to plant seeds for modulating gene expression |
BR112015015976A2 (en) | 2013-01-01 | 2018-04-10 | A. B. Seeds Ltd. | method for introducing dsrna into seeds to modulate gene expression |
WO2014113540A1 (en) | 2013-01-16 | 2014-07-24 | Iowa State University Research Foundation, Inc. | A deep intronic target for splicing correction on spinal muscular atrophy gene |
WO2014113089A2 (en) | 2013-01-17 | 2014-07-24 | Moderna Therapeutics, Inc. | Signal-sensor polynucleotides for the alteration of cellular phenotypes |
CA2898326C (en) | 2013-01-18 | 2022-05-17 | Foundation Medicine, Inc. | Methods of treating cholangiocarcinoma |
US9956294B2 (en) | 2013-01-18 | 2018-05-01 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Targeted sensitization of non-del(5q) malignant cells |
US10000767B2 (en) | 2013-01-28 | 2018-06-19 | Monsanto Technology Llc | Methods and compositions for plant pest control |
US9701708B2 (en) | 2013-01-31 | 2017-07-11 | Ionis Pharmaceuticals, Inc. | Method of preparing oligomeric compounds using modified coupling protocols |
US9359444B2 (en) | 2013-02-04 | 2016-06-07 | Oncomed Pharmaceuticals Inc. | Methods and monitoring of treatment with a Wnt pathway inhibitor |
US10568975B2 (en) | 2013-02-05 | 2020-02-25 | The Johns Hopkins University | Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof |
KR102169899B1 (en) | 2013-02-14 | 2020-10-26 | 아이오니스 파마수티컬즈, 인코포레이티드 | Modulation of apolipoprotein c-iii (apociii) expression in lipoprotein lipase deficient (lpld) populations |
US20150366890A1 (en) | 2013-02-25 | 2015-12-24 | Trustees Of Boston University | Compositions and methods for treating fungal infections |
CN105163755A (en) | 2013-03-12 | 2015-12-16 | 犹他大学研究基金会 | Compositions and methods for inducing apoptosis |
US20160024181A1 (en) | 2013-03-13 | 2016-01-28 | Moderna Therapeutics, Inc. | Long-lived polynucleotide molecules |
MX2015012334A (en) | 2013-03-13 | 2016-02-05 | Monsanto Technology Llc | Methods and compositions for weed control. |
WO2014142850A1 (en) | 2013-03-13 | 2014-09-18 | Illumina, Inc. | Methods and compositions for nucleic acid sequencing |
WO2014164761A1 (en) | 2013-03-13 | 2014-10-09 | Monsanto Technology Llc | Methods and compositions for weed control |
EP2971010B1 (en) | 2013-03-14 | 2020-06-10 | ModernaTX, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
ES2807379T3 (en) | 2013-03-14 | 2021-02-22 | Ionis Pharmaceuticals Inc | Compositions and methods to regulate the expression of Tau |
US9168300B2 (en) | 2013-03-14 | 2015-10-27 | Oncomed Pharmaceuticals, Inc. | MET-binding agents and uses thereof |
PE20160046A1 (en) | 2013-03-14 | 2016-02-14 | Alnylam Pharmaceuticals Inc | COMPOSITION OF RNAi AGAINST THE C5 COMPONENT OF THE COMPLEMENT AND METHODS FOR ITS USE |
US20140329881A1 (en) | 2013-03-14 | 2014-11-06 | Sarepta Therapeutics, Inc. | Exon skipping compositions for treating muscular dystrophy |
EP2971167B1 (en) | 2013-03-14 | 2019-07-31 | Caribou Biosciences, Inc. | Compositions and methods of nucleic acid-targeting nucleic acids |
US20140283211A1 (en) | 2013-03-14 | 2014-09-18 | Monsanto Technology Llc | Methods and Compositions for Plant Pest Control |
JP2016521119A (en) | 2013-03-14 | 2016-07-21 | サレプタ セラピューティクス, インコーポレイテッド | Exon skipping composition for treating muscular dystrophy |
EP3520895A1 (en) | 2013-03-15 | 2019-08-07 | Genmark Diagnostics Inc. | Fluid container with cantilevered lance |
EP2968991A2 (en) | 2013-03-15 | 2016-01-20 | Sarepta Therapeutics, Inc. | Improved compositions for treating muscular dystrophy |
EP2971165A4 (en) | 2013-03-15 | 2016-11-23 | Moderna Therapeutics Inc | Removal of dna fragments in mrna production process |
US10324011B2 (en) | 2013-03-15 | 2019-06-18 | The Trustees Of Princeton University | Methods and devices for high throughput purification |
US9347095B2 (en) | 2013-03-15 | 2016-05-24 | Bio-Rad Laboratories, Inc. | Digital assays for mutation detection |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
CA2907357A1 (en) | 2013-03-15 | 2014-09-18 | Kinemed, Inc. | Biomarkers |
US10568328B2 (en) | 2013-03-15 | 2020-02-25 | Monsanto Technology Llc | Methods and compositions for weed control |
CN114045295A (en) | 2013-03-15 | 2022-02-15 | 宾夕法尼亚大学理事会 | Foot and Mouth Disease Virus (FMDV) consensus proteins, coding sequences thereof, and vaccines made therefrom |
US10052364B2 (en) | 2013-03-15 | 2018-08-21 | The Trustees Of Columbia University In The City Of New York | Osteocalcin as a treatment for cognitive disorders |
CN110186835B (en) | 2013-03-15 | 2022-05-31 | Gpb科学有限公司 | On-chip microfluidic processing of particles |
WO2014144092A1 (en) | 2013-03-15 | 2014-09-18 | Nugen Technologies, Inc. | Sequential sequencing |
RU2015144149A (en) | 2013-03-15 | 2017-04-21 | Интермьюн, Инк. | PROTEOMIC MARKERS ILF |
EP4286517A3 (en) | 2013-04-04 | 2024-03-13 | President and Fellows of Harvard College | Therapeutic uses of genome editing with crispr/cas systems |
US10544461B2 (en) | 2013-04-16 | 2020-01-28 | The Johns Hopkins University | Diagnostic and prognostic test for sturge-weber syndrome, klippel-trenaunay-weber syndrome, and port-wine stains (PWSS) |
BR112015027377B1 (en) | 2013-05-01 | 2023-01-10 | Ionis Pharmaceuticals, Inc | OLIGOMERIC COMPOUNDS WITH CONJUGATE GROUPS, COMPOSITIONS COMPRISING THE SAID COMPOUNDS AND USES THEREOF |
EP2994167B1 (en) | 2013-05-06 | 2020-05-06 | Alnylam Pharmaceuticals, Inc. | Dosages and methods for delivering lipid formulated nucleic acid molecules |
CN111187811B (en) | 2013-05-06 | 2024-03-08 | 加利福尼亚太平洋生物科学股份有限公司 | Real-time electronic sequencing |
MX2015015891A (en) | 2013-05-22 | 2016-06-02 | Telomere Diagnostics Inc | Measures of short telomere abundance. |
SG10201913872XA (en) | 2013-05-22 | 2020-03-30 | Alnylam Pharmaceuticals Inc | SERPINA1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
SG11201510565TA (en) | 2013-05-22 | 2016-01-28 | Alnylam Pharmaceuticals Inc | Tmprss6 irna compositions and methods of use thereof |
US20160113911A1 (en) | 2013-06-06 | 2016-04-28 | The General Hospital Corporation | Methods and compositions for the treatment of cancer |
EP3007704B1 (en) | 2013-06-13 | 2021-01-06 | Antisense Therapeutics Ltd | Combination therapy for acromegaly |
WO2014203189A1 (en) | 2013-06-18 | 2014-12-24 | Rosetta Genomics Ltd. | Nanocarrier system for micrornas and uses thereof |
ES2778462T3 (en) | 2013-06-21 | 2020-08-10 | Ionis Pharmaceuticals Inc | Compounds and methods to modulate apolipoprotein C-III expression to improve a diabetic profile |
CN105452461B (en) | 2013-07-02 | 2021-04-13 | Ionis制药公司 | Modulators of growth hormone receptors |
HUE056760T2 (en) | 2013-07-11 | 2022-03-28 | Modernatx Inc | Compositions comprising synthetic polynucleotides encoding crispr related proteins and synthetic sgrnas and methods of use |
US10077236B2 (en) | 2013-07-15 | 2018-09-18 | The Regents Of The University Of California | Azacyclic constrained analogs of FTY720 |
US9850496B2 (en) | 2013-07-19 | 2017-12-26 | Monsanto Technology Llc | Compositions and methods for controlling Leptinotarsa |
EP3030663B1 (en) | 2013-07-19 | 2019-09-04 | Monsanto Technology LLC | Compositions and methods for controlling leptinotarsa |
TWI772856B (en) | 2013-07-19 | 2022-08-01 | 美商百健Ma公司 | Compositions for modulating tau expression |
US9944998B2 (en) | 2013-07-25 | 2018-04-17 | Bio-Rad Laboratories, Inc. | Genetic assays |
RS59991B1 (en) | 2013-08-08 | 2020-04-30 | Scripps Research Inst | A method for the site-specific enzymatic labelling of nucleic acids in vitro by incorporation of unnatural nucleotides |
TW201536329A (en) | 2013-08-09 | 2015-10-01 | Isis Pharmaceuticals Inc | Compounds and methods for modulation of dystrophia myotonica-protein kinase (DMPK) expression |
EP3033625B1 (en) | 2013-08-13 | 2020-01-22 | The Scripps Research Institute | Cysteine-reactive ligand discovery in proteomes |
EP3038627B1 (en) | 2013-08-28 | 2020-03-04 | Ionis Pharmaceuticals, Inc. | Modulation of prekallikrein (pkk) expression |
WO2015031837A1 (en) | 2013-08-29 | 2015-03-05 | City Of Hope | Cell penetrating conjugates and methods of use thereof |
AU2014315287A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
WO2015034925A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Circular polynucleotides |
US11236338B2 (en) | 2013-09-05 | 2022-02-01 | Sarepta Therapeutics, Inc. | Antisense-induced exon2 inclusion in acid alpha-glucosidase |
DK3044315T3 (en) | 2013-09-11 | 2019-05-20 | Synthena Ag | NUCLEAR INSURANCE AND PROCEDURES FOR TREATMENT OF PUMPS DISEASE |
SG10201913950XA (en) | 2013-09-11 | 2020-03-30 | Eagle Biologics Inc | Liquid protein formulations containing viscosity-lowering agents |
SG10201806787VA (en) | 2013-09-13 | 2018-09-27 | Ionis Pharmaceuticals Inc | Modulators of complement factor b |
US9708360B2 (en) | 2013-09-30 | 2017-07-18 | Geron Corporation | Phosphorodiamidate backbone linkage for oligonucleotides |
EP3052626A1 (en) | 2013-10-02 | 2016-08-10 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the lect2 gene |
WO2015051169A2 (en) | 2013-10-02 | 2015-04-09 | Moderna Therapeutics, Inc. | Polynucleotide molecules and uses thereof |
EA201690675A1 (en) | 2013-10-03 | 2016-08-31 | Модерна Терапьютикс, Инк. | POLYNUCLEOTES ENCODING THE RECEPTOR OF LOW DENSITY LIPOPROTEINS |
US10519446B2 (en) | 2013-10-04 | 2019-12-31 | Novartis Ag | Organic compounds to treat hepatitis B virus |
TW202310853A (en) | 2013-10-04 | 2023-03-16 | 美國西奈山伊坎醫學院 | Compositions and methods for inhibiting expression of the alas1 gene |
WO2015051366A2 (en) | 2013-10-04 | 2015-04-09 | Novartis Ag | Novel formats for organic compounds for use in rna interference |
CA2925129C (en) | 2013-10-04 | 2023-04-04 | Novartis Ag | 3' end caps for rnai agents for use in rna interference |
EP3055426B1 (en) | 2013-10-09 | 2019-06-19 | The United States of America as represented by The Secretary Department of Health and Human Services | Detection of hepatitis delta virus (hdv) for the diagnosis and treatment of sjögren's syndrome and lymphoma |
US11162096B2 (en) | 2013-10-14 | 2021-11-02 | Ionis Pharmaceuticals, Inc | Methods for modulating expression of C9ORF72 antisense transcript |
EP3057693A4 (en) | 2013-10-16 | 2017-08-09 | The University Of British Columbia | Device for formulating particles at small volumes |
CA2928779A1 (en) | 2013-10-21 | 2015-04-30 | The General Hospital Corporation | Methods relating to circulating tumor cell clusters and the treatment of cancer |
US9758546B2 (en) | 2013-10-21 | 2017-09-12 | Ionis Pharmaceuticals, Inc. | Method for solution phase detritylation of oligomeric compounds |
US9498778B2 (en) | 2014-11-11 | 2016-11-22 | Genmark Diagnostics, Inc. | Instrument for processing cartridge for performing assays in a closed sample preparation and reaction system |
USD881409S1 (en) | 2013-10-24 | 2020-04-14 | Genmark Diagnostics, Inc. | Biochip cartridge |
WO2015066341A2 (en) | 2013-10-30 | 2015-05-07 | Green Life Biotech, Llc | Pathogenesis quantification systems and treatment methods for citrus greening blight |
US10301622B2 (en) | 2013-11-04 | 2019-05-28 | Northwestern University | Quantification and spatio-temporal tracking of a target using a spherical nucleic acid (SNA) |
EP3066200A1 (en) | 2013-11-04 | 2016-09-14 | Monsanto Technology LLC | Compositions and methods for controlling arthropod parasite and pest infestations |
CA2929596C (en) | 2013-11-13 | 2022-07-05 | Nugen Technologies, Inc. | Compositions and methods for identification of a duplicate sequencing read |
JP2016537028A (en) | 2013-11-18 | 2016-12-01 | クリスパー セラピューティクス アーゲー | CRISPR-CAS System Materials and Methods |
EP3556869B1 (en) | 2013-11-26 | 2023-08-02 | Illumina Inc. | Compositions and methods for polynucleotide sequencing |
ES2797679T3 (en) | 2013-12-02 | 2020-12-03 | Ionis Pharmaceuticals Inc | Antisense compounds and their uses |
CN112107693B (en) | 2013-12-03 | 2023-05-26 | 西北大学 | Liposome particles, method for preparing said liposome particles and use thereof |
WO2015085274A1 (en) | 2013-12-05 | 2015-06-11 | Centrillion Technology Holdings Corporation | Methods for sequencing nucleic acids |
EP3077430A4 (en) | 2013-12-05 | 2017-08-16 | Centrillion Technology Holdings Corporation | Modified surfaces |
CN111118121A (en) | 2013-12-05 | 2020-05-08 | 生捷科技控股公司 | Preparation of patterned arrays |
CA2844640A1 (en) | 2013-12-06 | 2015-06-06 | The University Of British Columbia | Method for treatment of castration-resistant prostate cancer |
US10385388B2 (en) | 2013-12-06 | 2019-08-20 | Swift Biosciences, Inc. | Cleavable competitor polynucleotides |
UA119253C2 (en) | 2013-12-10 | 2019-05-27 | Біолоджикс, Інк. | Compositions and methods for virus control in varroa mite and bees |
WO2015085350A1 (en) | 2013-12-10 | 2015-06-18 | Conexio Genomics Pty Ltd | Methods and probes for identifying gene alleles |
WO2015089277A1 (en) | 2013-12-12 | 2015-06-18 | The Regents Of The University Of California | Methods and compositions for modifying a single stranded target nucleic acid |
CA2931090A1 (en) | 2013-12-12 | 2015-06-18 | Alnylam Pharmaceuticals, Inc. | Complement component irna compositions and methods of use thereof |
AU2014364520B2 (en) | 2013-12-20 | 2020-01-02 | The General Hospital Corporation | Methods and assays relating to circulating tumor cells |
JP6678583B2 (en) | 2013-12-20 | 2020-04-22 | バイオメッド バレー ディスカバリーズ,インコーポレイティド | Cancer treatment using a combination of type 2 MEK inhibitor and ERK inhibitor |
US9243289B2 (en) | 2013-12-23 | 2016-01-26 | Roche Molecular Systems, Inc. | Method for screening reagents used in PCR assays |
AU2014369900B2 (en) | 2013-12-24 | 2021-05-20 | Ionis Pharmaceuticals, Inc. | Modulation of angiopoietin-like 3 expression |
UA121462C2 (en) | 2014-01-15 | 2020-06-10 | Монсанто Текнолоджі Елелсі | Methods and compositions for weed control using epsps polynucleotides |
JP6666852B2 (en) | 2014-01-16 | 2020-03-18 | イルミナ インコーポレイテッド | Gene expression panel for prognosis of prostate cancer recurrence |
ES2838804T3 (en) | 2014-01-31 | 2021-07-02 | Univ Temple | BAG3 as a target for the treatment of heart failure |
AU2015214264B2 (en) | 2014-02-04 | 2018-12-20 | Curis, Inc. | Mutant Smoothened and methods of using the same |
CA2936158C (en) | 2014-02-05 | 2023-06-13 | Yeda Research And Development Co. Ltd. | Use of mir-135 or precursor thereof for the treatment and diagnosis of a bipolar disease |
WO2015123264A1 (en) | 2014-02-11 | 2015-08-20 | Alnylam Pharmaceuticals, Inc. | Ketohexokinase (khk) irna compositions and methods of use thereof |
WO2015127389A1 (en) | 2014-02-23 | 2015-08-27 | The Johns Hopkins University | Hypotonic enema formulations and methods of use |
WO2015131107A1 (en) | 2014-02-28 | 2015-09-03 | Nugen Technologies, Inc. | Reduced representation bisulfite sequencing with diversity adaptors |
US10036019B2 (en) | 2014-03-17 | 2018-07-31 | Ionis Pharmaceuticals, Inc. | Bicyclic carbocyclic nucleosides and oligomeric compounds prepared therefrom |
MX2016012123A (en) | 2014-03-19 | 2017-01-19 | Ionis Pharmaceuticals Inc | Compositions for modulating ataxin 2 expression. |
US10006027B2 (en) | 2014-03-19 | 2018-06-26 | Ionis Pharmaceuticals, Inc. | Methods for modulating Ataxin 2 expression |
US10350264B2 (en) | 2014-03-27 | 2019-07-16 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for modulating NCOA4-mediated autophagic targeting of ferritin |
US11060139B2 (en) | 2014-03-28 | 2021-07-13 | Centrillion Technology Holdings Corporation | Methods for sequencing nucleic acids |
ES2868305T3 (en) | 2014-03-28 | 2021-10-21 | Univ Washington Through Its Center For Commercialization | Vaccines against breast and ovarian cancer |
JP6574239B2 (en) | 2014-03-30 | 2019-09-11 | セフィエド | Modified thymine polynucleotide oligomers and methods |
US11091770B2 (en) | 2014-04-01 | 2021-08-17 | Monsanto Technology Llc | Compositions and methods for controlling insect pests |
ES2926869T3 (en) | 2014-04-01 | 2022-10-31 | Biogen Ma Inc | Compositions to modulate the expression of SOD-1 |
TWI638047B (en) | 2014-04-09 | 2018-10-11 | 史基普研究協會 | Import of unnatural or modified nucleoside triphosphates into cells via nucleic acid triphosphate transporters |
US10221416B2 (en) | 2014-04-24 | 2019-03-05 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds comprising alpha-beta-constrained nucleic acid |
CA2943894A1 (en) | 2014-05-01 | 2015-11-05 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating complement factor b expression |
EP3137115B1 (en) | 2014-05-01 | 2020-10-14 | Ionis Pharmaceuticals, Inc. | Method for synthesis of reactive conjugate clusters |
EP3757215A3 (en) | 2014-05-01 | 2021-03-17 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating growth hormone receptor expression |
US9382540B2 (en) | 2014-05-01 | 2016-07-05 | Isis Pharmaceuticals, Inc | Compositions and methods for modulating angiopoietin-like 3 expression |
KR102366078B1 (en) | 2014-05-01 | 2022-02-21 | 아이오니스 파마수티컬즈, 인코포레이티드 | Compositions and methods for modulating pkk expression |
WO2015171918A2 (en) | 2014-05-07 | 2015-11-12 | Louisiana State University And Agricultural And Mechanical College | Compositions and uses for treatment thereof |
US11918695B2 (en) | 2014-05-09 | 2024-03-05 | Yale University | Topical formulation of hyperbranched polymer-coated particles |
EP3721875B1 (en) | 2014-05-09 | 2023-11-08 | Yale University | Particles coated with hyperbranched polyglycerol and methods for their preparation |
US10335500B2 (en) | 2014-05-12 | 2019-07-02 | The Johns Hopkins University | Highly stable biodegradable gene vector platforms for overcoming biological barriers |
WO2015175539A1 (en) | 2014-05-12 | 2015-11-19 | The Johns Hopkins University | Engineering synthetic brain penetrating gene vectors |
TW201607559A (en) | 2014-05-12 | 2016-03-01 | 阿尼拉製藥公司 | Methods and compositions for treating a SERPINC1-associated disorder |
WO2015175977A2 (en) | 2014-05-16 | 2015-11-19 | Geller Bruce L | Antisense antibacterial compounds and methods |
US10391098B2 (en) | 2014-05-19 | 2019-08-27 | Board Of Regents, The University Of Texas System | Antisense antibacterial compounds and methods |
US10570169B2 (en) | 2014-05-22 | 2020-02-25 | Ionis Pharmaceuticals, Inc. | Conjugated antisense compounds and their use |
EA201692370A1 (en) | 2014-05-22 | 2017-03-31 | Элнилэм Фармасьютикалз, Инк. | COMPOSITIONS of mRNA ANGIOTENZINOGENA (AGT) AND METHODS OF THEIR USE |
TWI787678B (en) | 2014-05-23 | 2022-12-21 | 美商健臻公司 | Inhibiting or downregulating glycogen synthase by creating premature stop codons using antisense oligonucleotides |
US10456445B2 (en) | 2014-06-02 | 2019-10-29 | Children's Medical Center Corporation | Methods and compositions for immunomodulation |
WO2015191596A1 (en) | 2014-06-09 | 2015-12-17 | Biomed Valley Discoveries, Inc. | Combination therapies using platinum agents and agents that target tumor-associated stroma or tumor cells |
US10758614B2 (en) | 2014-06-09 | 2020-09-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services National Institutes Of Health | Combination therapies targeting tumor-associated stroma or tumor cells and topoisomerase |
US10799584B2 (en) | 2014-06-09 | 2020-10-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services National Institutes Of Health | Combination therapies using agents that target tumor-associated stroma or tumor cells and alkylating agents |
WO2015191617A2 (en) | 2014-06-09 | 2015-12-17 | Biomed Valley Discoveries, Inc. | Combination therapies using anti-metabolites and agents that target tumor-associated stroma or tumor cells |
US10758526B2 (en) | 2014-06-09 | 2020-09-01 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services National Institutes Of Health | Combination therapies using agents that target tumor-associated stroma or tumor cells and other pathways |
WO2015191590A2 (en) | 2014-06-09 | 2015-12-17 | Biomed Valley Discoveries, Inc. | Combination therapies targeting tumor-associated stroma or tumor cells and microtubules |
US11034757B2 (en) | 2014-06-09 | 2021-06-15 | Biomed Valley Discoveries, Inc. | Combination therapies using agents that target tumor-associated stroma or tumor cells and tumor vasculature |
WO2015190922A1 (en) | 2014-06-10 | 2015-12-17 | Erasmus University Medical Center Rotterdam | Antisense oligonucleotides useful in treatment of pompe disease |
EP3154696B1 (en) | 2014-06-10 | 2020-04-08 | DxTerity Diagnostics Incorporated | Devices and methods for collecting and stabilizing biological samples |
TW201620526A (en) | 2014-06-17 | 2016-06-16 | 愛羅海德研究公司 | Compositions and methods for inhibiting gene expression of alpha-1 antitrypsin |
AU2015280252A1 (en) | 2014-06-23 | 2017-01-12 | Monsanto Technology Llc | Compositions and methods for regulating gene expression via RNA interference |
US11807857B2 (en) | 2014-06-25 | 2023-11-07 | Monsanto Technology Llc | Methods and compositions for delivering nucleic acids to plant cells and regulating gene expression |
WO2015200697A1 (en) | 2014-06-25 | 2015-12-30 | The General Hospital Corporation | Targeting human satellite ii (hsatii) |
AU2015291151B2 (en) | 2014-07-15 | 2019-10-10 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Isolated polypeptides of CD44 and uses thereof |
JP2017524357A (en) * | 2014-07-16 | 2017-08-31 | モデルナティエックス インコーポレイテッドModernaTX,Inc. | Chimeric polynucleotide |
US9951327B1 (en) | 2014-07-17 | 2018-04-24 | Integrated Dna Technologies, Inc. | Efficient and rapid method for assembling and cloning double-stranded DNA fragments |
EP3169699A4 (en) | 2014-07-18 | 2018-06-20 | The University of Washington | Cancer vaccine compositions and methods of use thereof |
CA3176503A1 (en) | 2014-07-21 | 2016-01-28 | Illumina, Inc | Polynucleotide enrichment using crispr-cas systems |
EP3171895A1 (en) | 2014-07-23 | 2017-05-31 | Modernatx, Inc. | Modified polynucleotides for the production of intrabodies |
ES2752761T3 (en) | 2014-07-24 | 2020-04-06 | Abbott Molecular Inc | Compositions for the detection and analysis of mycobacterium tuberculosis |
US11072681B2 (en) | 2014-07-28 | 2021-07-27 | The Regents Of The University Of California | Compositions and methods of making polymerizing nucleic acids |
CA2955842A1 (en) | 2014-07-29 | 2016-02-04 | Monsanto Technology Llc | Compositions and methods for controlling insect pests |
MX2017001432A (en) | 2014-07-31 | 2017-05-09 | Uab Res Found | Apoe mimetic peptides and higher potency to clear plasma cholesterol. |
DK3174976T3 (en) | 2014-08-01 | 2020-11-23 | Gpb Scient Inc | Particle processing methods and systems |
US11046721B2 (en) | 2014-08-04 | 2021-06-29 | The Trustees Of The University Of Pennsylvania | Ruthenium-based photolinkers and methods of use |
US10980744B2 (en) | 2014-08-08 | 2021-04-20 | The Regents Of The University Of California | High density peptide polymers |
CA2958431A1 (en) | 2014-08-19 | 2016-02-25 | Northwestern University | Protein/oligonucleotide core-shell nanoparticle therapeutics |
US10465188B2 (en) | 2014-08-22 | 2019-11-05 | Auckland Uniservices Limited | Channel modulators |
WO2016030899A1 (en) | 2014-08-28 | 2016-03-03 | Yeda Research And Development Co. Ltd. | Methods of treating amyotrophic lateral scleroses |
ES2928500T3 (en) | 2014-08-29 | 2022-11-18 | Alnylam Pharmaceuticals Inc | Patisiran for use in the treatment of transthyretin-mediated amyloidosis |
JP2017526367A (en) | 2014-08-29 | 2017-09-14 | チルドレンズ メディカル センター コーポレーション | Methods and compositions for the treatment of cancer |
WO2016033424A1 (en) | 2014-08-29 | 2016-03-03 | Genzyme Corporation | Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b |
AU2015311563B2 (en) | 2014-09-05 | 2019-11-28 | Rsem, Limited Partnership | Compositions and methods for treating and preventing inflammation |
WO2016040589A1 (en) | 2014-09-12 | 2016-03-17 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting complement component c5 and methods of use thereof |
US10913973B2 (en) | 2014-09-17 | 2021-02-09 | Board Of Regents, The University Texas System | Methods and devices related to toehold-based strand displacement with loop-mediated isothermal amplification |
US10556020B2 (en) | 2014-09-26 | 2020-02-11 | University Of Massachusetts | RNA-modulating agents |
JP2017534295A (en) | 2014-09-29 | 2017-11-24 | ザ ジャクソン ラボラトリー | High-efficiency, high-throughput generation of genetically modified mammals by electroporation |
AU2015325055B2 (en) | 2014-10-01 | 2021-02-25 | Eagle Biologics, Inc. | Polysaccharide and nucleic acid formulations containing viscosity-lowering agents |
JOP20200115A1 (en) | 2014-10-10 | 2017-06-16 | Alnylam Pharmaceuticals Inc | Compositions And Methods For Inhibition Of HAO1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) Gene Expression |
WO2016057061A2 (en) | 2014-10-10 | 2016-04-14 | Massachusetts Eye And Ear Infirmary | Efficient delivery of therapeutic molecules in vitro and in vivo |
EP3206751A4 (en) | 2014-10-14 | 2018-06-13 | The J. David Gladstone Institutes | Compositions and methods for reactivating latent immunodeficiency virus |
WO2016061487A1 (en) | 2014-10-17 | 2016-04-21 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof |
US11370823B2 (en) | 2014-10-29 | 2022-06-28 | Massachusetts Eye And Ear Infirmary | Efficient delivery of therapeutic molecules to cells of the inner ear |
US11071790B2 (en) | 2014-10-29 | 2021-07-27 | Massachusetts Eye And Ear Infirmary | Method for efficient delivery of therapeutic molecules in vitro and in vivo |
WO2016069694A2 (en) | 2014-10-30 | 2016-05-06 | Alnylam Pharmaceuticals, Inc. | Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof |
JOP20200092A1 (en) | 2014-11-10 | 2017-06-16 | Alnylam Pharmaceuticals Inc | HEPATITIS B VIRUS (HBV) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
US10005080B2 (en) | 2014-11-11 | 2018-06-26 | Genmark Diagnostics, Inc. | Instrument and cartridge for performing assays in a closed sample preparation and reaction system employing electrowetting fluid manipulation |
US9598722B2 (en) | 2014-11-11 | 2017-03-21 | Genmark Diagnostics, Inc. | Cartridge for performing assays in a closed sample preparation and reaction system |
EP3218513B1 (en) | 2014-11-11 | 2018-10-31 | Illumina, Inc. | Polynucleotide amplification using crispr-cas systems |
EP3831481A1 (en) | 2014-11-11 | 2021-06-09 | Genmark Diagnostics Inc. | Instrument and cartridge for performing assays in a closed sample preparation and reaction system |
CN113846101A (en) | 2014-11-17 | 2021-12-28 | 阿尔尼拉姆医药品有限公司 | Apolipoprotein C3(APOC3) iRNA compositions and methods of use thereof |
WO2016081621A1 (en) | 2014-11-18 | 2016-05-26 | Yale University | Formulations for targeted release of agents under low ph conditions and methods of use thereof |
US10682422B2 (en) | 2014-11-18 | 2020-06-16 | Yale University | Formulations for targeted release of agents under low pH conditions and methods of use thereof |
JP7175608B2 (en) | 2014-11-19 | 2022-11-21 | ザ トラスティーズ オブ コロンビア ユニバーシティ イン ザ シティ オブ ニューヨーク | Osteocalcin as a treatment for age-related frailty |
CN107106493A (en) | 2014-11-21 | 2017-08-29 | 西北大学 | The sequence-specific cellular uptake of spherical nucleic acid nano particle conjugate |
WO2016086104A1 (en) | 2014-11-25 | 2016-06-02 | Ionis Pharmaceuticals, Inc. | Modulation of ube3a-ats expression |
CA2969464A1 (en) | 2014-12-12 | 2016-06-16 | Tod M. Woolf | Compositions and methods for editing nucleic acids in cells utilizing oligonucleotides |
US9909169B2 (en) | 2014-12-17 | 2018-03-06 | Roche Molecular Systems, Inc. | Allele-specific amplification of nucleic acids using blocking oligonucleotides for wild type suppression |
BR112017014116A2 (en) | 2014-12-30 | 2018-03-06 | Telomere Diagnostics Inc | quantitative multiplex pcr |
US9688707B2 (en) | 2014-12-30 | 2017-06-27 | Ionis Pharmaceuticals, Inc. | Bicyclic morpholino compounds and oligomeric compounds prepared therefrom |
AU2015372560B2 (en) | 2014-12-31 | 2021-12-02 | Board Of Regents, The University Of Texas System | Antisense antibacterial compounds and methods |
WO2016112132A1 (en) | 2015-01-06 | 2016-07-14 | Ionis Pharmaceuticals, Inc. | Compositions for modulating expression of c9orf72 antisense transcript |
US10538763B2 (en) | 2015-01-16 | 2020-01-21 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulation of DUX4 |
AU2016206475B2 (en) | 2015-01-16 | 2021-11-04 | City Of Hope | Cell penetrating antibodies |
US9434947B2 (en) | 2015-01-20 | 2016-09-06 | Oregon Health & Science University | Modulation of KCNH2 isoform expression by oligonucleotides as a therapeutic approach for long QT syndrome |
PL3256589T3 (en) | 2015-01-22 | 2022-02-21 | Monsanto Technology Llc | Compositions and methods for controlling leptinotarsa |
JP2018506715A (en) | 2015-01-23 | 2018-03-08 | ヴァンダービルト ユニバーシティー | Robust interferometer and method of use |
EP3250184A1 (en) | 2015-01-27 | 2017-12-06 | The Johns Hopkins University | Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces |
US10676726B2 (en) | 2015-02-09 | 2020-06-09 | Duke University | Compositions and methods for epigenome editing |
KR20210135626A (en) | 2015-02-10 | 2021-11-15 | 일루미나, 인코포레이티드 | The method and the composition for analyzing the cellular constituent |
CA2976445A1 (en) | 2015-02-13 | 2016-08-18 | Alnylam Pharmaceuticals, Inc. | Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof |
US10450342B2 (en) | 2015-02-23 | 2019-10-22 | Ionis Pharmaceuticals, Inc. | Method for solution phase detritylation of oligomeric compounds |
WO2016135559A2 (en) | 2015-02-23 | 2016-09-01 | Crispr Therapeutics Ag | Materials and methods for treatment of human genetic diseases including hemoglobinopathies |
HUE063406T2 (en) | 2015-02-24 | 2024-01-28 | Hope City | Chemically encoded spatially addressed library screening platforms |
CA2977965C (en) | 2015-02-26 | 2021-12-21 | Ionis Pharmaceuticals, Inc. | Allele specific modulators of p23h rhodopsin |
US11129844B2 (en) | 2015-03-03 | 2021-09-28 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating MECP2 expression |
EP3268475B1 (en) | 2015-03-11 | 2020-10-21 | Yissum Research and Development Company of the Hebrew University of Jerusalem Ltd. | Decoy oligonucleotides for the treatment of diseases |
MA41795A (en) | 2015-03-18 | 2018-01-23 | Sarepta Therapeutics Inc | EXCLUSION OF AN EXON INDUCED BY ANTISENSE COMPOUNDS IN MYOSTATIN |
US9708647B2 (en) | 2015-03-23 | 2017-07-18 | Insilixa, Inc. | Multiplexed analysis of nucleic acid hybridization thermodynamics using integrated arrays |
US10300452B2 (en) | 2015-03-24 | 2019-05-28 | Pacific Biosciences Of California, Inc. | Methods and compositions for single molecule composition loading |
US10168342B2 (en) | 2015-03-27 | 2019-01-01 | The Scripps Research Institute | Lipid probes and uses thereof |
BR112017020750A2 (en) | 2015-03-27 | 2018-06-26 | Harvard College | modified t-cells and methods of producing and using them |
EP4218771A1 (en) | 2015-03-27 | 2023-08-02 | Yeda Research and Development Co. Ltd | Methods of treating motor neuron diseases |
WO2016161201A2 (en) | 2015-03-31 | 2016-10-06 | Oncosec Medical Incorporated | Systems and methods for improved tissue-sensing based electroporation |
US10961532B2 (en) | 2015-04-07 | 2021-03-30 | The General Hospital Corporation | Methods for reactivating genes on the inactive X chromosome |
US10745702B2 (en) | 2015-04-08 | 2020-08-18 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the LECT2 gene |
US20180126014A1 (en) | 2015-04-15 | 2018-05-10 | Yale University | Compositions for enhancing delivery of agents across the blood brain barrier and methods of use thereof |
CN104845967B (en) | 2015-04-15 | 2020-12-11 | 苏州新海生物科技股份有限公司 | Oligonucleotide fragment, method for selectively amplifying target nucleic acid sequence variant by using same and application of oligonucleotide fragment |
KR102104163B1 (en) | 2015-04-16 | 2020-04-23 | 아이오니스 파마수티컬즈, 인코포레이티드 | Composition for modulating C9ORF72 expression |
US10407678B2 (en) | 2015-04-16 | 2019-09-10 | Ionis Pharmaceuticals, Inc. | Compositions for modulating expression of C9ORF72 antisense transcript |
WO2016176617A2 (en) | 2015-04-29 | 2016-11-03 | New York University | Method for treating high-grade gliomas |
EP3291677A4 (en) | 2015-05-04 | 2019-02-13 | Monsanto Technology LLC | Compositions and methods for controlling arthropod parasite and pest infestations |
WO2016181393A1 (en) | 2015-05-11 | 2016-11-17 | Yeda Research And Development Co. Ltd. | Citrin inhibitors for the treatment of cancer |
CA2986228A1 (en) | 2015-05-19 | 2016-11-24 | Sarepta Therapeutics, Inc. | Peptide oligonucleotide conjugates |
US10787664B2 (en) | 2015-05-26 | 2020-09-29 | City Of Hope | Compounds of chemically modified oligonucleotides and methods of use thereof |
US10196701B2 (en) | 2015-06-01 | 2019-02-05 | The Penn State Research Foundation | Hepatitis B virus capsid assembly |
EP3302497A4 (en) | 2015-06-01 | 2019-01-16 | Sarepta Therapeutics, Inc. | Antisense-induced exon exclusion in type vii collagen |
ES2886480T3 (en) | 2015-06-01 | 2021-12-20 | Univ Temple | Methods and compositions for RNA-guided treatment of HIV infection |
EP3302053B1 (en) | 2015-06-02 | 2021-03-17 | Monsanto Technology LLC | Compositions and methods for delivery of a polynucleotide into a plant |
EP3302030A4 (en) | 2015-06-03 | 2019-04-24 | Monsanto Technology LLC | Methods and compositions for introducing nucleic acids into plants |
EP3303634B1 (en) | 2015-06-03 | 2023-08-30 | The Regents of The University of California | Cas9 variants and methods of use thereof |
WO2016196897A1 (en) | 2015-06-04 | 2016-12-08 | Sarepta Therapeutics, Inc. | Methods and compounds for treatment of lymphocyte-related diseases and conditions |
CN108026494A (en) | 2015-06-05 | 2018-05-11 | 米罗库鲁斯公司 | Limitation evaporation and the digital microcurrent-controlled apparatus and method of air matrix of surface scale |
CN208562324U (en) | 2015-06-05 | 2019-03-01 | 米罗库鲁斯公司 | Digital microcurrent-controlled (DMF) device of air matrix |
WO2016201111A1 (en) | 2015-06-09 | 2016-12-15 | Centrillion Technology Holdings Corporation | Methods for sequencing nucleic acids |
EP3307316A1 (en) | 2015-06-12 | 2018-04-18 | Alnylam Pharmaceuticals, Inc. | Complement component c5 irna compositions and methods of use thereof |
WO2016205323A1 (en) | 2015-06-18 | 2016-12-22 | Alnylam Pharmaceuticals, Inc. | Polynucleotde agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof |
WO2016209862A1 (en) | 2015-06-23 | 2016-12-29 | Alnylam Pharmaceuticals, Inc. | Glucokinase (gck) irna compositions and methods of use thereof |
CA2990852A1 (en) | 2015-06-26 | 2016-12-29 | Beth Israel Deaconess Medical Center, Inc. | Cancer therapy targeting tetraspanin 33 (tspan33) in myeloid derived suppressor cells |
EP3313989A4 (en) | 2015-06-29 | 2018-12-05 | Ionis Pharmaceuticals, Inc. | Modified crispr rna and modified single crispr rna and uses thereof |
US9861621B2 (en) | 2015-06-29 | 2018-01-09 | Biomed Valley Discoveries, Inc. | LPT-723 and immune checkpoint inhibitor combinations and methods of treatment |
EP3314027A4 (en) | 2015-06-29 | 2019-07-03 | Caris Science, Inc. | Therapeutic oligonucleotides |
IL256622B2 (en) | 2015-07-10 | 2023-09-01 | Ionis Pharmaceuticals Inc | Modulators of diacyglycerol acyltransferase 2 (dgat2) |
WO2017011286A1 (en) | 2015-07-10 | 2017-01-19 | Alnylam Pharmaceuticals, Inc. | Insulin-like growth factor binding protein, acid labile subunit (igfals) and insulin-like growth factor 1 (igf-1) irna compositions and methods of use thereof |
WO2017011565A1 (en) | 2015-07-14 | 2017-01-19 | Abbott Molecular Inc. | Compositions and methods for identifying drug resistant tuberculosis |
CA2993652A1 (en) | 2015-07-28 | 2017-02-02 | Caris Science, Inc. | Targeted oligonucleotides |
WO2017021963A1 (en) | 2015-08-03 | 2017-02-09 | Biokine Therapeutics Ltd. | Cxcr4 binding agents for treatment of diseases |
WO2017023861A1 (en) | 2015-08-03 | 2017-02-09 | The Regents Of The University Of California | Compositions and methods for modulating abhd2 activity |
EP3332009A1 (en) | 2015-08-04 | 2018-06-13 | Yeda Research and Development Co., Ltd. | Methods of screening for riboswitches and attenuators |
JP7104462B2 (en) | 2015-08-06 | 2022-07-21 | シティ・オブ・ホープ | Cell-permeable protein-antibody conjugate and usage |
CN108271387B (en) | 2015-08-07 | 2023-06-27 | 箭头药业股份有限公司 | RNAi therapy of hepatitis B virus infection |
CN106434873B (en) | 2015-08-13 | 2021-08-27 | 生捷科技控股公司 | Method for synchronizing nucleic acid molecules |
WO2017035278A1 (en) | 2015-08-24 | 2017-03-02 | Halo-Bio Rnai Therapeutics, Inc. | Polynucleotide nanoparticles for the modulation of gene expression and uses thereof |
US10889813B2 (en) | 2015-09-02 | 2021-01-12 | Alnylam Pharmaceuticals, Inc. | Programmed cell death 1 ligand 1 (PD-L1) iRNA compositions and methods of use thereof |
US9499861B1 (en) | 2015-09-10 | 2016-11-22 | Insilixa, Inc. | Methods and systems for multiplex quantitative nucleic acid amplification |
EP3347714B1 (en) | 2015-09-10 | 2021-03-10 | InSilixa Inc. | Methods for multiplex quantitative nucleic acid amplification |
WO2017049286A1 (en) | 2015-09-17 | 2017-03-23 | Moderna Therapeutics, Inc. | Polynucleotides containing a morpholino linker |
CA2998287A1 (en) | 2015-09-24 | 2017-04-20 | Crispr Therapeutics Ag | Novel family of rna-programmable endonucleases and their uses in genome editing and other applications |
MX2018003685A (en) | 2015-09-24 | 2018-08-15 | Univ California | Synthetic sphingolipid-like molecules, drugs, methods of their synthesis and methods of treatment. |
AR106135A1 (en) | 2015-09-24 | 2017-12-13 | Ionis Pharmaceuticals Inc | KIRSTEN RAT SARCOMA EXPRESSION MODULATORS (KRAS) |
EP4285912A2 (en) | 2015-09-25 | 2023-12-06 | Ionis Pharmaceuticals, Inc. | Compositions and methods for modulating ataxin 3 expression |
CN108738310A (en) | 2015-09-30 | 2018-11-02 | 萨勒普塔医疗公司 | Method for treating muscular dystrophy |
JP2018530325A (en) | 2015-10-08 | 2018-10-18 | アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. | Compounds and methods for modulating the expression of angiotensinogen |
MA45819A (en) | 2015-10-09 | 2018-08-15 | Sarepta Therapeutics Inc | COMPOSITIONS AND METHODS FOR TREATING DUCHENNE MUSCLE DYSTROPHY AND RELATED DISORDERS |
US11905526B2 (en) | 2015-10-13 | 2024-02-20 | Duke University | Genome engineering with Type I CRISPR systems in eukaryotic cells |
EP3362102A1 (en) | 2015-10-14 | 2018-08-22 | Life Technologies Corporation | Ribonucleoprotein transfection agents |
EP3985116A1 (en) | 2015-10-15 | 2022-04-20 | City of Hope | Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof |
SK500652015A3 (en) | 2015-10-15 | 2017-05-03 | Ústav Polymérov Sav | A method for altering the functional state of mRNA allowing its selective and specific recognition |
WO2017075038A1 (en) | 2015-10-26 | 2017-05-04 | Rana Therapeutics, Inc. | Nanoparticle formulations for delivery of nucleic acid complexes |
US11369692B2 (en) | 2015-10-28 | 2022-06-28 | Vertex Pharmaceuticals Incorporated | Materials and methods for treatment of Duchenne Muscular Dystrophy |
CA3001362C (en) | 2015-10-30 | 2020-10-13 | Genentech, Inc. | Anti-htra1 antibodies and methods of use thereof |
AU2016349954B2 (en) | 2015-11-05 | 2022-08-25 | Antisense Therapeutics Ltd | Mobilizing leukemia cells |
CN109328231A (en) | 2015-11-06 | 2019-02-12 | 克里斯普治疗股份公司 | For treating the material and method of 1A type glycogen storage disease |
US20190046555A1 (en) | 2015-11-06 | 2019-02-14 | Ionis Pharmaceuticals, Inc. | Conjugated antisense compounds for use in therapy |
CN108348478A (en) | 2015-11-06 | 2018-07-31 | Ionis 制药公司 | Apolipoprotein (a) is adjusted to express |
EP3373939A4 (en) | 2015-11-10 | 2019-06-26 | B.G. Negev Technologies and Applications Ltd., at Ben-Gurion University | Means and methods for reducing tumorigenicity of cancer stem cells |
CA3005878A1 (en) | 2015-11-19 | 2017-05-26 | The Brigham And Women's Hospital, Inc. | Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity |
US20170145394A1 (en) | 2015-11-23 | 2017-05-25 | The Regents Of The University Of California | Tracking and manipulating cellular rna via nuclear delivery of crispr/cas9 |
US10946106B2 (en) | 2015-11-30 | 2021-03-16 | The Regents Of The University Of California | Tumor-specific payload delivery and immune activation using a human antibody targeting a highly specific tumor cell surface antigen |
EP3967758A1 (en) | 2015-12-01 | 2022-03-16 | CRISPR Therapeutics AG | Materials and methods for treatment of alpha-1 antitrypsin deficiency |
WO2017096395A1 (en) | 2015-12-04 | 2017-06-08 | Ionis Pharmaceuticals, Inc. | Methods of treating breast cancer |
EP3387127A1 (en) | 2015-12-07 | 2018-10-17 | Erasmus University Medical Center Rotterdam | Enzymatic replacement therapy and antisense therapy for pompe disease |
WO2017106304A1 (en) | 2015-12-15 | 2017-06-22 | Sarepta Therapeutics, Inc. | Peptide oligonucleotide conjugates |
CA3007108A1 (en) | 2015-12-17 | 2017-06-22 | Modernatx, Inc. | Polynucleotides encoding methylmalonyl-coa mutase |
WO2017106767A1 (en) | 2015-12-18 | 2017-06-22 | The Scripps Research Institute | Production of unnatural nucleotides using a crispr/cas9 system |
AU2016379399B2 (en) | 2015-12-23 | 2022-12-08 | Board Of Regents, The University Of Texas System | Antisense antibacterial compounds and methods |
EP3394262A4 (en) | 2015-12-23 | 2019-12-25 | Oregon State University | Antisense antibacterial compounds and methods |
WO2017109757A1 (en) | 2015-12-23 | 2017-06-29 | Crispr Therapeutics Ag | Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration |
EP3400300A4 (en) | 2016-01-05 | 2019-08-07 | Ionis Pharmaceuticals, Inc. | Methods for reducing lrrk2 expression |
JP7349788B2 (en) | 2016-01-06 | 2023-09-25 | ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア | Branch mixer and its use and manufacturing method |
SG11201805993UA (en) | 2016-01-15 | 2018-08-30 | Jackson Lab | Genetically modified non-human mammals by multi-cycle electroporation of cas9 protein |
US10627396B2 (en) | 2016-01-29 | 2020-04-21 | Vanderbilt University | Free-solution response function interferometry |
US20190038771A1 (en) | 2016-02-02 | 2019-02-07 | Crispr Therapeutics Ag | Materials and methods for treatment of severe combined immunodeficiency (scid) or omenn syndrome |
CN109071625A (en) | 2016-02-04 | 2018-12-21 | 柯瑞斯公司 | Smooth mutant and its application method |
MX2018009904A (en) | 2016-02-15 | 2019-07-08 | Univ Temple | Excision of retroviral nucleic acid sequences. |
WO2017143042A2 (en) | 2016-02-16 | 2017-08-24 | Yale University | Compositions for enhancing targeted gene editing and methods of use thereof |
AU2017221424A1 (en) | 2016-02-16 | 2018-09-20 | Yale University | Compositions and methods for treatment of cystic fibrosis |
EP3416689B1 (en) | 2016-02-18 | 2023-01-18 | CRISPR Therapeutics AG | Materials and methods for treatment of severe combined immunodeficiency (scid) or omenn syndrome |
CN109312347A (en) | 2016-02-19 | 2019-02-05 | 希望之城 | Bispecific aptamer |
JP7033072B2 (en) | 2016-02-25 | 2022-03-09 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド | Treatment for fibrosis targeting SMOC2 |
JP7025340B2 (en) | 2016-02-26 | 2022-02-24 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | Multiplexed single molecule RNA visualization using a two-probe proximity ligation system |
JP2019512014A (en) | 2016-02-26 | 2019-05-09 | イェール ユニバーシティーYale University | Compositions and methods of using piRNA in cancer diagnostics and therapeutics |
US20210189062A1 (en) | 2016-03-01 | 2021-06-24 | Alexion Pharmaceuticals, Inc. | Biodegradable activated polymers for therapeutic delivery |
WO2017155858A1 (en) | 2016-03-07 | 2017-09-14 | Insilixa, Inc. | Nucleic acid sequence identification using solid-phase cyclic single base extension |
WO2017152270A1 (en) | 2016-03-08 | 2017-09-14 | KeMyth Biotech Co., Ltd. | Use of pneumolysin peptides as antagonists against toll-like receptor 4 and methods of treating toll-like receptor 4 related diseases |
CA3013797A1 (en) | 2016-03-09 | 2017-09-14 | Ionis Pharmaceuticals, Inc. | Methods and compositions for inhibiting pmp22 expression |
US11083799B2 (en) | 2016-03-16 | 2021-08-10 | Crispr Therapeutics Ag | Materials and methods for treatment of hereditary haemochromatosis |
WO2017161172A1 (en) | 2016-03-16 | 2017-09-21 | Ionis Pharmaceuticals, Inc. | Methods of modulating keap1 |
WO2017161168A1 (en) | 2016-03-16 | 2017-09-21 | Ionis Pharmaceuticals, Inc. | Modulation of dyrk1b expression |
IL303936A (en) | 2016-03-18 | 2023-08-01 | Caris Science Inc | Oligonucleotide probes and uses thereof |
US11845938B2 (en) | 2016-03-31 | 2023-12-19 | City Of Hope | Aptamer compositions and the use thereof |
WO2017173453A1 (en) | 2016-04-01 | 2017-10-05 | The Brigham And Women's Hospital, Inc. | Stimuli-responsive nanoparticles for biomedical applications |
WO2017180835A1 (en) | 2016-04-13 | 2017-10-19 | Ionis Pharmaceuticals, Inc. | Methods for reducing c9orf72 expression |
WO2017181163A2 (en) | 2016-04-16 | 2017-10-19 | Oncocyte Corporation | Methods and compositions for detection and diagnosis of breast cancer |
EP3445405A4 (en) | 2016-04-18 | 2019-12-18 | Sarepta Therapeutics, Inc. | Antisense oligomers and methods of using the same for treating diseases associated with the acid alpha-glucosidase gene |
EP3445388A2 (en) | 2016-04-18 | 2019-02-27 | CRISPR Therapeutics AG | Materials and methods for treatment of hemoglobinopathies |
MA45295A (en) | 2016-04-19 | 2019-02-27 | Alnylam Pharmaceuticals Inc | HIGH DENSITY LIPOPROTEIN BINDING PROTEIN (HDLBP / VIGILINE) RNA COMPOSITION AND METHODS FOR USING THEM |
AU2017258642B2 (en) | 2016-04-29 | 2023-08-31 | Sarepta Therapeutics, Inc. | Oligonucleotide analogues targeting human LMNA |
AU2017259821A1 (en) | 2016-05-04 | 2018-12-13 | Abilita Bio, Inc. | Methods and platform for preparing multispanning membrane proteins |
WO2017191503A1 (en) | 2016-05-05 | 2017-11-09 | Crispr Therapeutics Ag | Materials and methods for treatment of hemoglobinopathies |
CA3022319A1 (en) | 2016-05-06 | 2017-11-09 | Tod M. Woolf | Improved methods for genome editing with and without programmable nucleases |
CN116397007A (en) | 2016-05-11 | 2023-07-07 | 伊鲁米那股份有限公司 | Polynucleotide enrichment and amplification Using the ARGONAUTE System |
WO2017197128A1 (en) | 2016-05-11 | 2017-11-16 | Yale University | Poly(amine-co-ester) nanoparticles and methods of use thereof |
WO2017201315A1 (en) | 2016-05-18 | 2017-11-23 | Roche Sequencing Solutions, Inc. | Quantitative real time pcr amplification using an electrowetting-based device |
US11472824B2 (en) | 2016-05-24 | 2022-10-18 | Sarepta Therapeutics, Inc. | Processes for preparing phosphorodiamidate morpholino oligomers |
WO2017205496A1 (en) | 2016-05-24 | 2017-11-30 | Sarepta Therapeutics, Inc. | Processes for preparing oligomers |
MA45362A (en) | 2016-05-24 | 2019-04-10 | Sarepta Therapeutics Inc | PROCESSES FOR THE PREPARATION OF MORPHOLINO OLIGOMERS OF PHOSPHORODIAMIDATE |
MX2018014129A (en) | 2016-05-24 | 2019-04-29 | Sarepta Therapeutics Inc | Pharmaceutical composition comprising eteplirsen. |
SG11201809499UA (en) | 2016-05-24 | 2018-12-28 | Sarepta Therapeutics Inc | Processes for preparing phosphorodiamidate morpholino oligomers |
CA3024456A1 (en) | 2016-05-24 | 2017-11-30 | Sarepta Therapeutics, Inc. | Processes for preparing phosphorodiamidate morpholino oligomers |
IL298701B2 (en) | 2016-05-25 | 2024-03-01 | Caris Science Inc | Oligonucleotide probes and uses thereof |
US11828755B2 (en) | 2016-06-09 | 2023-11-28 | The Regents Of The University Of California | Biomarker concentration and signal amplification for use in paper-based immunoassays and a single platform for extracting, concentrating, and amplifying DNA |
US11779657B2 (en) | 2016-06-10 | 2023-10-10 | City Of Hope | Compositions and methods for mitochondrial genome editing |
US20190256845A1 (en) | 2016-06-10 | 2019-08-22 | Alnylam Pharmaceuticals, Inc. | COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) |
US10544457B2 (en) | 2016-06-14 | 2020-01-28 | Pacific Biosciences Of California, Inc. | Methods and compositions for enriching compositions for polymerase enzyme complexes |
JP7069135B2 (en) | 2016-06-15 | 2022-05-17 | ユニヴァーシティー オブ ユタ リサーチ ファウンデーション | Compositions and Methods for Using Albumin-Based Nanopharmaceuticals |
US10337051B2 (en) | 2016-06-16 | 2019-07-02 | The Regents Of The University Of California | Methods and compositions for detecting a target RNA |
EP3471781A4 (en) | 2016-06-17 | 2020-05-06 | Ionis Pharmaceuticals, Inc. | Modulation of gys1 expression |
WO2017223528A1 (en) | 2016-06-24 | 2017-12-28 | The Scripps Research Institute | Novel nucleoside triphosphate transporter and uses thereof |
WO2018002812A1 (en) | 2016-06-29 | 2018-01-04 | Crispr Therapeutics Ag | Materials and methods for treatment of myotonic dystrophy type 1 (dm1) and other related disorders |
AU2017290614C1 (en) | 2016-06-29 | 2024-01-18 | Crispr Therapeutics Ag | Materials and methods for treatment of friedreich ataxia and other related disorders |
EP3478313B1 (en) | 2016-06-29 | 2022-05-04 | CRISPR Therapeutics AG | Materials and methods for treatment of amyotrophic lateral sclerosis (als) and other related disorders |
KR20190024977A (en) | 2016-06-30 | 2019-03-08 | 사렙타 쎄러퓨틱스 인코퍼레이티드 | Exon skipping oligomer for myopathies |
CN109152792B (en) | 2016-06-30 | 2021-09-14 | 萨勒普塔医疗公司 | Process for preparing phosphoric acid diamide morpholino oligomer |
AU2017292173B2 (en) | 2016-07-06 | 2022-01-13 | Vertex Pharmaceuticals Incorporated | Materials and methods for treatment of pain related disorders |
EP3481856A1 (en) | 2016-07-06 | 2019-05-15 | Crispr Therapeutics AG | Materials and methods for treatment of pain related disorders |
WO2018007871A1 (en) | 2016-07-08 | 2018-01-11 | Crispr Therapeutics Ag | Materials and methods for treatment of transthyretin amyloidosis |
US11253601B2 (en) | 2016-07-11 | 2022-02-22 | Translate Bio Ma, Inc. | Nucleic acid conjugates and uses thereof |
EP3485032B1 (en) | 2016-07-12 | 2021-02-17 | Life Technologies Corporation | Compositions and methods for detecting nucleic acid regions |
BR112019000356A2 (en) | 2016-07-15 | 2019-04-16 | Ionis Pharmaceuticals, Inc. | compounds and methods for smn2 modulation |
KR20230088522A (en) | 2016-07-21 | 2023-06-19 | 맥스시티 인코포레이티드 | Methods and compositions for modifying genomic dna |
US10711300B2 (en) | 2016-07-22 | 2020-07-14 | Pacific Biosciences Of California, Inc. | Methods and compositions for delivery of molecules and complexes to reaction sites |
WO2018020323A2 (en) | 2016-07-25 | 2018-02-01 | Crispr Therapeutics Ag | Materials and methods for treatment of fatty acid disorders |
CN109963564B (en) | 2016-07-27 | 2022-08-12 | 利兰斯坦福初级大学董事会 | Disaggregated cell-penetrating complexes for nucleic acid delivery |
JOP20170161A1 (en) | 2016-08-04 | 2019-01-30 | Arrowhead Pharmaceuticals Inc | RNAi Agents for Hepatitis B Virus Infection |
NL2017295B1 (en) | 2016-08-05 | 2018-02-14 | Univ Erasmus Med Ct Rotterdam | Antisense oligomeric compound for Pompe disease |
NL2017294B1 (en) | 2016-08-05 | 2018-02-14 | Univ Erasmus Med Ct Rotterdam | Natural cryptic exon removal by pairs of antisense oligonucleotides. |
CN109715781A (en) | 2016-08-22 | 2019-05-03 | 米罗库鲁斯公司 | Feedback system for the parallel drop control in digital microcurrent-controlled equipment |
WO2018039629A2 (en) | 2016-08-25 | 2018-03-01 | Northwestern University | Micellar spherical nucleic acids from thermoresponsive, traceless templates |
MX2019002339A (en) | 2016-09-02 | 2019-05-16 | Dicerna Pharmaceuticals Inc | 4'-phosphate analogs and oligonucleotides comprising the same. |
US20190218261A1 (en) | 2016-09-13 | 2019-07-18 | The Jackson Laboratory | Targeted enhanced dna demethylation |
WO2018053434A1 (en) | 2016-09-16 | 2018-03-22 | The Johns Hopkins University | Protein nanocages with enhanced mucus penetration for targeted tissue and intracellular delivery |
CA3036572A1 (en) | 2016-09-19 | 2018-03-22 | Genmark Diagnostics, Inc. | Instrument for processing cartridge for performing assays in a closed sample preparation and reaction system |
EP3515445A4 (en) | 2016-09-20 | 2020-05-27 | The Regents of The University of Colorado, A Body Corporate | Synthesis of backbone modified morpholino oligonucleotides and chimeras using phosphoramidite chemistry |
JOP20190065A1 (en) | 2016-09-29 | 2019-03-28 | Ionis Pharmaceuticals Inc | Compounds and methods for reducing tau expression |
CN110023494A (en) | 2016-09-30 | 2019-07-16 | 加利福尼亚大学董事会 | The nucleic acid modifying enzyme and its application method of RNA guidance |
US11400161B2 (en) | 2016-10-06 | 2022-08-02 | Ionis Pharmaceuticals, Inc. | Method of conjugating oligomeric compounds |
WO2018081817A2 (en) | 2016-10-31 | 2018-05-03 | University Of Massachusetts | Targeting microrna-101-3p in cancer therapy |
JOP20190104A1 (en) | 2016-11-10 | 2019-05-07 | Ionis Pharmaceuticals Inc | Compounds and methods for reducing atxn3 expression |
EP3538153A4 (en) | 2016-11-11 | 2020-06-24 | The Regents of the University of California | Anti-cd46 antibodies and methods of use |
WO2018089967A1 (en) | 2016-11-14 | 2018-05-17 | Virginia Commonwealth University | Inhibitors of cancer invasion, attachment, and/or metastasis |
TW202313978A (en) | 2016-11-23 | 2023-04-01 | 美商阿尼拉製藥公司 | Serpina1 irna compositions and methods of use thereof |
EP3330276A1 (en) | 2016-11-30 | 2018-06-06 | Universität Bern | Novel bicyclic nucleosides and oligomers prepared therefrom |
US11033570B2 (en) | 2016-12-02 | 2021-06-15 | Cold Spring Harbor Laboratory | Modulation of Lnc05 expression |
AU2017378153B2 (en) | 2016-12-13 | 2024-03-28 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Methods of exogenous drug activation of chemical-induced signaling complexes expressed in engineered cells in vitro and in vivo |
TWI790217B (en) | 2016-12-16 | 2023-01-21 | 美商阿尼拉製藥公司 | METHODS FOR TREATING OR PREVENTING TTR-ASSOCIATED DISEASES USING TRANSTHYRETIN (TTR) iRNA COMPOSITIONS |
WO2018112470A1 (en) | 2016-12-16 | 2018-06-21 | The Brigham And Women's Hospital, Inc. | Co-delivery of nucleic acids for simultaneous suppression and expression of target genes |
SG10202012839TA (en) | 2016-12-19 | 2021-01-28 | Sarepta Therapeutics Inc | Exon skipping oligomer conjugates for muscular dystrophy |
CN110337308B (en) | 2016-12-19 | 2023-09-01 | 萨勒普塔医疗公司 | Exon-skipping oligomer conjugates for muscular dystrophy |
IL267246B2 (en) | 2016-12-19 | 2023-03-01 | Sarepta Therapeutics Inc | Exon skipping oligomer conjugates for muscular dystrophy |
WO2018126082A1 (en) | 2016-12-28 | 2018-07-05 | Miroculis Inc. | Digital microfluidic devices and methods |
CN110268060A (en) | 2017-01-10 | 2019-09-20 | 箭头药业股份有限公司 | α -1 antitrypsin (AAT) RNAi substance, composition and application method comprising AAT RNAi substance |
EP3570829A4 (en) | 2017-01-18 | 2021-03-10 | The Scripps Research Institute | Photoreactive ligands and uses thereof |
RU2021133626A (en) | 2017-01-23 | 2022-01-31 | Регенерон Фармасьютикалз, Инк. | HSD17B13 OPTIONS AND THEIR APPLICATIONS |
WO2018140329A1 (en) | 2017-01-24 | 2018-08-02 | Tsavachidou Dimitra | Methods for constructing copies of nucleic acid molecules |
US20200040061A1 (en) | 2017-02-22 | 2020-02-06 | Crispr Therapeutics Ag | Materials and methods for treatment of early onset parkinson's disease (park1) and other synuclein, alpha (snca) gene related conditions or disorders |
WO2018154387A1 (en) | 2017-02-22 | 2018-08-30 | Crispr Therapeutics Ag | Compositions and methods for gene editing |
EP3585899A1 (en) | 2017-02-22 | 2020-01-01 | CRISPR Therapeutics AG | Materials and methods for treatment of primary hyperoxaluria type 1 (ph1) and other alanine-glyoxylate aminotransferase (agxt) gene related conditions or disorders |
US20200216857A1 (en) | 2017-02-22 | 2020-07-09 | Crispr Therapeutics Ag | Materials and methods for treatment of spinocerebellar ataxia type 2 (sca2) and other spinocerebellar ataxia type 2 protein (atxn2) gene related conditions or disorders |
WO2018154439A1 (en) | 2017-02-22 | 2018-08-30 | Crispr Therapeutics Ag | Materials and methods for treatment of spinocerebellar ataxia type 1 (sca1) and other spinocerebellar ataxia type 1 protein (atxn1) gene related conditions or disorders |
EP3596099A4 (en) | 2017-03-06 | 2020-12-09 | Singular Genomics Systems, Inc. | Nucleic acid sequencing-by-synthesis (sbs) methods that combine sbs cycle steps |
WO2018165564A1 (en) | 2017-03-09 | 2018-09-13 | Ionis Pharmaceuticals, Inc. | Morpholino modified oligomeric compounds |
WO2018169960A1 (en) | 2017-03-17 | 2018-09-20 | The Johns Hopkins University | Nanoparticle formulations for enhanced drug delivery to the bladder |
JOP20190215A1 (en) | 2017-03-24 | 2019-09-19 | Ionis Pharmaceuticals Inc | Modulators of pcsk9 expression |
US20180284123A1 (en) | 2017-03-30 | 2018-10-04 | California Institute Of Technology | Barcoded rapid assay platform useful for efficient analysis of candidate molecules and methods of making and using the platform |
WO2018187493A1 (en) | 2017-04-04 | 2018-10-11 | Yale University | Compositions and methods for in utero delivery |
US11623219B2 (en) | 2017-04-04 | 2023-04-11 | Miroculus Inc. | Digital microfluidics apparatuses and methods for manipulating and processing encapsulated droplets |
TWI801377B (en) | 2017-04-18 | 2023-05-11 | 美商阿尼拉製藥公司 | Methods for the treatment of subjects having a hepatitis b virus (hbv) infection |
EP3612546B1 (en) | 2017-04-20 | 2022-07-13 | Synthena AG | Modified oligomeric compounds comprising tricyclo-dna nucleosides and uses thereof |
CN110536694A (en) | 2017-04-20 | 2019-12-03 | Atyr 医药公司 | For treating pulmonary inflammatory composition and method |
WO2018193428A1 (en) | 2017-04-20 | 2018-10-25 | Synthena Ag | Modified oligomeric compounds comprising tricyclo-dna nucleosides and uses thereof |
AU2018255972A1 (en) | 2017-04-21 | 2019-10-31 | Phi Therapeutics, Inc. | Compositions comprising propionibacterium acnes bacteriophages for treating acne |
US20200384115A1 (en) | 2017-04-21 | 2020-12-10 | The Broad Institute , Inc. | Targeted delivery to beta cells |
CA3061738A1 (en) | 2017-04-28 | 2018-11-01 | Auckland Uniservices Limited | Methods of treatment and novel constructs |
US11453891B2 (en) | 2017-05-10 | 2022-09-27 | The Regents Of The University Of California | Directed editing of cellular RNA via nuclear delivery of CRISPR/CAS9 |
US11299776B2 (en) | 2017-05-10 | 2022-04-12 | Board Of Regents, The University Of Texas System | Methods and devices related to amplifying nucleic acid at a variety of temperatures |
BR112019023608A2 (en) | 2017-05-12 | 2020-05-26 | Crispr Therapeutics Ag | MATERIALS AND METHODS FOR HANDLED CELLS AND THEIR USES IN IMMUNO-ONCOLOGY |
EP3626821A4 (en) | 2017-05-18 | 2021-03-03 | Kyoto University | Composition for prevention or treatment of spinocerebellar ataxia type 36 |
US11554178B2 (en) | 2017-06-30 | 2023-01-17 | City Of Hope | Compositions and methods of modulating macrophage activity |
TWI821192B (en) | 2017-07-11 | 2023-11-11 | 美商新索思股份有限公司 | Incorporation of unnatural nucleotides and methods thereof |
JP2020526558A (en) | 2017-07-13 | 2020-08-31 | ノースウェスタン ユニバーシティ | Common and direct methods for preparing oligonucleotide functionalized metal-organic framework nanoparticles |
EP3652317A1 (en) | 2017-07-13 | 2020-05-20 | Alnylam Pharmaceuticals, Inc. | Lactate dehydrogenase a (ldha) irna compositions and methods of use thereof |
EP3651807B1 (en) | 2017-07-13 | 2023-11-01 | City of Hope | Phosphorothioate-conjugated peptides and methods of using the same |
CA3069179A1 (en) | 2017-07-13 | 2019-01-17 | Massachusetts Institute Of Technology | Targeting the hdac2-sp3 complex to enhance synaptic function |
GB201711809D0 (en) | 2017-07-21 | 2017-09-06 | Governors Of The Univ Of Alberta | Antisense oligonucleotide |
CN110892258A (en) | 2017-07-24 | 2020-03-17 | 米罗库鲁斯公司 | Digital microfluidic system and method with integrated plasma collection device |
US11459306B2 (en) | 2017-07-31 | 2022-10-04 | The Trustees Of Columbia University In The City Of New York | Compounds, compositions, and methods for treating T-cell acute lymphoblastic leukemia |
KR20200035092A (en) | 2017-08-03 | 2020-04-01 | 신톡스, 인크. | Cytokine conjugates for the treatment of autoimmune diseases |
NL2019390B1 (en) | 2017-08-04 | 2019-02-21 | Univ Leiden | Screening Method |
EP3665202A1 (en) | 2017-08-09 | 2020-06-17 | Massachusetts Institute Of Technology | Albumin binding peptide conjugates and methods thereof |
CN111542326A (en) | 2017-08-11 | 2020-08-14 | 希望之城 | RNA aptamers to transferrin receptor (TfR) |
CA3071033A1 (en) | 2017-08-18 | 2019-02-21 | Ionis Pharmaceuticals, Inc. | Modulation of the notch signaling pathway for treatment of respiratory disorders |
LT3675826T (en) | 2017-08-31 | 2023-09-11 | Life Technologies Corporation | Cationic lipid compositions for tissue-specific delivery |
CN115582155A (en) | 2017-09-01 | 2023-01-10 | 米罗库鲁斯公司 | Digital microfluidic device and method of use thereof |
CN111315890A (en) | 2017-09-08 | 2020-06-19 | 生命技术公司 | Methods and compositions for enhancing homologous recombination |
US20190119701A1 (en) | 2017-09-08 | 2019-04-25 | Life Technologies Corporation | Methods for improved homologous recombination and compositions thereof |
WO2019051173A1 (en) | 2017-09-08 | 2019-03-14 | Ionis Pharmaceuticals, Inc. | Modulators of smad7 expression |
JP2021508333A (en) | 2017-09-19 | 2021-03-04 | アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. | Therapeutic compositions and methods for transthyretin (TTR) -mediated amyloidosis |
EA201991450A1 (en) | 2017-09-22 | 2019-12-30 | Сарепта Терапьютикс, Инк. | OLIGOMER CONJUGATES FOR EXONISM SKIP IN MUSCULAR DYSTROPHY |
US20200254002A1 (en) | 2017-09-28 | 2020-08-13 | Sarepta Therapeutics, Inc. | Combination therapies for treating muscular dystrophy |
EP3687547A1 (en) | 2017-09-28 | 2020-08-05 | Sarepta Therapeutics, Inc. | Combination therapies for treating muscular dystrophy |
JP2020536058A (en) | 2017-09-28 | 2020-12-10 | サレプタ セラピューティクス, インコーポレイテッド | Combination therapy to treat muscular dystrophy |
MX2020004043A (en) | 2017-10-17 | 2021-05-27 | Crispr Therapeutics Ag | Compositions and methods for gene editing for hemophilia a. |
US11555189B2 (en) | 2017-10-18 | 2023-01-17 | Sarepta Therapeutics, Inc. | Antisense oligomer compounds |
US11099202B2 (en) | 2017-10-20 | 2021-08-24 | Tecan Genomics, Inc. | Reagent delivery system |
US20210180091A1 (en) | 2017-10-26 | 2021-06-17 | Vertex Pharmaceuticals Incorporated | Materials and methods for treatment of hemoglobinopathies |
AU2018360697A1 (en) | 2017-11-01 | 2020-05-14 | Alnylam Pharmaceuticals, Inc. | Complement component C3 iRNA compositions and methods of use thereof |
EP3704245A1 (en) | 2017-11-01 | 2020-09-09 | Novartis AG | Synthetic rnas and methods of use |
EP3707155A2 (en) | 2017-11-09 | 2020-09-16 | Vertex Pharmaceuticals Incorporated | Crispr/cas systems for treatment of dmd |
TWI809004B (en) | 2017-11-09 | 2023-07-21 | 美商Ionis製藥公司 | Compounds and methods for reducing snca expression |
US11691141B2 (en) | 2017-11-13 | 2023-07-04 | Roche Sequencing Solutions, Inc. | Devices for sample analysis using epitachophoresis |
WO2019099610A1 (en) | 2017-11-16 | 2019-05-23 | Alnylam Pharmaceuticals, Inc. | Kisspeptin 1 (kiss1) irna compositions and methods of use thereof |
US10953036B2 (en) | 2017-11-20 | 2021-03-23 | University Of Georgia Research Foundation, Inc. | Compositions and methods of modulating HIF-2A to improve muscle generation and repair |
WO2019100039A1 (en) | 2017-11-20 | 2019-05-23 | Alnylam Pharmaceuticals, Inc. | Serum amyloid p component (apcs) irna compositions and methods of use thereof |
US20190153440A1 (en) | 2017-11-21 | 2019-05-23 | Casebia Therapeutics Llp | Materials and methods for treatment of autosomal dominant retinitis pigmentosa |
US11728007B2 (en) | 2017-11-30 | 2023-08-15 | Grail, Llc | Methods and systems for analyzing nucleic acid sequences using mappability analysis and de novo sequence assembly |
WO2019113149A1 (en) | 2017-12-05 | 2019-06-13 | Crispr Therapeutics Ag | Crispr-cas9 modified cd34+ human hematopoietic stem and progenitor cells and uses thereof |
JP2021506239A (en) | 2017-12-14 | 2021-02-22 | アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. | Composite antisense compounds and their use |
JP2021506251A (en) | 2017-12-14 | 2021-02-22 | クリスパー セラピューティクス アーゲー | New RNA programmable endonuclease system, as well as its use in genome editing and other applications |
MX2020006012A (en) | 2017-12-18 | 2020-09-14 | Alnylam Pharmaceuticals Inc | High mobility group box-1 (hmgb1) irna compositions and methods of use thereof. |
US11939575B2 (en) | 2017-12-19 | 2024-03-26 | City Of Hope | Modified tracrRNAs gRNAs, and uses thereof |
EP3728594A1 (en) | 2017-12-21 | 2020-10-28 | CRISPR Therapeutics AG | Materials and methods for treatment of usher syndrome type 2a |
EP3728595A1 (en) | 2017-12-21 | 2020-10-28 | CRISPR Therapeutics AG | Materials and methods for treatment of usher syndrome type 2a and/or non-syndromic autosomal recessive retinitis pigmentosa (arrp) |
WO2019126641A2 (en) | 2017-12-21 | 2019-06-27 | Ionis Pharmaceuticals, Inc. | Modulation of frataxin expression |
US11242568B2 (en) | 2017-12-29 | 2022-02-08 | City Of Hope | DNA methylation diagnostic test for breast cancer |
WO2019140330A1 (en) | 2018-01-12 | 2019-07-18 | Casebia Therapeutics Limited Liability Partnership | Compositions and methods for gene editing by targeting transferrin |
CN111902537A (en) | 2018-01-15 | 2020-11-06 | Ionis制药公司 | Modulators of DNM2 expression |
EP3740472A1 (en) | 2018-01-19 | 2020-11-25 | Synthena AG | Tricyclo-dna nucleoside precursors and processes for preparing the same |
WO2019147743A1 (en) | 2018-01-26 | 2019-08-01 | Massachusetts Institute Of Technology | Structure-guided chemical modification of guide rna and its applications |
EP3749768A1 (en) | 2018-02-05 | 2020-12-16 | Vertex Pharmaceuticals Incorporated | Materials and methods for treatment of hemoglobinopathies |
EP3749767A1 (en) | 2018-02-05 | 2020-12-16 | Vertex Pharmaceuticals Incorporated | Materials and methods for treatment of hemoglobinopathies |
WO2019155465A1 (en) | 2018-02-08 | 2019-08-15 | Yeda Research And Development Co. Ltd. | Methods of identifying and using agents for treating diseases associated with intestinal barrier dysfunction |
JP7317029B2 (en) | 2018-02-12 | 2023-07-28 | アイオーニス ファーマシューティカルズ, インコーポレーテッド | Modified compounds and uses thereof |
EP3752616A1 (en) | 2018-02-16 | 2020-12-23 | CRISPR Therapeutics AG | Compositions and methods for gene editing by targeting fibrinogen-alpha |
AU2019224159A1 (en) | 2018-02-26 | 2020-10-01 | Synthorx, Inc. | IL-15 conjugates and uses thereof |
TW202000199A (en) | 2018-03-02 | 2020-01-01 | 美商Ionis製藥公司 | Modulators of IRF4 expression |
EP3759127A4 (en) | 2018-03-02 | 2022-03-30 | Ionis Pharmaceuticals, Inc. | Compounds and methods for the modulation of amyloid-beta precursor protein |
CN112105625A (en) | 2018-03-07 | 2020-12-18 | 赛诺菲 | Nucleotide precursors, nucleotide analogs, and oligomeric compounds containing the same |
AU2019234836A1 (en) | 2018-03-13 | 2020-09-17 | The Regents Of The University Of California | Inhibitors of integrin alpha 2 beta 1 and methods of use |
EP3768834A1 (en) | 2018-03-19 | 2021-01-27 | CRISPR Therapeutics AG | Novel rna-programmable endonuclease systems and uses thereof |
EP3768694A4 (en) | 2018-03-22 | 2021-12-29 | Ionis Pharmaceuticals, Inc. | Methods for modulating fmr1 expression |
CA3095545A1 (en) | 2018-03-30 | 2019-10-03 | Rheinische Friedrich-Wilhelms-Universitat Bonn | Aptamers for targeted activaton of t cell-mediated immunity |
JP2021520781A (en) | 2018-04-06 | 2021-08-26 | チルドレンズ メディカル センター コーポレーションChildren’S Medical Center Corporation | Compositions and Methods for Somatic Cell Reprogramming and Imprinting Modulation |
JP7275164B2 (en) | 2018-04-11 | 2023-05-17 | アイオーニス ファーマシューティカルズ, インコーポレーテッド | Regulators of EZH2 expression |
WO2019204668A1 (en) | 2018-04-18 | 2019-10-24 | Casebia Therapeutics Limited Liability Partnership | Compositions and methods for knockdown of apo(a) by gene editing for treatment of cardiovascular disease |
US20210189460A1 (en) | 2018-04-25 | 2021-06-24 | Qiagen Sciences Llc | Sequential paired-end sequencing |
UY38225A (en) | 2018-05-09 | 2019-11-29 | Ionis Pharmaceuticals Inc | COMPOUNDS AND METHODS TO REDUCE THE EXPRESSION OF ATXN3 |
JP7438135B2 (en) | 2018-05-09 | 2024-02-26 | アイオーニス ファーマシューティカルズ, インコーポレーテッド | Compounds and methods for reducing expression of FXI |
TW202016304A (en) | 2018-05-14 | 2020-05-01 | 美商阿尼拉製藥公司 | Angiotensinogen (agt) irna compositions and methods of use thereof |
US10765760B2 (en) | 2018-05-29 | 2020-09-08 | Sarepta Therapeutics, Inc. | Exon skipping oligomer conjugates for muscular dystrophy |
CN113166191A (en) | 2018-05-30 | 2021-07-23 | Dtx医药有限公司 | Lipid-modified nucleic acid compounds and methods |
US10987428B2 (en) | 2018-06-01 | 2021-04-27 | City Of Hope | Phosphorothioate-conjugated miRNAs and methods of using the same |
EP3806868A4 (en) | 2018-06-13 | 2022-06-22 | Sarepta Therapeutics, Inc. | Exon skipping oligomers for muscular dystrophy |
EP3807411A4 (en) | 2018-06-14 | 2022-08-03 | Ionis Pharmaceuticals, Inc. | Compounds and methods for increasing stmn2 expression |
SG11202011864XA (en) | 2018-06-27 | 2020-12-30 | Ionis Pharmaceuticals Inc | Compounds and methods for reducing lrrk2 expression |
BR112020025824A2 (en) | 2018-06-28 | 2021-03-23 | Crispr Therapeutics Ag | compositions and methods for genome editing by inserting donor polynucleotides |
SG11202100077PA (en) | 2018-07-25 | 2021-02-25 | Ionis Pharmaceuticals Inc | Compounds and methods for reducing atxn2 expression |
TW202020153A (en) | 2018-07-27 | 2020-06-01 | 美商薩羅塔治療公司 | Exon skipping oligomers for muscular dystrophy |
US10857174B2 (en) | 2018-07-27 | 2020-12-08 | United States Government As Represented By The Department Of Veterans Affairs | Morpholino oligonucleotides useful in cancer treatment |
EP3830301A1 (en) | 2018-08-01 | 2021-06-09 | Mammoth Biosciences, Inc. | Programmable nuclease compositions and methods of use thereof |
EP3830278A4 (en) | 2018-08-01 | 2022-05-25 | University of Georgia Research Foundation, Inc. | Compositions and methods for improving embryo development |
US20210189431A1 (en) | 2018-08-10 | 2021-06-24 | Yale University | Compositions and methods for embryonic gene editing in vitro |
JP2021533767A (en) | 2018-08-13 | 2021-12-09 | アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. | Hepatitis B virus (HBV) dsRNA substance composition and its usage |
EP3837367A1 (en) | 2018-08-16 | 2021-06-23 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of the lect2 gene |
AU2019325255A1 (en) | 2018-08-20 | 2021-04-15 | Rogcon, Inc. | Antisense oligonucleotides targeting SCN2A for the treatment of SCN1A encephalopathies |
WO2020047229A1 (en) | 2018-08-29 | 2020-03-05 | University Of Massachusetts | Inhibition of protein kinases to treat friedreich ataxia |
US20210338815A1 (en) | 2018-08-31 | 2021-11-04 | Yale University | Compositions and methods for enhancing triplex and nuclease-based gene editing |
EP3844287A1 (en) | 2018-08-31 | 2021-07-07 | Yale University | Compositions and methods for enhancing donor oligonucleotide-based gene editing |
WO2020051507A1 (en) | 2018-09-06 | 2020-03-12 | The Broad Institute, Inc. | Nucleic acid assemblies for use in targeted delivery |
US10724052B2 (en) | 2018-09-07 | 2020-07-28 | Crispr Therapeutics Ag | Universal donor cells |
EP3620520A1 (en) | 2018-09-10 | 2020-03-11 | Universidad del Pais Vasco | Novel target to treat a metabolic disease in an individual |
US20230011240A1 (en) | 2018-09-11 | 2023-01-12 | Singular Genomics Systems, Inc. | Modified archaeal family b polymerases |
AU2019339509A1 (en) | 2018-09-14 | 2021-05-13 | Northwestern University | Programming protein polymerization with DNA |
JP2022500003A (en) | 2018-09-18 | 2022-01-04 | アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. | Ketohexokinase (KHK) iRNA composition and its usage |
TW202023573A (en) | 2018-09-19 | 2020-07-01 | 美商Ionis製藥公司 | Modulators of pnpla3 expression |
US20210393740A1 (en) | 2018-09-19 | 2021-12-23 | La Jolla Institute For Immunology | Ptprs and proteoglycans in rheumatoid arthritis |
WO2020074742A1 (en) | 2018-10-12 | 2020-04-16 | F. Hoffmann-La Roche Ag | Detection methods for epitachophoresis workflow automation |
MX2021004455A (en) | 2018-10-17 | 2021-08-11 | Crispr Therapeutics Ag | Compositions and methods for delivering transgenes. |
WO2020086834A1 (en) | 2018-10-25 | 2020-04-30 | Singular Genomics Systems, Inc. | Nucleotide analogues |
US10913951B2 (en) | 2018-10-31 | 2021-02-09 | University of Pittsburgh—of the Commonwealth System of Higher Education | Silencing of HNF4A-P2 isoforms with siRNA to improve hepatocyte function in liver failure |
TW202028222A (en) | 2018-11-14 | 2020-08-01 | 美商Ionis製藥公司 | Modulators of foxp3 expression |
CN113646430A (en) | 2018-11-15 | 2021-11-12 | Ionis制药公司 | Modulators of IRF5 expression |
NL2022043B1 (en) | 2018-11-21 | 2020-06-03 | Akershus Univ Hf | Tagmentation-Associated Multiplex PCR Enrichment Sequencing |
US20220025366A1 (en) | 2018-11-21 | 2022-01-27 | Ionis Pharmaceuticals, Inc. | Compounds and methods for reducing prion expression |
IL263184A (en) | 2018-11-21 | 2020-05-31 | Yarden Yosef | Method of treating cancer and compositions for same |
WO2020112195A1 (en) | 2018-11-30 | 2020-06-04 | Yale University | Compositions, technologies and methods of using plerixafor to enhance gene editing |
WO2020118259A1 (en) | 2018-12-06 | 2020-06-11 | Northwestern University | Protein crystal engineering through dna hybridization interactions |
EA202191601A1 (en) | 2018-12-13 | 2022-01-19 | Сарепта Терапьютикс, Инк. | OLIGOMER CONJUGATES FOR EXON SKIP IN MUSCULAR DYSTROPHY |
CN112639126A (en) | 2018-12-14 | 2021-04-09 | 伊卢米纳剑桥有限公司 | Reducing phasing with unlabeled nucleotides during sequencing |
JP2022512265A (en) | 2018-12-17 | 2022-02-03 | イルミナ ケンブリッジ リミテッド | Primer oligonucleotides for sequencing |
CA3103744A1 (en) | 2018-12-17 | 2020-06-25 | Pietro GATTI-LAFRANCONI | Compositions for use in polynucleotide sequencing |
HUE064532T2 (en) | 2018-12-20 | 2024-03-28 | Vir Biotechnology Inc | Combination hbv therapy |
AU2019406186A1 (en) | 2018-12-20 | 2021-07-15 | Praxis Precision Medicines, Inc. | Compositions and methods for the treatment of KCNT1 related disorders |
EP3674702A1 (en) | 2018-12-27 | 2020-07-01 | Imec VZW | Method for sequencing a polynucleotide using a biofet |
WO2020142754A2 (en) | 2019-01-04 | 2020-07-09 | Mammoth Biosciences, Inc. | Programmable nuclease improvements and compositions and methods for nucleic acid amplification and detection |
US10822653B1 (en) | 2019-01-08 | 2020-11-03 | Singular Genomics Systems, Inc. | Nucleotide cleavable linkers and uses thereof |
TW202043471A (en) | 2019-01-16 | 2020-12-01 | 美商健贊公司 | Serpinc1 irna compositions and methods of use thereof |
WO2020157760A1 (en) | 2019-01-31 | 2020-08-06 | Bar Ilan University | Neoantigens created by aberrant-induced splicing and uses thereof in enhancing immunotherapy |
SG11202107399WA (en) | 2019-01-31 | 2021-08-30 | Ionis Pharmaceuticals Inc | Modulators of yap1 expression |
CN113811334B (en) | 2019-02-01 | 2024-02-20 | 利兰斯坦福初级大学董事会 | Lytic cell penetrating complexes for delivery of nucleic acids to the lung |
SG11202107354WA (en) | 2019-02-06 | 2021-08-30 | Synthorx Inc | Il-2 conjugates and methods of use thereof |
EP3921418A4 (en) | 2019-02-06 | 2023-02-08 | Singular Genomics Systems, Inc. | Compositions and methods for nucleic acid sequencing |
CA3129532A1 (en) | 2019-02-15 | 2020-08-20 | Crispr Therapeutics Ag | Gene editing for hemophilia a with improved factor viii expression |
WO2020171889A1 (en) | 2019-02-19 | 2020-08-27 | University Of Rochester | Blocking lipid accumulation or inflammation in thyroid eye disease |
WO2020170240A1 (en) | 2019-02-21 | 2020-08-27 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Method for reduction drug-induced nephrotoxicity |
US11504425B2 (en) | 2019-02-26 | 2022-11-22 | Wayne State University | Amphiphilic oligodeoxynucleotide conjugates as adjuvant enhancers |
JP2022523214A (en) | 2019-02-27 | 2022-04-21 | アイオーニス ファーマシューティカルズ, インコーポレーテッド | Modulator of MALAT1 expression |
EP3935184A1 (en) | 2019-03-04 | 2022-01-12 | King Abdullah University Of Science And Technology | Compositions and methods of targeted nucleic acid enrichment by loop adapter protection and exonuclease digestion |
GB2595606B (en) | 2019-03-07 | 2022-09-21 | Univ California | CRISPR-Cas effector polypeptides and methods of use thereof |
CN113825834A (en) | 2019-03-11 | 2021-12-21 | 索伦托药业有限公司 | Improved process for DNA construct integration using RNA-guided endonuclease |
SG11202109741VA (en) | 2019-03-12 | 2021-10-28 | Crispr Therapeutics Ag | Novel high fidelity rna-programmable endonuclease systems and uses thereof |
EP3937780A4 (en) | 2019-03-14 | 2022-12-07 | InSilixa, Inc. | Methods and systems for time-gated fluorescent-based detection |
MA55515A (en) | 2019-03-28 | 2022-02-09 | Sarepta Therapeutics Inc | METHODS OF TREATING MUSCULAR DYSTROPHY WITH CASIMERSEN |
CA3198063A1 (en) | 2019-03-29 | 2020-10-08 | Mitsubishi Tanabe Pharma Corporation | Compound, method and pharmaceutical composition for modulating expression of dux4 |
TW202043251A (en) | 2019-03-29 | 2020-12-01 | 美商Ionis製藥公司 | Compounds and methods for modulating ube3a-ats |
AU2020253823A1 (en) | 2019-03-29 | 2021-10-14 | Dicerna Pharmaceuticals, Inc. | Compositions and methods for the treatment of KRAS associated diseases or disorders |
EP3953041A4 (en) | 2019-04-08 | 2023-01-25 | Miroculus Inc. | Multi-cartridge digital microfluidics apparatuses and methods of use |
WO2020214763A1 (en) | 2019-04-18 | 2020-10-22 | Sarepta Therapeutics, Inc. | Compositions for treating muscular dystrophy |
US11814464B2 (en) | 2019-04-29 | 2023-11-14 | Yale University | Poly(amine-co-ester) polymers and polyplexes with modified end groups and methods of use thereof |
BR112021021686A2 (en) | 2019-05-03 | 2022-03-22 | Dicerna Pharmaceuticals Inc | Double-stranded nucleic acid inhibitor molecules with short sense strands |
WO2020225606A1 (en) | 2019-05-08 | 2020-11-12 | Crispr Therapeutics Ag | Crispr/cas all-in-two vector systems for treatment of dmd |
CN114126628A (en) | 2019-05-13 | 2022-03-01 | 维尔生物科技有限公司 | Compositions and methods for treating Hepatitis B Virus (HBV) infection |
EP3969583A1 (en) | 2019-05-14 | 2022-03-23 | F. Hoffmann-La Roche AG | Devices and methods for sample analysis |
EP3969591A1 (en) | 2019-05-15 | 2022-03-23 | Squadra Lifesciences, Inc | Aptamers against glioblastoma |
US20220396794A1 (en) | 2019-06-04 | 2022-12-15 | Apterna Limited | APTAMERS AGAINST TRANSFERRIN RECEPTOR (TfR) |
EP3983543A4 (en) | 2019-06-14 | 2023-05-03 | The Scripps Research Institute | Reagents and methods for replication, transcription, and translation in semi-synthetic organisms |
CA3142521A1 (en) | 2019-06-17 | 2020-12-24 | Vertex Pharmaceuticals Incorporated | Compositions and methods for editing beta-globin for treatment of hemaglobinopathies |
US20220296633A1 (en) | 2019-06-19 | 2022-09-22 | Sarepta Therapeutics, Inc. | Methods for treating muscular dystrophy |
US20220372474A1 (en) | 2019-06-21 | 2022-11-24 | Yale University | Hydroxymethyl-modified gamma-pna compositions and methods of use thereof |
WO2020257776A1 (en) | 2019-06-21 | 2020-12-24 | Yale University | Peptide nucleic acid compositions with modified hoogsteen binding segments and methods of use thereof |
US11377655B2 (en) | 2019-07-16 | 2022-07-05 | Pacific Biosciences Of California, Inc. | Synthetic nucleic acids having non-natural structures |
BR112022001315A2 (en) | 2019-07-25 | 2022-04-12 | Aspen Neuroscience Inc | Methods for identification of dopaminergic neurons and progenitor cells |
US11524298B2 (en) | 2019-07-25 | 2022-12-13 | Miroculus Inc. | Digital microfluidics devices and methods of use thereof |
WO2021021673A1 (en) | 2019-07-26 | 2021-02-04 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating gfap |
US20220280656A1 (en) | 2019-07-31 | 2022-09-08 | Yale University | Compositions and methods for treating sickle cell disease |
EP4007811A2 (en) | 2019-08-01 | 2022-06-08 | Alnylam Pharmaceuticals, Inc. | Carboxypeptidase b2 (cpb2) irna compositions and methods of use thereof |
WO2021022109A1 (en) | 2019-08-01 | 2021-02-04 | Alnylam Pharmaceuticals, Inc. | SERPIN FAMILY F MEMBER 2 (SERPINF2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
WO2021025899A1 (en) | 2019-08-02 | 2021-02-11 | Sarepta Therapeutics, Inc. | Phosphorodiamidate morpholino oligomer pharmaceutical compositions |
WO2021030522A1 (en) | 2019-08-13 | 2021-02-18 | Alnylam Pharmaceuticals, Inc. | SMALL RIBOSOMAL PROTEIN SUBUNIT 25 (RPS25) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF |
MX2022001770A (en) | 2019-08-14 | 2022-05-20 | Codiak Biosciences Inc | Extracellular vesicle linked to molecules and uses thereof. |
KR20220062517A (en) | 2019-08-15 | 2022-05-17 | 아이오니스 파마수티컬즈, 인코포레이티드 | Linkage-modified oligomeric compounds and uses thereof |
CN114555128A (en) | 2019-08-15 | 2022-05-27 | 新索思股份有限公司 | Combination immunooncology therapy with IL-2 conjugates |
CA3148135A1 (en) | 2019-08-23 | 2021-03-04 | Carolina E. CAFFARO | Il-15 conjugates and uses thereof |
JP2022546699A (en) | 2019-08-30 | 2022-11-07 | イェール ユニバーシティー | Compositions and methods for delivering nucleic acids to cells |
JP2022546570A (en) | 2019-09-03 | 2022-11-04 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | Compositions and methods for inhibiting expression of the LECT2 gene |
MX2022002663A (en) | 2019-09-05 | 2022-04-07 | Crispr Therapeutics Ag | Universal donor cells. |
AU2020341186A1 (en) | 2019-09-05 | 2022-03-03 | Crispr Therapeutics Ag | Universal donor cells |
EP4025582A1 (en) | 2019-09-05 | 2022-07-13 | Sanofi | Oligonucleotides containing nucleotide analogs |
JP2022547078A (en) | 2019-09-10 | 2022-11-10 | シンソークス, インコーポレイテッド | IL-2 conjugates and methods of use for treating autoimmune diseases |
TW202124406A (en) | 2019-09-10 | 2021-07-01 | 美商歐姆尼歐美公司 | Reversible modification of nucleotides |
JP2022547678A (en) | 2019-09-11 | 2022-11-15 | ボシュ ヘルス アイルランド リミテッド | Methods of treating non-alcoholic fatty liver disease (NAFLD) using IL-17RA antibodies |
US11512295B2 (en) | 2019-09-12 | 2022-11-29 | Singular Genomics Systems, Inc. | Modified thermoccocus polymerases |
EP4038189A1 (en) | 2019-10-04 | 2022-08-10 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for silencing ugt1a1 gene expression |
WO2021071909A1 (en) | 2019-10-08 | 2021-04-15 | Life Technologies Corporation | Compositions and methods for homology-directed recombination |
JP2022552249A (en) | 2019-10-14 | 2022-12-15 | アストラゼネカ・アクチエボラーグ | Modulators of PNPLA3 expression |
WO2021076828A1 (en) | 2019-10-18 | 2021-04-22 | Alnylam Pharmaceuticals, Inc. | Solute carrier family member irna compositions and methods of use thereof |
BR112022007540A2 (en) | 2019-10-22 | 2022-07-12 | Alnylam Pharmaceuticals Inc | COMPONENTS COMPLEMENTARY C3 IRNA COMPOSITIONS AND METHODS OF USE THEREOF |
SG11202110571YA (en) | 2019-10-25 | 2021-10-28 | Illumina Cambridge Ltd | Methods for generating, and sequencing from, asymmetric adaptors on the ends of polynucleotide templates comprising hairpin loops |
MX2022004388A (en) | 2019-11-01 | 2022-05-06 | Alnylam Pharmaceuticals Inc | HUNTINGTIN (HTT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF. |
US20230040920A1 (en) | 2019-11-01 | 2023-02-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for silencing dnajb1-prkaca fusion gene expression |
IL291786A (en) | 2019-11-04 | 2022-06-01 | Synthorx Inc | Interleukin 10 conjugates and uses thereof |
TW202132568A (en) | 2019-11-13 | 2021-09-01 | 美商阿尼拉製藥公司 | Methods and compositions for treating an angiotensinogen- (agt-) associated disorder |
US20230056569A1 (en) | 2019-11-22 | 2023-02-23 | Alnylam Pharmaceuticals, Inc. | Ataxin3 (atxn3) rnai agent compositions and methods of use thereof |
JP2023503635A (en) | 2019-11-27 | 2023-01-31 | クリスパー・セラピューティクス・アクチェンゲゼルシャフト | Methods of synthesizing RNA molecules |
JP2023504191A (en) | 2019-12-04 | 2023-02-01 | ザ・ボード・オブ・トラスティーズ・オブ・ザ・リーランド・スタンフォード・ジュニア・ユニバーシティ | Enhancement of blood-brain barrier drug transport by targeting endogenous regulators |
EP4073251A1 (en) | 2019-12-13 | 2022-10-19 | Alnylam Pharmaceuticals, Inc. | Human chromosome 9 open reading frame 72 (c9orf72) irna agent compositions and methods of use thereof |
WO2021126734A1 (en) | 2019-12-16 | 2021-06-24 | Alnylam Pharmaceuticals, Inc. | Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof |
EP4077676A1 (en) | 2019-12-18 | 2022-10-26 | Novartis AG | Compositions and methods for the treatment of hemoglobinopathies |
US20230054569A1 (en) | 2019-12-18 | 2023-02-23 | Alia Therapeutics Srl | Compositions and methods for treating retinitis pigmentosa |
CA3165862A1 (en) | 2019-12-23 | 2021-07-01 | The Regents Of The University Of California | Stabilization of mhc complexes |
CA3165571C (en) | 2019-12-23 | 2023-02-07 | Singular Genomics Systems, Inc. | Methods for long read sequencing |
EP4085135A4 (en) | 2019-12-31 | 2023-08-02 | Singular Genomics Systems, Inc. | Polynucleotide barcodes for long read sequencing |
US11859172B2 (en) | 2020-01-02 | 2024-01-02 | The Trustees Of Columbia University In The City Of New York | Programmable and portable CRISPR-Cas transcriptional activation in bacteria |
MX2022008738A (en) | 2020-01-15 | 2022-09-23 | Dicerna Pharmaceuticals Inc | 4'-o-methylene phosphonate nucleic acids and analogues thereof. |
US20230057461A1 (en) | 2020-01-27 | 2023-02-23 | The U.S.A., As Represented By The Secretary, Department Of Health And Human Services | Rab13 and net1 antisense oligonucleotides to treat metastatic cancer |
WO2021154941A1 (en) | 2020-01-31 | 2021-08-05 | Alnylam Pharmaceuticals, Inc. | Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als) |
WO2021163066A1 (en) | 2020-02-10 | 2021-08-19 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for silencing vegf-a expression |
WO2021163281A1 (en) | 2020-02-12 | 2021-08-19 | Accutar Biotechnology Inc. | Antisense oligonucleotides and their use for treating pendred syndrome |
MX2022010052A (en) | 2020-02-18 | 2022-09-05 | Alnylam Pharmaceuticals Inc | Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof. |
US11034942B1 (en) | 2020-02-27 | 2021-06-15 | Singular Genomics Systems, Inc. | Modified pyrococcus polymerases and uses thereof |
PE20221913A1 (en) | 2020-02-28 | 2022-12-23 | Ionis Pharmaceuticals Inc | COMPOUNDS AND METHODS FOR MODULATING SMN2 |
EP4114947A1 (en) | 2020-03-05 | 2023-01-11 | Alnylam Pharmaceuticals, Inc. | Complement component c3 irna compositions and methods of use thereof for treating or preventing complement component c3-associated diseases |
WO2021178778A1 (en) | 2020-03-06 | 2021-09-10 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of transthyretin (ttr) |
WO2021178893A2 (en) | 2020-03-06 | 2021-09-10 | Singular Genomics Systems, Inc. | Linked paired strand sequencing |
EP4114948A1 (en) | 2020-03-06 | 2023-01-11 | Alnylam Pharmaceuticals, Inc. | Ketohexokinase (khk) irna compositions and methods of use thereof |
EP4121534A1 (en) | 2020-03-18 | 2023-01-25 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for treating subjects having a heterozygous alanine-glyoxylate aminotransferase gene (agxt) variant |
TW202204615A (en) | 2020-03-26 | 2022-02-01 | 美商阿尼拉製藥公司 | Coronavirus irna compositions and methods of use thereof |
WO2021202443A2 (en) | 2020-03-30 | 2021-10-07 | Alnylam Pharmaceucticals, Inc. | Compositions and methods for silencing dnajc15 gene expression |
BR112022020145A2 (en) | 2020-04-06 | 2023-01-03 | Alnylam Pharmaceuticals Inc | COMPOSITIONS AND METHODS FOR SILENCING THE MYOC EXPRESSION |
TW202204617A (en) | 2020-04-07 | 2022-02-01 | 美商艾爾妮蘭製藥公司 | Compositions and methods for silencing scn9a expression |
EP4133077A1 (en) | 2020-04-07 | 2023-02-15 | Alnylam Pharmaceuticals, Inc. | Transmembrane serine protease 2 (tmprss2) irna compositions and methods of use thereof |
EP4133076A1 (en) | 2020-04-07 | 2023-02-15 | Alnylam Pharmaceuticals, Inc. | Angiotensin-converting enzyme 2 (ace2) irna compositions and methods of use thereof |
EP4117682A4 (en) | 2020-04-24 | 2023-09-13 | Singular Genomics Systems, Inc. | Modified nucleotides and uses thereof |
EP4143319A1 (en) | 2020-04-27 | 2023-03-08 | Alnylam Pharmaceuticals, Inc. | Apolipoprotein e (apoe) irna agent compositions and methods of use thereof |
CA3181198A1 (en) | 2020-04-30 | 2021-11-04 | Alnylam Pharmaceuticals, Inc. | Complement factor b (cfb) irna compositions and methods of use thereof |
JP2023524065A (en) | 2020-05-01 | 2023-06-08 | アイオーニス ファーマシューティカルズ, インコーポレーテッド | Compounds and methods for modulating ATXN1 |
CA3181786A1 (en) | 2020-05-01 | 2021-11-04 | The Regents Of The University Of California | Inhibitors of alpha 2 beta 1 integrin and methods of use thereof |
WO2021230286A1 (en) | 2020-05-12 | 2021-11-18 | 田辺三菱製薬株式会社 | Compound, method and pharmaceutical composition for regulating expression of ataxin 3 |
EP4150078A1 (en) | 2020-05-15 | 2023-03-22 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of argininosuccinate lyase (asl) |
WO2021231827A2 (en) | 2020-05-15 | 2021-11-18 | Life Technologies Corporation | Sirna sequences targeting coronavirus-2 |
WO2021231679A1 (en) | 2020-05-15 | 2021-11-18 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of gap junction protein beta 2 (gjb2) |
US20210355463A1 (en) | 2020-05-15 | 2021-11-18 | Crispr Therapeutics Ag | Messenger rna encoding cas9 for use in genome-editing systems |
WO2021231675A1 (en) | 2020-05-15 | 2021-11-18 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of argininosuccinate synthetase (ass1) |
WO2021231692A1 (en) | 2020-05-15 | 2021-11-18 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of otoferlin (otof) |
EP4150089A1 (en) | 2020-05-15 | 2023-03-22 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of retinoschisin 1 (rs1) |
EP4150086A1 (en) | 2020-05-15 | 2023-03-22 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of leucine rich repeat kinase 2 (lrrk2) |
EP4150077A1 (en) | 2020-05-15 | 2023-03-22 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of transmembrane channel-like protein 1 (tmc1) |
WO2021231680A1 (en) | 2020-05-15 | 2021-11-18 | Korro Bio, Inc. | Methods and compositions for the adar-mediated editing of methyl-cpg binding protein 2 (mecp2) |
WO2021237097A1 (en) | 2020-05-21 | 2021-11-25 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting marc1 gene expression |
EP4153747A2 (en) | 2020-05-22 | 2023-03-29 | Wave Life Sciences Ltd. | Double stranded oligonucleotide compositions and methods relating thereto |
US11408000B2 (en) | 2020-06-03 | 2022-08-09 | Triplet Therapeutics, Inc. | Oligonucleotides for the treatment of nucleotide repeat expansion disorders associated with MSH3 activity |
EP4161552A1 (en) | 2020-06-05 | 2023-04-12 | The Broad Institute, Inc. | Compositions and methods for treating neoplasia |
WO2021252557A1 (en) | 2020-06-09 | 2021-12-16 | Alnylam Pharmaceuticals, Inc. | Rnai compositions and methods of use thereof for delivery by inhalation |
KR20230026455A (en) | 2020-06-18 | 2023-02-24 | 알닐람 파마슈티칼스 인코포레이티드 | Xanthine dehydrogenase (XDH) iRNA compositions and methods of use thereof |
JP2023531444A (en) | 2020-06-19 | 2023-07-24 | イェール ユニバーシティー | Poly(amine-co-ester) polymers with modified end groups and enhanced pulmonary delivery |
BR112022026316A2 (en) | 2020-06-24 | 2023-03-07 | Vir Biotechnology Inc | ENGINEERED HEPATITIS B VIRUS NEUTRALIZING ANTIBODIES AND THEIR USES |
TW202216203A (en) | 2020-06-25 | 2022-05-01 | 美商欣爍克斯公司 | Immuno oncology combination therapy with il-2 conjugates and anti-egfr antibodies |
KR20230029837A (en) | 2020-06-29 | 2023-03-03 | 아이오니스 파마수티컬즈, 인코포레이티드 | Compounds and methods for modulating PLP1 |
EP4179079A1 (en) | 2020-07-10 | 2023-05-17 | Horizon Discovery Limited | Method for producing genetically modified cells |
EP4153606A2 (en) | 2020-07-13 | 2023-03-29 | Singular Genomics Systems, Inc. | Methods of sequencing complementary polynucleotides |
MX2023001541A (en) | 2020-08-04 | 2023-03-08 | Dicerna Pharmaceuticals Inc | Systemic delivery of oligonucleotides. |
KR20230084469A (en) | 2020-08-04 | 2023-06-13 | 애보트 라피드 다이어그노스틱스 인터내셔널 언리미티드 컴퍼니 | Assays to detect SARS-COV-2 |
IL300528A (en) | 2020-08-07 | 2023-04-01 | Fortis Therapeutics Inc | Immunoconjugates targeting cd46 and methods of use thereof |
EP4200250A1 (en) | 2020-08-18 | 2023-06-28 | Regenacellx.SL | Compositions and methods for detecting sars-cov-2 spike protein |
EP4204002A1 (en) | 2020-08-31 | 2023-07-05 | Yale University | Compositions and methods for delivery of nucleic acids to cells |
TW202227102A (en) | 2020-09-22 | 2022-07-16 | 瑞典商阿斯特捷利康公司 | Method of treating fatty liver disease |
EP4217489A1 (en) | 2020-09-24 | 2023-08-02 | Alnylam Pharmaceuticals, Inc. | Dipeptidyl peptidase 4 (dpp4) irna compositions and methods of use thereof |
EP4222264A1 (en) | 2020-09-30 | 2023-08-09 | CRISPR Therapeutics AG | Materials and methods for treatment of amyotrophic lateral sclerosis |
TW202229552A (en) | 2020-10-05 | 2022-08-01 | 美商艾拉倫製藥股份有限公司 | G protein-coupled receptor 75 (gpr75) irna compositions and methods of use thereof |
EP3978608A1 (en) | 2020-10-05 | 2022-04-06 | SQY Therapeutics | Oligomeric compound for dystrophin rescue in dmd patients throughout skipping of exon-51 |
TW202228786A (en) | 2020-10-09 | 2022-08-01 | 美商欣爍克斯公司 | Immuno oncology therapies with il-2 conjugates |
AU2021356693A1 (en) | 2020-10-09 | 2023-06-15 | Synthorx, Inc. | Immuno oncology combination therapy with il-2 conjugates and pembrolizumab |
EP4228637A1 (en) | 2020-10-15 | 2023-08-23 | Yeda Research and Development Co. Ltd | Method of treating myeloid malignancies |
WO2022084331A2 (en) | 2020-10-20 | 2022-04-28 | Sanofi | Novel ligands for asialoglycoprotein receptor |
AU2021365822A1 (en) | 2020-10-21 | 2023-06-08 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for treating primary hyperoxaluria |
EP4232582A1 (en) | 2020-10-23 | 2023-08-30 | Alnylam Pharmaceuticals, Inc. | Mucin 5b (muc5b) irna compositions and methods of use thereof |
CA3200595A1 (en) | 2020-11-13 | 2022-05-19 | Alnylam Pharmaceuticals, Inc. | Coagulation factor v (f5) irna compositions and methods of use thereof |
CA3201661A1 (en) | 2020-11-18 | 2022-05-27 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating angiotensinogen expression |
WO2022106695A1 (en) | 2020-11-23 | 2022-05-27 | Alpha Anomeric Sas | Nucleic acid duplexes |
WO2022113056A1 (en) | 2020-11-30 | 2022-06-02 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
TW202237150A (en) | 2020-12-01 | 2022-10-01 | 美商艾拉倫製藥股份有限公司 | Methods and compositions for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression |
WO2022125490A1 (en) | 2020-12-08 | 2022-06-16 | Alnylam Pharmaceuticals, Inc. | Coagulation factor x (f10) irna compositions and methods of use thereof |
GB2603454A (en) | 2020-12-09 | 2022-08-10 | Ucl Business Ltd | Novel therapeutics for the treatment of neurodegenerative disorders |
GB202019692D0 (en) | 2020-12-14 | 2021-01-27 | Apterna Ltd | Aptamer-sirna fusions |
WO2022140126A1 (en) | 2020-12-21 | 2022-06-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Dna vector and uses thereof for detecting hiv and siv |
WO2022140535A1 (en) | 2020-12-23 | 2022-06-30 | Sarepta Therapeutics, Inc. | Compositions comprising exon skipping oligonucleotide conjugates for treating muscular dystrophy |
JP2024501288A (en) | 2020-12-23 | 2024-01-11 | フラッグシップ パイオニアリング イノベーションズ シックス,エルエルシー | Compositions of modified TREM and uses thereof |
EP4271798A1 (en) | 2020-12-30 | 2023-11-08 | CRISPR Therapeutics AG | Compositions and methods for differentiating stem cells into nk cells |
KR20230146007A (en) | 2020-12-31 | 2023-10-18 | 크리스퍼 테라퓨틱스 아게 | universal donor cells |
WO2022150260A1 (en) | 2021-01-05 | 2022-07-14 | Alnylam Pharmaceuticals, Inc. | COMPLEMENT COMPONENT 9 (C9) iRNA COMPOSITIONS AND METHODS OF USE THEREOF |
US20240067954A1 (en) | 2021-01-05 | 2024-02-29 | Horizon Discovery Limited | Method for producing genetically modified cells |
US11486001B2 (en) | 2021-02-08 | 2022-11-01 | Singular Genomics Systems, Inc. | Methods and compositions for sequencing complementary polynucleotides |
TW202245843A (en) | 2021-02-12 | 2022-12-01 | 美商欣爍克斯公司 | Skin cancer combination therapy with il-2 conjugates and cemiplimab |
BR112023015761A2 (en) | 2021-02-12 | 2023-11-07 | Alnylam Pharmaceuticals Inc | SUPEROXIDE DISMUTASE 1 (SOD1) IRNA COMPOSITIONS AND METHODS OF USE THEREOF TO TREAT OR PREVENT NEURODEGENERATIVE DISEASES ASSOCIATED WITH SUPEROXIDE DISMUTASE 1 (SOD1) |
TW202302148A (en) | 2021-02-12 | 2023-01-16 | 美商欣爍克斯公司 | Lung cancer combination therapy with il-2 conjugates and an anti-pd-1 antibody or antigen-binding fragment thereof |
JP2024506711A (en) | 2021-02-17 | 2024-02-14 | ロンザ セールス アーゲー | Extracellular vesicles linked to biologically active molecules via optimized linkers and anchor moieties |
WO2022182864A1 (en) | 2021-02-25 | 2022-09-01 | Alnylam Pharmaceuticals, Inc. | Prion protein (prnp) irna compositions and methods and methods of use thereof |
EP4298218A1 (en) | 2021-02-26 | 2024-01-03 | Alnylam Pharmaceuticals, Inc. | Ketohexokinase (khk) irna compositions and methods of use thereof |
KR20230150843A (en) | 2021-03-04 | 2023-10-31 | 알닐람 파마슈티칼스 인코포레이티드 | Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of using the same |
WO2022187697A1 (en) | 2021-03-05 | 2022-09-09 | The Board Of Trustees Of The Leland Stanford Junior University | In vivo dna assembly and analysis |
US11884977B2 (en) | 2021-03-12 | 2024-01-30 | Singular Genomics Systems, Inc. | Nanoarrays and methods of use thereof |
EP4263868A1 (en) | 2021-03-12 | 2023-10-25 | Singular Genomics Systems, Inc. | Nanoarrays and methods of use thereof |
EP4305169A1 (en) | 2021-03-12 | 2024-01-17 | Alnylam Pharmaceuticals, Inc. | Glycogen synthase kinase 3 alpha (gsk3a) irna compositions and methods of use thereof |
US20220288181A1 (en) | 2021-03-12 | 2022-09-15 | Northwestern University | Antiviral vaccines using spherical nucleic acids |
JP2024512608A (en) | 2021-03-24 | 2024-03-19 | ジェネンテック, インコーポレイテッド | Efficient TCR gene editing in T lymphocytes |
KR20230162024A (en) | 2021-03-29 | 2023-11-28 | 알닐람 파마슈티칼스 인코포레이티드 | Huntingtin (HTT) iRNA preparation composition and method of use thereof |
EP4314293A1 (en) | 2021-04-01 | 2024-02-07 | Alnylam Pharmaceuticals, Inc. | Proline dehydrogenase 2 (prodh2) irna compositions and methods of use thereof |
EP4326873A1 (en) | 2021-04-22 | 2024-02-28 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating cancer |
BR112023022284A2 (en) | 2021-04-26 | 2023-12-26 | Alnylam Pharmaceuticals Inc | COMPOSITIONS OF TRANSMEMBRANE PROTEASE IRNA, SERINE 6 (TMPRSS6) AND METHODS OF USE THEREOF |
EP4294920A1 (en) | 2021-04-27 | 2023-12-27 | Singular Genomics Systems, Inc. | High density sequencing and multiplexed priming |
WO2022232343A1 (en) | 2021-04-29 | 2022-11-03 | Alnylam Pharmaceuticals, Inc. | Signal transducer and activator of transcription factor 6 (stat6) irna compositions and methods of use thereof |
IL307937A (en) | 2021-04-30 | 2023-12-01 | Sarepta Therapeutics Inc | Treatment methods for muscular dystrophy |
WO2022235537A1 (en) | 2021-05-03 | 2022-11-10 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for treating transthyretin (ttr) mediated amyloidosis |
EP4341401A1 (en) | 2021-05-18 | 2024-03-27 | Alnylam Pharmaceuticals, Inc. | Sodium-glucose cotransporter-2 (sglt2) irna compositions and methods of use thereof |
WO2022246023A1 (en) | 2021-05-20 | 2022-11-24 | Korro Bio, Inc. | Methods and compositions for adar-mediated editing |
WO2022251644A1 (en) | 2021-05-28 | 2022-12-01 | Lyell Immunopharma, Inc. | Nr4a3-deficient immune cells and uses thereof |
CN115404240A (en) | 2021-05-28 | 2022-11-29 | 上海环码生物医药有限公司 | Constructs, methods for making circular RNA and uses thereof |
WO2022256283A2 (en) | 2021-06-01 | 2022-12-08 | Korro Bio, Inc. | Methods for restoring protein function using adar |
TW202317762A (en) | 2021-06-02 | 2023-05-01 | 美商艾拉倫製藥股份有限公司 | Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof |
AU2022286947A1 (en) | 2021-06-02 | 2023-12-14 | Lyell Immunopharma, Inc. | NR4A-deficient cells expressing c-Jun and uses thereof |
WO2022256534A1 (en) | 2021-06-03 | 2022-12-08 | Synthorx, Inc. | Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab |
IL308743A (en) | 2021-06-04 | 2024-01-01 | Alnylam Pharmaceuticals Inc | HUMAN CHROMOSOME 9 OPEN READING FRAME 72 (C9ORF72) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF |
AR126070A1 (en) | 2021-06-08 | 2023-09-06 | Alnylam Pharmaceuticals Inc | COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING STARGARDT DISEASE AND/OR DISORDERS ASSOCIATED WITH RETINOL BORDER PROTEIN 4 (RBP4) |
BR112023023768A2 (en) | 2021-06-11 | 2024-02-27 | Bayer Ag | TYPE V RNA PROGRAMMABLE ENDONUCLEASE SYSTEMS |
EP4101928A1 (en) | 2021-06-11 | 2022-12-14 | Bayer AG | Type v rna programmable endonuclease systems |
CA3223192A1 (en) | 2021-06-18 | 2022-12-22 | Ionis Pharmaceuticals, Inc. | Compounds and methods for reducing ifnar1 expression |
US20230014010A1 (en) | 2021-06-23 | 2023-01-19 | Crispr Therapeutics Ag | Engineered cells with improved protection from natural killer cell killing |
WO2022269518A2 (en) | 2021-06-23 | 2022-12-29 | Novartis Ag | Compositions and methods for the treatment of hemoglobinopathies |
US20230194709A9 (en) | 2021-06-29 | 2023-06-22 | Seagate Technology Llc | Range information detection using coherent pulse sets with selected waveform characteristics |
WO2023278410A1 (en) | 2021-06-29 | 2023-01-05 | Korro Bio, Inc. | Methods and compositions for adar-mediated editing |
KR20240026203A (en) | 2021-06-30 | 2024-02-27 | 알닐람 파마슈티칼스 인코포레이티드 | Methods and compositions for treating angiotensinogen (AGT)-related disorders |
WO2023285431A1 (en) | 2021-07-12 | 2023-01-19 | Alia Therapeutics Srl | Compositions and methods for allele specific treatment of retinitis pigmentosa |
TW202333748A (en) | 2021-07-19 | 2023-09-01 | 美商艾拉倫製藥股份有限公司 | Methods and compositions for treating subjects having or at risk of developing a non-primary hyperoxaluria disease or disorder |
KR20240037293A (en) | 2021-07-23 | 2024-03-21 | 알닐람 파마슈티칼스 인코포레이티드 | Beta-catenin (CTNNB1) iRNA composition and methods of use thereof |
WO2023009687A1 (en) | 2021-07-29 | 2023-02-02 | Alnylam Pharmaceuticals, Inc. | 3-hydroxy-3-methylglutaryl-coa reductase (hmgcr) irna compositions and methods of use thereof |
IL310244A (en) | 2021-08-03 | 2024-03-01 | Alnylam Pharmaceuticals Inc | Transthyretin (ttr) irna compositions and methods of use thereof |
CA3228255A1 (en) | 2021-08-04 | 2023-02-09 | Alnylam Pharmaceuticals, Inc. | Irna compositions and methods for silencing angiotensinogen (agt) |
AR126771A1 (en) | 2021-08-13 | 2023-11-15 | Alnylam Pharmaceuticals Inc | RNAi COMPOSITIONS AGAINST FACTOR XII (F12) AND THEIR METHODS OF USE |
US11833221B2 (en) | 2021-09-01 | 2023-12-05 | Ionis Pharmaceuticals, Inc. | Oligomeric compounds for reducing DMPK expression |
WO2023034515A2 (en) | 2021-09-03 | 2023-03-09 | Sarepta Therapeutics, Inc. | Delivery of anitsense oligomers by mirror image peptides |
WO2023034920A2 (en) | 2021-09-03 | 2023-03-09 | Singular Genomics Systems, Inc. | Amplification oligonucleotides |
EP4144841A1 (en) | 2021-09-07 | 2023-03-08 | Bayer AG | Novel small rna programmable endonuclease systems with impoved pam specificity and uses thereof |
WO2023044370A2 (en) | 2021-09-17 | 2023-03-23 | Alnylam Pharmaceuticals, Inc. | Irna compositions and methods for silencing complement component 3 (c3) |
AU2022345881A1 (en) | 2021-09-20 | 2024-03-21 | Alnylam Pharmaceuticals, Inc. | Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof |
US20230096386A1 (en) | 2021-09-30 | 2023-03-30 | Illumina Cambridge Limited | Polynucleotide sequencing |
CA3233242A1 (en) | 2021-09-30 | 2023-04-06 | Sarepta Therapeutics, Inc. | Antisense oligonucleotides having one or more abasic units |
WO2023070086A1 (en) | 2021-10-22 | 2023-04-27 | Sarepta Therapeutics, Inc. | Morpholino oligomers for treatment of peripheral myelin protein 22 related diseases |
WO2023069603A1 (en) | 2021-10-22 | 2023-04-27 | Korro Bio, Inc. | Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing |
WO2023076451A1 (en) | 2021-10-29 | 2023-05-04 | Alnylam Pharmaceuticals, Inc. | Complement factor b (cfb) irna compositions and methods of use thereof |
TW202334418A (en) | 2021-10-29 | 2023-09-01 | 美商艾拉倫製藥股份有限公司 | Huntingtin (htt) irna agent compositions and methods of use thereof |
WO2023086295A2 (en) | 2021-11-10 | 2023-05-19 | University Of Rochester | Antisense oligonucleotides for modifying protein expression |
WO2023086292A2 (en) | 2021-11-10 | 2023-05-19 | University Of Rochester | Gata4-targeted therapeutics for treatment of cardiac hypertrophy |
GB202117758D0 (en) | 2021-12-09 | 2022-01-26 | Ucl Business Ltd | Therapeutics for the treatment of neurodegenerative disorders |
WO2023122573A1 (en) | 2021-12-20 | 2023-06-29 | Synthorx, Inc. | Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab |
WO2023118349A1 (en) | 2021-12-21 | 2023-06-29 | Alia Therapeutics Srl | Type ii cas proteins and applications thereof |
WO2023122750A1 (en) | 2021-12-23 | 2023-06-29 | Synthorx, Inc. | Cancer combination therapy with il-2 conjugates and cetuximab |
WO2023118068A1 (en) | 2021-12-23 | 2023-06-29 | Bayer Aktiengesellschaft | Novel small type v rna programmable endonuclease systems |
US20230212667A1 (en) | 2021-12-29 | 2023-07-06 | Illumina Cambridge Limited | Methods of nucleic acid sequencing using surface-bound primers |
US11772093B2 (en) | 2022-01-12 | 2023-10-03 | Miroculus Inc. | Methods of mechanical microfluidic manipulation |
WO2023141314A2 (en) | 2022-01-24 | 2023-07-27 | Alnylam Pharmaceuticals, Inc. | Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof |
WO2023159189A1 (en) | 2022-02-18 | 2023-08-24 | Yale University | Branched poly(amine-co-ester) polymers for more efficient nucleic expression |
WO2023168427A1 (en) | 2022-03-03 | 2023-09-07 | Yale University | Compositions and methods for delivering therapeutic polynucleotides for exon skipping |
WO2023172885A1 (en) | 2022-03-09 | 2023-09-14 | The Board Of Trustees Of The Leland Stanford Junior University | Branched lipid charge-altering releasable transporters for nucleic acid delivery |
WO2023172665A2 (en) | 2022-03-10 | 2023-09-14 | Singular Genomics Systems, Inc. | Nucleic acid delivery scaffolds |
WO2023178230A1 (en) | 2022-03-17 | 2023-09-21 | Sarepta Therapeutics, Inc. | Phosphorodiamidate morpholino oligomer conjugates |
WO2023177866A1 (en) | 2022-03-18 | 2023-09-21 | Dicerna Pharmaceuticals, Inc. | Decarboxylative acetoxylation using mn(ii) or mn(iii) reagent for synthesis of 4'-acetoxy- nucleoside and use thereof for synthesis of corresponding 4'-(dimethoxyphosphoryl)methoxy- nucleotide |
WO2023194359A1 (en) | 2022-04-04 | 2023-10-12 | Alia Therapeutics Srl | Compositions and methods for treatment of usher syndrome type 2a |
WO2023212294A1 (en) | 2022-04-29 | 2023-11-02 | Broadwing Bio Llc | Angiopoietin-related protein 7-specific antibodies and uses thereof |
WO2023212298A1 (en) | 2022-04-29 | 2023-11-02 | Broadwing Bio Llc | Bispecific antibodies and methods of treating ocular disease |
WO2023212293A1 (en) | 2022-04-29 | 2023-11-02 | Broadwing Bio Llc | Complement factor h related 4-specific antibodies and uses thereof |
WO2023225665A1 (en) | 2022-05-19 | 2023-11-23 | Lyell Immunopharma, Inc. | Polynucleotides targeting nr4a3 and uses thereof |
WO2023230201A1 (en) | 2022-05-26 | 2023-11-30 | The Board Of Trustees Of The Leland Stanford Junior University | Small molecule conjugated charge-altering releasable transporters for nucleic acid delivery |
WO2023231959A2 (en) | 2022-05-30 | 2023-12-07 | Shanghai Circode Biomed Co., Ltd | Synthetic circular rna compositions and methods of use thereof |
WO2023233339A1 (en) | 2022-06-01 | 2023-12-07 | Crispr Therapeutics Ag | Compositions and methods for differentiating stem cells into nk cells |
WO2023233342A2 (en) | 2022-06-01 | 2023-12-07 | Crispr Therapeutics Ag | Gene-edited natural killer cells |
WO2023237587A1 (en) | 2022-06-10 | 2023-12-14 | Bayer Aktiengesellschaft | Novel small type v rna programmable endonuclease systems |
WO2024006927A1 (en) | 2022-06-29 | 2024-01-04 | Life Technologies Corporation | Compositions, kits, and methods for detecting nucleic acids using intra-channel multiplexing |
WO2024015962A1 (en) | 2022-07-15 | 2024-01-18 | Pacific Biosciences Of California, Inc. | Blocked asymmetric hairpin adaptors |
WO2024015924A2 (en) | 2022-07-15 | 2024-01-18 | Entrada Therapeutics, Inc. | Hybrid oligonucleotides |
WO2024026474A1 (en) | 2022-07-29 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle |
WO2024039776A2 (en) | 2022-08-18 | 2024-02-22 | Alnylam Pharmaceuticals, Inc. | Universal non-targeting sirna compositions and methods of use thereof |
WO2024044352A1 (en) | 2022-08-26 | 2024-02-29 | The General Hospital Corporation | Methods and compositions for prognosis and treatment of dilated cardiomyopathy and heart failure |
WO2024050261A1 (en) | 2022-08-29 | 2024-03-07 | University Of Rochester | Antisense oligonucleotide-based anti-fibrotic therapeutics |
WO2024059165A1 (en) | 2022-09-15 | 2024-03-21 | Alnylam Pharmaceuticals, Inc. | 17b-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof |
WO2024056880A2 (en) | 2022-09-16 | 2024-03-21 | Alia Therapeutics Srl | Enqp type ii cas proteins and applications thereof |
WO2024064237A2 (en) | 2022-09-21 | 2024-03-28 | Sarepta Therapeutics, Inc. | Dmd antisense oligonucleotide-mediated exon skipping efficiency |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63303341A (en) * | 1987-06-03 | 1988-12-09 | Kuraray Co Ltd | Photosensitive composition |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE171185T1 (en) * | 1985-03-15 | 1998-10-15 | Antivirals Inc | POLYNUCLEOTIDE IMMUNOTESTING AGENTS AND METHODS |
DE69034209T2 (en) * | 1989-09-15 | 2006-08-10 | Southern Research Institute, Birmingham | 2'-DEOXY-4'-THIORIBONUCLEOSIDE AS ANTIVIRAL AND ANTIBODY |
-
1989
- 1989-12-20 US US07/454,055 patent/US5034506A/en not_active Expired - Lifetime
-
1990
- 1990-12-20 WO PCT/US1990/007565 patent/WO1991009073A1/en active IP Right Grant
- 1990-12-20 KR KR1019920701480A patent/KR0154317B1/en not_active IP Right Cessation
- 1990-12-20 DE DE69032167T patent/DE69032167T2/en not_active Expired - Fee Related
- 1990-12-20 JP JP50289391A patent/JP3172174B2/en not_active Expired - Fee Related
- 1990-12-20 AT AT91902401T patent/ATE164081T1/en not_active IP Right Cessation
- 1990-12-20 CA CA002069906A patent/CA2069906C/en not_active Expired - Lifetime
- 1990-12-20 EP EP91902401A patent/EP0506845B1/en not_active Expired - Lifetime
- 1990-12-20 AU AU71587/91A patent/AU654473B2/en not_active Ceased
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63303341A (en) * | 1987-06-03 | 1988-12-09 | Kuraray Co Ltd | Photosensitive composition |
Non-Patent Citations (2)
Title |
---|
Izv. Akad. Nauk SSSR, Ser. Khim Number 4, (1971) (BELIKOV et al.); pages 849-851 "Effect of the polarity of substituents on the decomposition rate of beta-nitroamines"; see Abstract. * |
Nucleic Acids Research Vol 17, Number 15 (1989), (STIRCHAK, E.P.), pages 6129-6141, "Uncharged stereoregular nucleic acid analogs: 2. Morpholino nucleoside oligomers with carbamate internucleoside linkages"; see entire document. * |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1993020236A1 (en) * | 1992-04-03 | 1993-10-14 | Applied Biosystems, Inc. | Probe composition and method |
WO1993020239A1 (en) | 1992-04-03 | 1993-10-14 | Applied Biosystems, Inc. | Probe method and composition for detecting different dna sequences |
EP0773950A1 (en) * | 1994-07-15 | 1997-05-21 | Isis Pharmaceuticals, Inc. | Linked peptide nucleic acids |
EP0773950A4 (en) * | 1994-07-15 | 2000-05-17 | Isis Pharmaceuticals Inc | Linked peptide nucleic acids |
WO1996003417A1 (en) * | 1994-07-25 | 1996-02-08 | Hybridon, Inc. | Improved methods of detritylation for oligonucleotide synthesis |
WO1998032467A2 (en) * | 1997-01-24 | 1998-07-30 | Antivirals, Inc. | Method and conjugate for treating h. pylori infection |
WO1998032467A3 (en) * | 1997-01-24 | 1998-09-17 | Antivirals Inc | Method and conjugate for treating h. pylori infection |
WO2000044897A1 (en) * | 1999-01-29 | 2000-08-03 | Avi Biopharma, Inc. | Method of treating restenosis by antisense targeting of c-myc |
EP2002018A2 (en) * | 2006-03-07 | 2008-12-17 | AVI BioPharm, Inc. | Antisense antiviral compound and method for treating arenavirus infection |
EP2002018A4 (en) * | 2006-03-07 | 2009-03-25 | Avi Biopharma Inc | Antisense antiviral compound and method for treating arenavirus infection |
US7855283B2 (en) | 2006-03-07 | 2010-12-21 | Avi Biopharma, Inc. | Antisense antiviral compound and method for treating arenavirus infection |
AU2007223776B2 (en) * | 2006-03-07 | 2014-05-22 | Sarepta Therapeutics, Inc. | Antisense antiviral compound and method for treating Arenavirus infection |
Also Published As
Publication number | Publication date |
---|---|
KR0154317B1 (en) | 1998-12-01 |
ATE164081T1 (en) | 1998-04-15 |
EP0506845A1 (en) | 1992-10-07 |
EP0506845B1 (en) | 1998-03-18 |
DE69032167D1 (en) | 1998-04-23 |
AU7158791A (en) | 1991-07-18 |
CA2069906C (en) | 1996-11-26 |
JP3172174B2 (en) | 2001-06-04 |
EP0506845A4 (en) | 1992-10-21 |
JPH05504564A (en) | 1993-07-15 |
CA2069906A1 (en) | 1991-06-21 |
AU654473B2 (en) | 1994-11-10 |
KR920703692A (en) | 1992-12-18 |
DE69032167T2 (en) | 1998-10-29 |
US5034506A (en) | 1991-07-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0506845B1 (en) | Uncharged morpholino-based polymers having achiral intersubunit linkages | |
EP0962463B1 (en) | Uncharged morpholino-based polymers having phosphorus-containing chiral intersubunit linkages | |
US5235033A (en) | Alpha-morpholino ribonucleoside derivatives and polymers thereof | |
US5185444A (en) | Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages | |
US5521063A (en) | Polynucleotide reagent containing chiral subunits and methods of use | |
US5378841A (en) | Alpha-morpholino ribonucleoside derivatives and polymers thereof | |
US5217866A (en) | Polynucleotide assay reagent and method | |
US5142047A (en) | Uncharged polynucleotide-binding polymers | |
AU676704B2 (en) | Sequence-specific binding polymers for duplex nucleic acids | |
AU665560B2 (en) | Sequence-specific binding polymers for duplex nucleic acids | |
US5470974A (en) | Uncharged polynucleotide-binding polymers |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP KR |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2069906 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1019920701480 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1991902401 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1991902401 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1991902401 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2069906 Country of ref document: CA Kind code of ref document: A |